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The adrenal gland is an important endocrine organ, protecting the body against acute and 
chronic stress. The adrenal cortex consists of three morphologically and functionally 
distinct zones: the outer zona glomerulosa (zG), the zona fasciculata (zF), and the 
innermost zona reticularis (zR). In rodents, zG cells produce mineralocorticoids (mainly 
aldosterone), while zF cells secrete glucocorticoids (mainly corticosterone). The 
functions of zG and zF are defined by the mutually exclusive expression of Cyp11b2 and 
Cyp11b1 that encode the enzymes aldosterone synthase and 11β-hydroxylase, which 
catalyze the terminal reactions in the production of aldosterone and corticosterone, 
respectively. This thesis aims to investigate the maintenance of the definitive mouse 
adrenal cortex. This involves studies to identify the location of adrenal stem/progenitor 
cells, and the mechanisms by which differentiated adrenocortical cells are replenished in 
the adult mice.  
BrdU pulse-chase studies provided valuable information about cell division and cell fate 
under physiological or pathophysiological stimulations. The distribution of 
adrenocortical cells with nuclei stained positively for BrdU and/or Ki67 was identified. 
Ki67 labelling marked actively dividing cells and showed that adrenocortical cells 
originate at or around the zG/zF interface. BrdU labelling indicated that, following cell 
division, cells are displaced inwards and outwards. Acute angiotensin II treatment was 
shown to have no significant effects on the cell proliferation or turnover in any of the 
adrenocortical zones. The pathophysiological effects of long-term ACTH treatment were 
analyzed in a mouse model of congenital adrenal hyperplasia caused by a null mutation 
of Cyp11b1. Cell hypertrophy was evident in all regions of the adrenal cortex due to the 
impaired negative-feedback of the HPA axis. Adrenocortical cell proliferation was also 
increased particularly in the outer zona fasciculata at the border between zG and zF 




between cell proliferation and the final differentiation into steroidogenic zG and zF cells 
have yet to be discovered.  
A visual method of monitoring levels of Cyp11b2 and Cyp11b1would offer a convenient 
approach to track the stages of adult stem cell differentiation that lead to normal adrenal 
maintenance in vivo and in vitro. In the present study an AS-mCherry-11B-EGFP BAC 
construct was successfully engineered, in which Cyp11b2 and Cyp11b1 were substituted 
by mCherry and EGFP, respectively. This BAC construct was characterized in mouse 
adrenocortical Y1 cells. It was determined that EGFP faithfully recapitulated the 
expression of Cyp11b1. Forskolin or cAMP treatment induced a rapid cell rounding 
effect and caused the increased expression of EGFP transgene and endogenous Cyp11b1.  
An attempt was made to establish a transgenic mouse model, in which zG and zF cells 
would be marked with mCherry and EGFP respectively, allowing the differentiation of 
an adrenocortical stem cell to be traced. Following microinjection of the BAC into 
mouse zygotes, twoAS-mCherry-11B-EGFP transgenic founder mice were identified. 
Unfortunately, neither of them was able to transmit the transgene through germline, 
suggesting the mosaicism of transgene integration. Indeed, mosaicism of the transgenic 
adrenals was demonstrated by RT-PCR and immunostaining, which also revealed that 
the exogenous EGFP expression faithfully recapitulated the endogenous Cyp11b1 in 
adrenals. 
Although it is assumed that expression of Cyp11b2 and Cyp11b1 are mutually exclusive, 
zG and zF cells may have the plasticity to allow the transition from one cell type into 
another. The AS-mCherry-11B-EGFP BAC construct is a useful tool for studying in 
vitro ES cell differentiation towards the adrenocortical lineage. Transgenic AS-
mCherry-11B-EGFP ES cells were successfully differentiated into mesenchymal stem 
cells, as identified by the expression of molecular markers for the mesenchymal lineage. 
It has been reported that steroidogenic factor (Sf1) can promote the differentiation of 
MSCs into steroidogenic cells, and Shh plays an important role in Sf1 expression and the 




transformation of mesenchymal cells into adrenocortical cells. It is thought there might 
be a requirement for additional factors to combine with Shh in promoting the 
transdifferentiation of ESC-derived mesenchymal cells. Future studies will focus on the 
genetic control of Cyp11b1 and Cyp11b2 in transgenic AS-mCherry-11B-EGFP ES cells. 
In conclusion, the location and fate of the adrenocortical progenitor cells were 
demonstrated by the BrdU pulse-chase studies in different mouse models. An AS-
mCherry-11B-EGFP BAC construct was generated, and used to study the mutual and 
differential controls of Cyp11b1 and Cyp11b2 expression in adrenocortical cells in vitro 
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1.1 The adrenal gland 
1.1.1 Endocrine system and hormones 
Various parts of the body have to communicate properly with each other to maintain 
homeostasis and to respond to changes in the internal and external environment. Two 
major communication channels are the nervous system and the hormonal system. 
Generally speaking, the former transmits information more rapidly while the latter is 
suitable for more widespread and long-lasting actions.  
Hormones are molecules produced predominantly by endocrine glands throughout the 
body, including the hypothalamus, the pituitary glands, the thyroid gland, the 
parathyroid gland, the adrenal glands, the pancreas and the gonads (testes and ovaries) 
(Fig. 1.1). In response to specific stimuli, hormones are released into the bloodstream 
and then circulated to their target organs. The hypothalamus and the pituitary gland are 
the principal regulators of the endocrine system. The hypothalamus produces 
neuropeptides such as oxytocin and vasopressin that are transported to and released from 
the posterior pituitary to regulate water retention in the kidney and the milk ejection 
reflex, and produces hypothalamic releasing hormones such as corticotropin-releasing 
hormone (CRH) and inhibiting hormones such as dopamine which act on the 
downstream anterior pituitary. Anterior pituitary hormones, such as thyroid stimulating 
hormone (TSH), adrenocorticotropic hormone (ACTH) and the gonadotrophins (follicle 
stimulating hormone; luteinising hormone), regulate the functions of downstream 
endocrine glands, respectively the thyroid gland, the adrenal glands and the gonads. 
CRH and ACTH are important components of the hypothalamic-pituitary-adrenal (HPA) 
axis which regulates the production and release of corticosteroids in the adrenal gland. 




homeostatic feedback. Constant negative-feedback information from targeted glands 
such as adrenals reciprocally affects the pituitary and hypothalamus to ensure the 
hormone circulatory levels remain within the appropriate boundaries (Gorman and 





Fig. 1.1. Schematic representation of locations of the major endocrine 
glands producing hormones throughout the human body  
Both male and female gonads are presented here for the purpose of illustration (Gorman 










1.1.2 General structure and function of the adrenal gland 
The adrenal glands are small structures situated on top of the kidneys and consist of two 
structurally-distinct compartments, the outer steroidogenic adrenal cortex and the inner 
neuroendocrine adrenal medulla (Fig. 1.3). The adrenal medulla is an important part of 
the sympathetic nervous system, composed of ganglion and chromaffin cells secreting 
catecholamines in response to acute stress. Catecholamines are primarily epinephrine 
and norepinephrine but other vasoactive substances are also secreted including 
dopamine, serotonin and various neuropeptides (eg. adrenomedullin) (Coulter, 2005; 
Kempna and Fluck, 2008). Although chromaffin cells of the adrenal medulla and 
adrenocortical cells of the adrenal cortex are functionally and embryologically distinct, 
there is evidence showing interactions between them (Ehrhart-Bornstein et al., 1998; 
Gorman and Chiasera, 2013). 
Fig. 1.2. Schematic representation of negative-feedback loops which 
control activities of the endocrine system 
In some situations, hormones released from targeted glands act back on the pituitary 
or hypothalamus to shut off the whole system. ‘+’ = stimulates; ‘–’= inhibits (Gorman 










The typical mammalian adrenal cortex, initially described in 1866 by Arnold, can be 
divided into three morphologically and functionally distinct concentric layers: the 
outermost zona glomerulosa (zG) beneath the capsule, the intermediate zona fasciculata 
(zF), and the innermost zona reticularis (zR) (Vinson, 2003).  These three adrenocortical 
zones can be identified by their unique cellular arrangements although zonal boundaries 
are sometimes less distinguishable in mice and their thickness varies between different 
mouse strains, particularly in zR (Chang et al., 2011; Tanaka and Matsuzawa, 1995; 
Tanaka et al., 1995). The small basophilic zG cells have little cytoplasm and are grouped 
in the globular arched-like clusters. The larger eosinophilic zF cells are arrayed in 
columns and contain abundant cytoplasmic lipid droplets for steroid synthesis. The small 
zR cells retain some lipid droplets and show a compacted morphology (Vinson, 2003) 
(Fig. 1.4).  
Fig. 1.3. Common structure of the adrenal gland 
(A) Bilateral adrenal glands are located on top of kidneys.  
(B)  The transverse section of the mammalian adrenal gland comprising the outermost 











The zona glomerulosa cells synthesize mineralocorticoids, mainly aldosterone secreted 
into the blood stream as part of the renin-angiotensin system (Bassett et al., 2004). 
Aldosterone was first isolated by Simpson and Tait in 1953 (Simpson et al., 1953). It 
acts on mineralocorticoid receptors of distal tubules and collecting ducts of the kidney to 
cause sodium conservation, secretion of potassium, increased water retention. Plasma 
volume expands which increases blood pressure (Bassett et al., 2004; Peters, 2012). 
Spironolactone, a competitive antagonist of aldosterone binding to mineralocorticoid 
receptors, is a drug widely used to lower blood pressure. Conversely, when aldosterone 
synthesis is impaired (such as in Addison’s disease), patients are hypotensive and are at 
Fig. 1.4. Morphology and principal hormone products of different adrenal 
cells 
The principal mammalian mineralocorticoid aldosterone is produced in the globular cells 
of the outer zona glomerulosa. The major glucocorticoids synthesized in the columnar 
zona fasciculata are respectively cortisol and corticosterone in humans and rodents. 
Adrenal androgens (DHEA) are produced in the compacted zona reticularis of the human 






risks of cardiovascular collapse because of reduced blood volume. Aldosterone is also 
known to have direct effects on the heart. Excess aldosterone causes a pathological 
remodelling of the heart tissue, perhaps by stimulating fibrosis and cellular proliferation 
(Tillmann et al., 2002; White, 2003). 
The zona fasciculata cells produce glucocorticoids. Corticosterone (B) is the major type 
of glucocorticoids in rodents, which helps maintain the appropriate level of blood 
glucose protecting the body from stress and inflammation. The fasciculata cells 
primarily synthesize cortisol not corticosterone in human, as their smooth endoplasmic 
reticulum (SER) membranes also harbour cytochrome P450 17α-hydroxylase (P450c17) 
(Ishimura and Fujita, 1997; Pelletier et al., 2001). In cortisol-secreting species, 
pregnenolone and progesterone are hydroxylated at the C17 position leading to the 
production of deoxycortisol which is then hydroxylated at the 11 position to form 
cortisol.  
The zona reticularis cells can produce small amounts of glucocorticoids and adrenal 
androgens. In humans, they can synthesize dehydroepiandrosterone (DHEA) which is 
ultimately converted to androgen (eg. testosterone) by extra-adrenal tissues (Keegan and 
Hammer, 2002).  
  
1.2 Steroidogenesis in the adrenal cortex 
1.2.1 Steroidogenic pathways in the adrenal cortex 
The biosynthesis of steroid hormones from the substrate cholesterol in the adrenal cortex 
is a series of successive steps involving two groups of enzymes, the cytochrome P450 
family members and the steroid dehydrogenases. Table 1.1 lists the mouse and human 
genes that encode the cytochrome P450 steroidogenic enzymes, and also the 
chromosomal location of each gene, their nomenclature and synonyms, their molecular 




of each enzyme in various species (mouse, rat, human, bovine etc.) are highly 
homologous in the amino acid sequence. All these enzymes are expressed in a cell- or 
tissue-specific manner (Payne and Hales, 2004). 
Table 1.1. Cytochrome P450 steroidogenic enzymes in adrenals, gonads 
and placenta  
Gene
 
Chromosomal location Protein and Major 
Synonyms 
Major Expression 
Sites Mouse Human Mouse Human 
Cyp11a1 CYP11A1 9 (31cM) 
15 
q23-q24 






























Cyp17 CYP17 19 (46cM) 10q24.3 











Cyp19 CYP19 9 (31cM) 15q21.1 

















This table is adapted from Payne’s review of steroidogenic enzymes involved in the 
pathways converting cholesterol to active steroid hormones (Payne and Hales, 2004). 
 
Steroid biosynthetic pathways in three adrenocortical zones share many components 




common precursor, cholesterol, which is transported into the inner mitochondrial 
membrane of adrenocortical cells and is converted to pregnenolone by cholesterol side-
chain cleavage enzyme (cytochrome P450scc; CYP11A1). Pregnenolone is further 
processed by isozymes of 3β-hydroxysteroid dehydrogenase (3β-HSD) and 21-
hydroxylase (P450c21c, CYP21) to become deoxycorticosterone (DOC). The terminal 
reactions converting DOC to either mineralocorticoids or glucocorticoids are catalyzed 
by two different steroidogenic enzymes in a zone-specific manner: aldosterone synthase 
(CYP11B2) in zG cells and 11β-hydroxylase (CYP11B1) in zF cells, respectively 
(Lavoie and King, 2009). Aldosterone synthase catalyzes a series of three hydroxylation 
reactions to produce aldosterone: the conversion of 11-DOC to corticosterone, the 
conversion of corticosterone to 18-hydroxycorticosterone and the conversion of 18-
hydroxycorticosterone to aldosterone (Williams et al. 2005). In mice, 11β-hydroxylase 
converts 11-deoxycorticosterone to corticosterone. In human, deoxycortisol is the main 





Fig. 1.5. Steroid biosynthesis in mammalian adrenal cortex 
In this diagram, all the catalytic enzymes are marked in red. The hormones marked in 
black present the steroid products in rodents. The hormones marked in green present the 
steroid products in zona fasciculata and zona reticularis in humans.  
All the steroidogenic cells share the first three reaction steps. Note that P450c17 has 
both 17
α
-hydroxylase and 17, 20-lyase activities.  
 





1.2.2 Cyp11b2  
The functional zG cell is defined by the expression of Cyp11b2 gene (cytochrome P450, 
family 11, subfamily B, polypeptide 2), which encodes the enzyme aldosterone synthase 
(AS). Cyp11b2 spans about 7kb and is located on Chromosome 15:74.83-74.84 Mb in 
the mouse genome. It consists of 9 exons and 8 introns, and encodes a 1,625bp mRNA 
transcript (NM_009991.3) in the mouse adrenals. The mature aldosterone synthase 
protein comprises 476 amino acids.  
Lee and colleagues generated a Cyp11b2-null mouse model (Lee et al., 2005) to study 
the effects of the absence or reduced amounts of aldosterone on the adrenal development 
and the endocrine function. They disrupted the mouse Cyp11b2 gene by replacing its 
coding region with coding sequence (CDS) of enhanced green fluorescent protein 
(EGFP). Notably, the AS-null pups fail to survive normally after birth with a 30% death 
rate between day 7 and day 28. The adult null mice were small, weighing only 75% of 
wild types. Aldosterone deficiency leads to remarkable cellular and molecular changes 
in the mouse adrenal cortex. Compared with WT mice, the renin-angiotensin system is 
greatly activated, glucocorticoid production is up-regulated and adrenocortical cell 
turnover is promoted in the Cyp11b2-null mice (Lee et al., 2005). 
 
1.2.3 Cyp11b1  
The functional zF cell is defined by the expression of the Cyp11b1 gene (cytochrome 
P450, family 11, subfamily B, polypeptide 1). It is located on Chromosome 15:74.85-
74.86 Mb in the mouse genome adjacent to Cyp11b2 and consists of 9 exons and 8 
introns. Cyp11b1 spans about 7kb and encodes a 2,398bp mRNA transcript 
(NM_001033229.3) in the mouse adrenals and the mature 11β-hydroxylase protein 
comprises 476 amino acids.  
A Cyp11b1-null mouse model has been generated (Mullins et al., 2009) in which exon 




expected, the expression of ECFP reporter was observed exclusively in the zona 
fasciculata of the Cyp11b1-null adrenal cortex. In the adrenals of homozygous Cyp11b1-
null mice, there was no immunohistochemical evidence of 11β-hydroxylase expression, 
and urinary steroid analysis showed a marked accumulation of 11β-hydroxylase 
substrate DOC and a reduction in corticosterone levels. The Cyp11b1-null mouse 
exhibits glucocorticoid deficiency, mineralocorticoid excess (due to excess 
deoxycorticosterone), mild hypertension, adrenal hyperplasia, hypokalemia and glucose 
intolerance. Interestingly, the adult Cyp11b1
-/-
 females are infertile and their ovaries 
showed an absence of corpora lutea. These Cyp11b1-null females respond normally to 
superovulation procedure, which suggests that the female infertility might result from 
increased adrenal progesterone levels, an earlier intermediate in the biosynthesis of 
corticosterone. In 8% of patients with congenital adrenal hyperplasia (CAH) disease, the 
cause has been ascribed to mutations of Cyp11b1. Like Cyp11b1-null mice, these CAH 
patients exhibit glucocorticoid deficiency, an accumulation of deoxycorticosterone and 
adrenal hyperplasia (Barr et al., 2006; Krone et al., 2005; Paperna et al., 2005). Unlike 
Cyp11b1-null mice, CAH patients produce excessive amounts of adrenal androgen 
which causes external genital virilization in females and precocious puberty in males.  
 
1.2.4 Cyp11b2- Cyp11b1 locus 
Mouse Cyp11b2 and Cyp11b1 share 95% sequence homology and lie in tandem about 
10kb apart on the long arm of chromosome 15 in the mouse genome (Mornet et al., 
1989). Cyp11b2 lies upstream of Cyp11b1. The purified cytochrome P450aldo 
(aldosterone synthase) and cytochrome P45011β (11β-hydroxylase) are approximately 
49.5kDa and 51.5kDa respectively, as estimated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) (Ogishima et al., 1989).  
Unique insights into the control of Cyp11b1/b2 locus have been provided by its natural 




sequence homology between Cyp11b2 and Cyp11b1, there is an increased likelihood of 
cross-over events at meiosis leading to significant abnormalities in the control and 
enzymatic properties of aldosterone synthase and 11β-hydroxylase, and ultimately the 
altered steroid hormone profiles (Portrat et al., 2001).  For example, the normal synthesis 
of aldosterone is disturbed in the inherited hypertensive syndrome known as 
glucocorticoid-suppressible hyperaldosteronism (GSH). The cause of GSH is a 
duplication hybrid Cyp11b gene which arose during an unequal crossing-over during 
meiosis (Lifton et al., 1992a; Lifton et al., 1992b; Pascoe et al., 1992). The hypertension 
caused by excess aldosterone levels can be controlled by a synthetic glucocorticoid 
which suppresses the HPA axis. This unequal crossing-over results in a chimeric fusion 
gene with the promoter, exon 1-6 of Cyp11b1 and exon 7-9 of Cyp11b2, and the 
chimeric protein catalyses the same reactions as aldosterone synthase but under the 
primary control of the hypothalamo-pituitary adrenal (HPA) axis. The clear implication 
of these studies is that distinct enzymatic activities and zone-specific expressions of 
Cyp11b2 and Cyp11b1 are due to differences in the coding and upstream promoter 






1.3 The control of steroidogenesis in the adrenal cortex 
Plasma cortisol levels show normal circadian variations, peaking in the early morning 
(approximately 8 a.m.) and reaching the lowest level at midnight, but may also display 
short-term ‘fight or slight’ spikes in response to acute physiological stress or danger. 
The zone-specific control of steroidogenesis in the adrenal cortex is mediated by 
separate factors with acute (minutes) and chronic (days to weeks) responses. Acute 
increases in glucocorticoid levels are typically invoked in response to fright or pain, and 
in response to changes from a lying to a standing position in the case of aldosterone. 
More long-term adaptive responses, such as increased production and release of cortisol 
to stimulating peripheral fat and protein catabolism to support glucose synthesis in liver, 
and the production and release of aldosterone to regulate electrolyte balance, are 
required to maintain homeostasis in response to physiological stress or changes in 
dietary intake of salt. 
 
1.3.1 Acute control 
1.3.1.1 Uptake of substrate cholesterol 
Cholesterol is available from three sources: 1) de novo synthesis from acetyl-CoA, 2) 
cholesterol esters stored in lipid droplets and converted to free cholesterol, 3) circulating 
lipoproteins such as LDL via LDL receptors in human or HDL via scavenger receptor in 
rodents (Go and Mani, 2012; Mineo and Shaul, 2012). All steroids derive from 
cholesterol and are synthesized on demand in response to physiological stimulation. The 
movement of hydrophobic cholesterol within the aqueous cellular microenvironment is 
aided by several intracellular proteins. The uptake of cholesterol into the inner 
mitochondria is the first and rate-limiting step in steroid production which is increased 
within minutes by mobilizing cholesterol stores under stimulations. Steroidogenic cells 
possess a multi-protein machine termed the transduceosome consisting of cytoplasmic 




translocates the cholesterol from the outer mitochondrial membrane to the inner 
mitochondrial membrane, and converts it to pregnenolone. All signaling systems 
converging on the regulation of cholesterol uptake are mediated by steroidogenic acute 
regulatory protein (StAR) which is a critical component of the cytoplasmic 
transduceosome (Midzak et al., 2011).  
 
1.3.1.2 Major physiological regulations 
Adrenocortical steroids are acutely synthesized in response to circulating hormones such 
as ACTH. The major neuroendocrine components of acute stress responses of 
steroidogenesis include stimulation of the sympathoadrenal system and activation of the 
HPA axis. While pituitary ACTH mediates rapid increases in plasma glucocorticoid 
levels, sympathetic activation results in elevated renin secretion in the kidney and results 
in increased circulating level of angiotensin II (Peters, 2012).  
 
1.3.1.2.1 Corticotropin 
ACTH is a polypeptide of 39 amino acids predominantly synthesized and secreted in the 
anterior lobe of the pituitary controlled by the HPA axis. ACTH plays an important role 
in stimulating the production of adrenocortical steroids, primarily glucocorticoids in the 
zona fasciculata, and in causing fasciculata cell proliferation and hypertrophy. In 
addition, acute ACTH treatment has been seen to cause a transient increase in 
aldosterone production. Hormone-producing adrenocortical tumors and hyperplasia of 
the zona fasciculata lead to excessive amounts of corticosterone which is the main cause 
of several adrenal disorders including Cushing Syndrome. ACTH is proven to regulate 
the production of glucocorticoids through the cAMP signaling pathway (Simpson and 
Waterman, 1988). Melanocortin 2 receptor (MC2R), a specific cell-surface receptor of 




primarily in the adrenocortical cells. Upon binding to ACTH, MC2R undergoes 
conformational changes that stimulate the intracellular signaling cascades such as 
adenylyl cyclase action to promote the flow of cholesterol to the inner mitochondrial 
membrane (Midzak et al., 2011).  
 
1.3.1.2.2 Cyclic AMP 
Cyclic AMP (cAMP) is the second messenger for ACTH (Waterman and Bischof, 1996). 
The cAMP pathway via protein kinase A (PKA) is the most predominant intracellular 
signaling pathway which increases the activity of mitochondria-targeted StAR protein 
upon PKA-mediated phosporylation.  
 
1.3.1.2.3 Angiotensin II and Potassium 
Angiotensin II (Ang II) and potassium (K
+
) are the core regulators for aldosterone 
synthesis. They act synergistically exerting functions via increasing the intracellular 
calcium (Ca
2+
) and protein kinase C activity (Spat and Hunyady, 2004). Potassium 
signaling involves a depolarization of the cell membrane, causing an influx of calcium in 
glomerulosa cells. The elevated level of intracellular calcium increases the expression of 
Cyp11b2 transcript. The renin-angiotensin-aldosterone system (RAAS) primarily 
regulates the blood pressure and the intravascular volume. Dysregulation of RAAS is 
linked to several types of hypertensive diseases (White, 1994).  
 
1.3.2 Chronic control 
As mentioned above, many factors including ACTH, angiotensin II and potassium are 
considered essential for the regulation of steroidogenic gene expression in the 




expression of steroidogenic genes and/or cell hypertrophy/ hyperplasia of particular 
zones of the adrenal cortex.  
 
1.3.2.1 Trophic factors 
Trophic factors involved in the chronic control of steroidogenesis are generally the same 
as those involved in acute responses via the same cellular signaling systems.  
Targeted ablation of ACTH in the pituitary has demonstrated the appropriate expression 
of Cyp11b2, but not that of Cyp11b1, is maintained in the adrenals with extremely low 
circulating ACTH (Allen et al., 1995). Chronic ACTH stress (Aguilera et al., 1996) 
leads to elevated levels of circulating glucocorticoids and to decreased glucocorticoid 
clearance. However, chronic treatment with ACTH may ultimately decrease plasma 
aldosterone level and Cyp11b2 expression via negative feedback of the renin-
angiotensin system. Chronic ACTH stimulates glucocorticoid synthesis and the 
intermediate deoxycorticosterone both of which can act as MR agonists (Abayasekara et 
al., 1989; Denner et al., 1996; Fuchs-Hammoser et al., 1980; Oertle and Muller, 1993).  
Basal and cAMP-activated expression levels of steroidogenic genes are thought to be 
mediated by common elements in the 5’-flanking region of these genes, which include a 
cAMP-response element (CRE) and a key binding factor, steroidogenic factor 1 (SF-1). 
All Cyp11b genes are proven to be positively regulated by the cAMP signaling pathways 
(Clyne et al., 1997). 
In keeping with slower adaptive responses to dietary electrolyte intake, the aldosterone 
production is controlled by changes in zona glomerulosa cell proliferation, apoptosis and 
hypertrophy as well as changes in expression of key steroidogenic enzymes. For 
example, one of the chronic effects of Ang II and K
+
 under sodium diet restriction is to 
increase the aldosterone production mainly through the up-regulated expression of 




thought to inhibit ACTH-stimulated cAMP signaling in zona glomerulosa cells, which 
chronically reduces Cyp11b2 expression (Begeot et al., 1988).  
 
1.3.2.2 Transcriptional control of Cyp11b1 and Cyp11b2 
Cyp11b1 and Cyp11b2 genes are identical in their exon-intron organizations and encode 
structurally homologous proteins. However, the 5’ flanking regions of Cyp11b1 and 
Cyp11b2 are significantly different from each other (Mukai et al., 1993; Mukai et al., 
1991) which is thought to explain the differences in their transcriptional regulation.  
At least three factors are implicated in the transcriptional control of Cyp11b2/b1, 
including CRE-binding protein (Moore et al., 1990; Takayama et al., 1994), adrenal-
specific protein (Kagawa and Waterman, 1991, 1992) and Ad4-binding protein (Ad4BP) 
which is also referred as SF-1 (Honda et al., 1993; Morohashi et al., 1992). However, 
these factors are present throughout three zones of the adrenal cortex, thus they are 
unlikely to determine the zone-specific gene expression and steroid production. 
The regulation of Cyp11b2 expression by Ang II and K
+
 also requires two cis-regulatory 
elements including CRE and a second orphan nuclear receptor, chicken ovalbumin 
upstream promoter transcription factor (COUP-TF) (Clyne et al., 1997).  Recent analysis 
by the chromatin immunoprecipitation (ChIP) technique suggests that the transcriptional 
factors, including activator transcriptional factor (ATF) and CRE-binding protein,  are 
recruited to the Cyp11b2 CRE region after Ang II and K
+
 induction (Nogueira and 
Rainey, 2010). Taken together, the control of Cyp11b2 expression and aldosterone 
production is mediated by Ang II and K
+
 upon the presence of crucial regulatory 
domains in the promoter region of Cyp11b2. 
In summary, ACTH, Angiotensin II and potassium act through distinct cellular 
mechanisms to differentially regulate the Cyp11b2 and Cyp11b1 transcription, which are 




1.4 Transcriptional factors and signaling pathways involved in the 
development and function of the adrenal cortex 
 
1.4.1 Critical transcriptional factors 
The proper development and function of organs throughout the body is maintained and 
regulated by a complicated network of transcriptional factors. Various transcriptional 
factors in the adrenal cortex have been identified by the extensive analyses of targeted 
mutagenesis in mice and of naturally-occurring mutations in humans with congenital 
adrenal hypoplasia. Herein five key transcriptional factors in the adrenal cortex are 
reviewed: SF-1; dosage-sensitive sex reversal, adrenal hypoplasia congenital, X-linked-1 
(DAX1); Wilms Tumor 1 (WT1); pre-B-cell transcriptional factor 1 (PBX1); and 
CBP/p300-interacting transactivator with Glu/Asp-rich C-terminal domain 2 (CITED2) 
(Hammer et al., 2005; Mazilu and McCabe, 2011a; Val and Swain, 2010). 
 
1.4.1.1 SF-1  
SF-1, as described earlier, is an orphan nuclear receptor, which was initially identified as 
a key regulator of steroidogenic enzyme expression in the mouse adrenocortical Y1 cell 
line (Lala et al., 1992).  SF-1 positively regulates the transcriptional expression of StAR, 
Cyp11a1, Cyp21, Cyp17 and 3β-HSD (Peter and Dubuis, 2000) by binding to the 
cognate sites in their promoters as a monomer and recruiting an array of co-activators to 
perform the transactivation of target genes (Yu et al., 1998). SF-1 has also been shown 
to regulate cell responsiveness to ACTH by mediating the expression of ACTH receptor 
in adrenocortical cells. SF-1 plays a key physiological role in Cyp11b1 transcription in 
zF but is much less active in the control of Cyp11b2 expression in zG (Honda et al., 




regulation of the transcription of Cyp11b1 and Cyp11b2 by SF-1 might be one of the 
molecular mechanisms controlling zone-specific steroid synthesis within the adrenal 
cortex.  
Expression of SF-1 has also been detected in the pituitary gonadotrophs and the 
ventromedial hypothalamus (VMH) (Ingraham et al., 1994; Shinoda et al., 1995). The 
spatial and temporal patterns of SF-1 expression are shown in Fig. 1.6. SF-1 is expressed 
as early as E9.0 in the urogenital ridge during mouse embryonic development (Hatano et 
al., 1994; Morohashi, 1997), and it is a master factor which might determine the 
developmental fate of cells within the urogenital ridge (Morohashi et al., 1994). 
Regulatory systems of SF-1 appear to be different in the fetal and adult stages of the 




Fig. 1.6. Schematic illustration of adrenal and gonadal development from 
the urogenital ridge showing critical genes involved in these processes 








Loss-of-function studies have demonstrated that SF-1 is a key component in the 
establishment of the steroidogenic tissues (Luo et al., 1994; Nomura et al., 1995; 
Nomura et al., 1996). The SF-1 null mice are born with adrenal aplasia and die 12 hr 
after birth due to the fatal agenesis of adrenal glands and gonads (Luo et al., 1994). 
Studies with SF-1
+/-
 mice suggest that gene dosage is very important (Beuschlein et al., 
2002; Bland et al., 2004). In humans, heterozygous SF-1 alteration is linked to a delayed 
adrenal insufficiency and premature ovarian insufficiency in females while heterozygous 
SF-1 mutation causes adrenal defects and male-to-female sex reversal in males 
(Achermann et al., 2001; Lin et al., 2006; Phelan and McCabe, 2001). Also, it has been 
suggested that over-expression of SF-1 might result in adrenocortical carcinoma 
(Schimmer and White, 2010). 
 
1.4.1.2 DAX1  
In 1994, mutations in DAX1 were reported to be linked to abnormal adrenal 
development in 17 families with adrenal hypoplasia congenita (AHC). AHC is an 
adrenal insufficiency disorder resulting from congenital adrenal agenesis and 
hypogonadotropic hypogonadism (Zanaria et al., 1994). DAX1 expression starts at 
E10.5 in the urogenital ridge and continues in the adrenogonadal primordium (AGP) and 
further in the fetal adrenal cortex and fetal ovary (Achermann et al., 2001). The gene 
dosage of DAX1 is proposed to play a role in sex determination by acting as an anti-
testis signal (Achermann et al., 2001; Goodfellow and Camerino, 1999). 
DAX1 is associated with SF-1 and they appear to work either cooperatively or 
antagonistically. Multiple binding sites of SF-1 are found in the DAX1 promoter (Yu et 
al., 1998).  DAX1 suppresses the action of SF-1 either by interacting directly with SF-1 
or by recruiting a variety of repressors (Ito et al., 1997). Additional reports have 





In adult adrenocortical cells, a negative feedback loop appears to underlie the molecular 
relationship between DAX1 and SF-1. Upon stimulations with excessive glucocorticoids, 
SF-1 and glucocorticoid receptor bind together to the DAX1 promoter activating DAX1 
transcription, which represses SF-1 and reduces steroid production (Gummow et al., 
2006).  Upon ACTH stimulation, the complex of glucocorticoid receptor and SF-1 is 
suppressed, allowing the initiation of steroid production and subsequently decreasing the 
DAX1 transcription (Gummow et al., 2006). However, it is still unclear how the 
interplay between SF-1 and DAX1 works in adrenal organogenesis and in maintenance 
of the mouse definitive adrenal cortex. 
In Sf1-null mice, DAX1 expression in adrenals is greatly reduced but not eliminated, 
suggesting other DAX1 transcriptional factors or signaling pathways are present (Ikeda 
et al., 1996). In vitro studies have revealed that DAX1 can bind to its own promoter, 
showing the possibility of its auto-regulation (Zazopoulos et al., 1997).  
 
1.4.1.3 WT1  
WT1 is a zinc finger tumor suppressor protein which was first identified in the abnormal 
development of several familial childhood tumors in the embryonic kidney (Haber et al., 
1990; Hohenstein and Hastie, 2006). Recent investigations have shown that WT1 is 
essential for the development of the urogenital ridge, as well as its derivatives such as 
the kidney, the adrenal cortex and the gonads (Keegan and Hammer, 2002; Klattig et al., 
2007; Val and Swain, 2010). In mice, WT1 is expressed as early as E9.0 in mice. WT1-
null mice have an arrested thickening of coelomic epithelium which can not differentiate 
further. 
WT1 has been found to be the first indispensible transcriptional factor for fetal adrenal 
development. It was reported by Wilhelm and Englert (Wilhelm and Englert, 2002) that 
the expression of SF-1 in AGP relies on an active signal from WT1. The following 




interactions between WT1 and another transcriptional factor, CITED2 (described in 
Section 1.4.1.5), which promotes the SF-1 function separating AGP to form adrenal and 
gonadal primordium. WT1 is expressed only for a short window and WT1 expression is 
silenced in the primitive adrenal cortex once it is separated from the gonadal and nephric 
tissues (Hammer et al., 2005; Val et al., 2007; Val and Swain, 2010).  
 
1.4.1.4 PBX1  
PBX1 has recently been indicated to be a homeodomain protein. Its expression is 
detected in the developmental urogenital ridge as early as E13.5 in mice and in cells of 
the adrenal cortex, Mullerian duct and metanephric mesenchyme of adults (Schnabel et 
al., 2003). Mice lacking PBX1 develop an abnormal phenotype with incomplete 
urogenital ridge: small metanephric kidneys, absence of the adrenal cortex, and 
deficiency of the Mullerian duct in females (Schnabel et al., 2003). The adrenal 
abnormality is linked to decreased SF-1 expression whilst WT1 expression is not 
affected. The adrenal and gonadal deficiency in PBX1
-/-
 mice might result from 
decreased cell proliferation. The adrenals of PBX1
+/-
 mice are smaller and show reduced 
cell proliferation when compared with wild-type mice. Moreover, upon unilateral 
adrenalectomy, PBX1
+/-
 mice did not undergo the expected adrenal compensatory 
growth suggesting that PBX1 also plays an additional role in maintenance and function 
of the adult adrenal cortex (Lichtenauer et al., 2007). 
 
1.4.1.5 CITED2  
CITED2 is a transcriptional co-activator of CRE-binding protein which is associated 
with the development and function of many organs, such as the adrenal, cardiac and 
neural tissues (Haase et al., 2007). In wild-type mice, Cited2 expression is found in the 




adrenocortical cells as embryo development proceeds. In vitro investigations have 
revealed that Cited2 also acts as a transcriptional co-activator of WT1 in the SF-1 
promoter region (Val et al., 2007). 
A novel model is proposed by Val and Swain for the activities of transcriptional factors 
in the adrenocortical development (Val and Swain, 2010): first, WT1 initiates the 
expression of SF-1 in the adrenogonadal primordium, then CITED2 interacts with WT1 
synergistically to maintain SF-1 expression. Secondly, PBX1 interacts with the FAdE 
sequence in the SF-1 promoter to enhance SF-1 expression in separated adrenocortical 
primordium. Lastly, SF-1 continues and sustains its own expression into adulthood (Val 





1.4.2 Key signalling pathways 
Several signalling pathways are proven to be crucial for cell proliferation, patterning, 
development and function in the adrenal cortex. For example, recent genetic studies 
have identified importance of the sonic hedgehog, Wnt/ β-Catenin, TGF-β and FGF 
signalling pathways in the mouse adrenal cortex. 
 
1.4.2.1 Sonic hedgehog signalling 
The hedgehog signalling pathway is essential for cell proliferation, tissue development 
and differentiation. There are three key ligands: Sonic hedgehog (Shh), Indian hedgehog 
(Ihh) and Desert hedgehog (Dhh). The membrane receptors of these ligands are named 
Ptch1 and Ptch2 on hedgehog-responding cells.  
The first suggestion of Shh function in the adrenal development came from an 
observation in 1980 of hypoadrenalism in infants with Pallister-Hall syndrome. This is 
an autosomal dominant disorder caused by mutations in Gli3, the final transcriptional 
factor in the hedgehog signalling cascade (Hall et al., 1980; Kang et al., 1997). Shh was 
shown to be the only member of the hedgehog family expressed at the periphery of 
adrenal cortex at E14.5 and in the subcapsular region after birth in mice. The Shh signal 
was found to come from the relatively undifferentiated subcapsular cells. The location of 
Shh-responsive cells was identified by Ptch1 and Gli1 expression in an adjacent Sf1-
positive layer of cells in the outer adrenal cortex (Bitgood and McMahon, 1995; King et 
al., 2008). King and colleagues also observed abnormal adrenal development  in Shh-
deficient mice as early as E12.5 (King et al., 2008). Both capsular and subcapsular 
mesenchymal cells might respond to Shh signals (King et al., 2009). Conditional 
deletion of Shh in adrenals results in reduced adrenal cell proliferation and a thinner 





1.4.2.2 Wnt-4/β-Catenin signalling 
Wnt signalling has been suggested to be important in normal development (growth and 
maintenance) and tumorigenesis of organs. Dysregulation of Wnt signalling is often seen 
in human adrenal carcinoma cases. Wnt-4 is known as a key factor in the genesis of 
multiple organs and may play a role in the separation and migration of adrenal and 
gonadal cells from AGP during early embryonic development (Heikkila et al., 2002). 
Wnt-4 is expressed as early as E11.5, especially in the outermost subcapsular region of 
the cortex including the zona glomerulosa.  
Wnt-4 acts via β-catenin signalling. β-catenin is a transcriptional co-activator of SF-1 
and is reported to synergize with SF-1 to regulate target genes (Gummow et al., 2003). 
In addition, targeted disruption of Wnt-4 is linked to abnormal differentiation of distinct 
zones in the definitive adrenal cortex (Heikkila et al., 2002; Jeays-Ward et al., 2003; Val 
et al., 2007). Wnt-4 null mice have a smaller zG, leading to the decreased production of 
aldosterone. This defect is considered to result from an abnormal regulation of Cyp11b2 
expression in the adrenal cortex (Heikkila et al., 2002). Furthermore, Wnt-4 and β-
catenin have been shown to co-localize in zG suggesting that the Wnt-4/β-Catenin 
signalling pathway may be essential for zona glomerulosa formation and for the 
maintenance of functional zonation in the adrenal cortex. 
Kim and colleagues used the Cre-loxP transgenic strategy to define the role of β-catenin 
by conditionally inactivating the β-catenin in the mouse adrenal cortex (Kim et al., 
2008a). They observed a complete lack of the adrenal cortex in β-catenin-disrupted mice. 






1.4.2.3 TGF-beta/activinA/BMP signalling 
The TGF-beta superfamily consists of various ligand members, including TGF-beta, 
inhibin, activin and bone morphogenic protein (BMP) (Jimenez et al., 2003; Johnsen and 
Beuschlein, 2010; Vanttinen et al., 2003). All of these ligands appear to be involved in 
the regulation of the adrenal cortex. ActivinA inhibits the expression and action of 
steroidogenic enzymes, and increases cell apoptosis (Vanttinen et al., 2003). Members of 
the BMP superfamily have been reported to inhibit or stimulate steroidogenesis, and are 
also thought to participate in the differentiation of neural crest cells into chromaffin cells 
(Vanttinen et al., 2003). Inhibins are competitive antagonists of activin/BMP activities 
and are important in the adrenal growth and function. Inhibin-null mice have adrenal 
glands with an ovarian phenotype synthesizing estrogens normally seen in ovarian theca 
and granulosa cells (Kim et al., 2009; Looyenga and Hammer, 2006).  
 
1.4.2.4 IGF and bFGF signalling 
Insulin-like growth factor (IGF) ligands and receptors are expressed in fetal and adult 
adrenal glands (Keegan and Hammer, 2002). IGF-I participates in normal adrenal 
maintenance upon ACTH stimulation while IGF-II is responsible for fetal adrenal 
development (Jimenez et al., 2003). Interestingly, various components of IGF signalling 
cascades are dysregulated in adrenocortical tumor cells (Jimenez et al., 2003). A 
predominant subgroup of the fibroblast growth factor (FGF) family in the adrenal glands 
is the basic FGF (bFGF) (Mesiano and Jaffe, 1997; Val and Swain, 2010). bFGF is 
shown to enhance the mitogenic effects of ACTH and acts as an angiogenic factor in the 






1.5 Origins of adrenocortical zonation 
Structure and function studies not only have established clear differences but also have 
found overlapping and interrelated functions between adrenocortical zones which can 
contribute to cardiovascular risk, such as glucocorticoid suppressible 
hyperaldosteronism, congenital adrenal hyperplasia and polymorphic variants of the 
Cyp11b1/Cyp11b2 locus. Questions about the origins and maintenance of adrenocortical 
cells of different zones are raised. Three experimental paradigms have been used to 
study these processes: the ontogeny of the fetal adrenal cortex, the functional zonation of 
the adult adrenal cortex and the identification of potential adrenocortical stem cells.   
 
1.5.1 Ontogeny of the fetal adrenal cortex 
In human and rodents, ontogeny of the fetal adrenal cortex is organised by unknown 
mechanisms. AGP, the common precursor for adrenal cortex and gonads, forms via the 
proliferation of the mesoderm-derived mesonephric mesenchymal cells which sit 
between the urogenital ridge and the dorsal mesentery. The process by which the 
urogenital ridge forms AGP is not known. The subsequent bidirectional development of 
the AGP to form either adrenal or gonadal primordium is regulated by several factors. 
Neural crest cells which will form the adrenal medulla become associated with the 
separated adrenal primordium before being enveloped by mesenchymal (capsular) cells. 
Cells of the adrenal primordium then terminally differentiate into the definitive adrenal 
cortex (Wood and Hammer, 2011) (Fig. 1.7). 











1.5.1.1 Development origin of the human adult adrenal cortex 
The study on human adrenocortical development was first described in the 1960s. By 
week 7 of gestation, cells committed to be adrenocortical cells have separated from the 
AGP, and migrated to form a rudimentary human fetal cortex. They further divide into a 
fetal zone and a more immature definitive zone (Hammer et al., 2005; Ishimoto and 
Jaffe, 2011; Keegan and Hammer, 2002). Mesenchymal cells encapsulate the fetal 
adrenal cortex during gestation week 9, when the neural crest cells invade the centre of 
the fetal adrenal cortex. It has been suggested that the capsule provides crucial factors 
which modulate the adrenocortical growth and differentiation. During the remaining 
weeks of the gestation period, the fetal zone undergoes multiple remodelling processes 
Fig. 1.7. Organogenesis of the adrenal glands 
The adrenal gland is formed from the adrenogonadal primordium and becomes matured 
through zonation of the definitive cortex. Colours of the respective cell types are: 
adrenogonadal primordium, purple; fetal adrenal cells, red; gonadal cells, blue; neural 
crest/medullary cells, yellow; mesenchymal/capsular cells, green; definitive cortex, 







and resembles the primitive adult adrenal cortex. Those neural crest-derived cells 
differentiate to become chromaffin cells and scatter as discrete islands under the effect 
of glucocorticoids secreted from the cortex. The human fetal adrenal gland exists and its 
structure persists throughout the whole gestation while the functional adult adrenal 
cortex does not appear until after birth. A typical human fetal adrenal gland at middle or 
later gestation stage comprises three layers underneath the capsule (Fig. 1.8): the 
definitive zone (DZ), a thin layer of small and tightly packed cells; the transitional zone 
(TZ) and the inner large irregularly-aligned fetal zone (FZ) (Mesiano et al., 1993). After 
birth, the adrenal medulla is encapsulated and the human fetal cortex starts to regress 
while the adult adrenal cortex is zoned into three morphologically and functionally 






1.5.1.2 Development origin of the rodent adult adrenal cortex 
The fundamental processes and regulatory gene expressions appear to be very similar 
between human and rodents. Mouse embryo undergoes a compressed period of 
approximately 21 days in the uterus, and the mouse adrenal glands are considerably less 
Fig. 1.8. A schematic presentation of the structure of human fetal 




developed at birth. A common pool of precursor cells forms AGP at E10.5. The cortex is 
also formed by budding from the coelomic epithelium between the urogenital ridge and 
mesogastrium, and then pushed out between the mesonephros and the aorta where the 
first medullary cells appear and intermingle with cortical cells at the same time. The 
mesenchymal capsular cells begin to encapsulate the adrenal cortex at E14. The fetal 
adrenal cortex comprises an outer thinner definitive adult zone (small and tightly packed 
cells) and an inner thick fetal zone (irregularly aligned large cells) (Keegan and Hammer, 
2002). The functional murine adrenal gland appears around birth (Keegan and Hammer, 
2002; Mitani et al., 1999; Schulte et al., 2007). 
Despite much progress which has been made, little is understood about the underlying 
mechanisms regulating the differential development of the fetal and adult adrenal cortex. 
It was controversial whether a fetal adrenal cortex was present in mice until a so-called 
X-zone was revealed using the lineage tracing studies. The X-zone (like the fetal zone in 
human) resides between zF/zR and the medulla, and its cells are arranged in a less 
ordered manner when compared with the other cortical regions. It has been proven that 
the fetal adrenal cortex exists in the mouse fetus, but is replaced by the X-zone after 
birth (Zubair et al., 2008). As the mouse embryo develops, the fetal zone becomes 
thinner while the definitive zone gets thicker. The newly formed inner layer, termed as 
X-zone, is first evident at D10-14 after birth and enlarges until 3 weeks old. It then 
disappears at the pubertal stage in males via cell apoptosis while it persists until the first 
pregnancy in females (Fig. 1.9). The steroidogenic potential and function of the X-zone 
are not completely understood (Zubair et al., 2006). The enzyme 20alpha-hydroxysteroid 
dehydrogenase (20alpha-HSD) is specifically expressed in the X-zone metabolising 
progesterone and 11-deoxy-corticosterone to biologically inactive 20 hydroxylated 













Figure 1.9. Time course of the adrenocortical developmental cascade in 
human and mice 
This figure is adapted from Hammer’s review (Keegan and Hammer, 2002). (a) The 
progression of human adrenocortical development from the urogenital ridge to the final 
zonation. Two distinct populations of cells migrate from the coelomic epithelial cells to 
form the fetal and definitive zones, which condense to form the adrenal primordial. 
Neural crest cells migrate to form the adrenal medulla while the adrenal primordial is 
encapsulated by mesenchymal cells, which form the fetal zone. The fetal zone 
undergoes apoptosis after birth, followed by the encapsulation of medulla and the 
functional zonation of adrenal cortex. (b) The progression of mouse adrenocortical 
development from the urogenital ridge to the X-zone regression. The whole process is 
similar to humans expect the fact that the zonation of mouse adrenal cortex is 





Both fetal mice and rats show the first appearance of morphological zonation of the 
adrenal cortex and a distinct AS-positive zona glomerulosa around E18. Curiously, AS-
positive cells are first seen within the rat central cortex at E16, but it is not known if 
these contribute to the peripheral AS-positive zG population which emerges at day 18 
(Wotus et al., 1998). A distinct morphological intermediate zone (IZ), otherwise termed 
the undifferentiated zone (ZU), is clearly seen in the adult rat adrenals, but not in the 
fetal rat and also not in the adult mouse adrenals (Kim et al., 2009; Wood and Hammer, 
2011) . 
 
1.5.2 Functional zonation of the adult adrenal cortex 
The adrenal gland undergoes a series of histological changes and differentiation events 
during the embryonic stages and postnatal periods to form a functionally zonated 
steroidogenic organ in the adults. As described earlier, the adrenocortical cells in each 
zone have a distinct endocrine function, and this phenomenon is termed “functional 
zonation” of the adrenal cortex. The amount of aldosterone required to control salt 
balance is 1000-fold less than that of corticosterone needed to control carbohydrate 
metabolism (Bassett et al., 2004). However, mechanisms underlying the zonal 
differentiation during embryonic development of the adrenal cortex are incompletely 
understood. The origin and establishment of the distinct adrenocortical zones as well as 
their maintenance in adults also remain elusive. 
The fetal zone in human regresses after birth, and the definitive zone begins to partition 
into three anatomically and functionally distinct compartments: zG, zF and zR (Ben-
David et al., 2007). Compared to humans, the functional zonation of the mouse 
definitive adrenal cortex occurs during the perinatal period, which is characterized by 
the expression of specific steroidogenic enzymes in distinct zones: Cyp11b2 in zG and 




Studies on functional zonation in the rat adrenal cortex by Mitani and colleagues (Mitani 
et al., 1999) have indicated that, after birth, the DNA-synthesizing cells (proliferating 
cells) are found to localize near an undifferentiated zone between zG and zF and migrate 
centripetally to replenish the apoptotic adrenocortical cells. This contrasts with the cell 
distribution during the fetal stage, when the rapid-proliferating cells are found scattered 
without significant migration. The migration of divided adrenocortical cells is postulated 
to be very significant for the growth and differentiation of the adrenal cortex in the early 
postnatal stage as well as in the adulthood.  
As is the case in other tissues, the development of the adrenal cortex and adrenocortical 
zonation are thought to require a strictly-controlled dynamic balance between cell 
proliferation, cell differentiation and cell apoptosis (Nussdorfer, 1970; Schwartzman and 
Cidlowski, 1993; Wyllie et al., 1973). Cell apoptosis, also called programmed cell death, 
is thought to appear in the boundary between the innermost zona reticularis of the cortex 
and the medulla, where many macrophages exist (Mitani et al., 1999). There have been 
four major hypotheses put forward so far concerning cell proliferation within the adrenal 
cortex: (1) These cells proliferate and renew in each zone independently; (2) The 
adrenocortical cells proliferate in the capsular or subcapsular region, and migrate 
centripetally from zG to zR, and eventually die in zR; (3) The adrenocortical cells 
proliferate in zG and migrate unidirectionally down to zF and zR, and eventually die in 
zR; (4) The adrenocortical cells proliferate at the boundary between zG and zF, and 
migrate bidirectionally towards the outer zG and the inner zF and zR (Nussdorfer, 1986).  
 
1.5.3 Potential adrenocortical stem cells  
Like many other tissues or organs, the unipotent adult stem cells are thought to reside in 
the adrenal cortex, which should have extensive potential for tissue regeneration. The 
existence of stem/progenitor cells in the adrenal cortex has also been inferred from other 




enucleation (Ennen et al., 2005; Mitani et al., 1995) or the differentiation of primary 
adrenocortical cells in culture under special conditions (Roskelley and Auersperg, 1993). 
These stem/progenitor cells are characterized by their abilities to maintain the 
homeostasis of the adrenal cortex as well as the absence of steroidogenic gene 
expression (Kim and Hammer, 2007), undergoing a series of processes strictly regulated 
by an unknown system. The importance of Shh signaling pathways studied reported by 
King et al. is reviewed in Section 1.4.2.1 and Section 6.1.3. 
The location and properties of adrenocortical stem cells was reviewed by Hammer’s 
group in detail (Wood and Hammer, 2011). The major challenge to further define the 
characteristics of adult adrenocortical stem/progenitor cells is the lack of reliable 
specific molecular markers though progress in identifying some cell specific 
transcription factors may begin to address this problem (King et al., 2009). The 
adrenocortical stem/progenitor cells are believed to be the pivotal targets of 
tumorigenesis and neoplastic transformation in the adrenal cortex (Bielinska et al., 2006; 
Doghman et al., 2008; Keegan and Hammer, 2002). A better understanding of adult 
adrenal cortex maintenance will contribute to improvement in the clinical treatments for 






1.6 Adrenocortical disorders  
The most common causes of adrenal failure are typical tuberculosis and various types of 
infections including bacteria, fungal and cytomegalovirus (Stewart 2011). Moreover, 
dysregulation of adrenocortical zonation underlies several disease processes. Adrenal 
disease can either be primary which is independent of the HPA axis, or be secondary 
which is linked to the function of the HPA axis. The former results from disorders 
within the adrenal gland while the latter is caused by defects in the hypothalamic-
pituitary (Mazilu and McCabe, 2011b). Recent studies also indicate that genes involved 
in development, signal-transduction processes and cholesterol supply also affect adrenal 
structure or morphology. Herein some of the most frequent adrenocortical disorders in 
humans or mice are described. 
 
1.6.1 Cushing Syndrome 
Cushing's syndrome describes the symptoms associated with prolonged exposure to 
inappropriately high levels of cortisol. Cushing's disease refers to a pituitary-dependent 
cause of Cushing's syndrome: a tumor in the pituitary gland produces large amounts of 
ACTH, causing the adrenal glands to produce elevated levels of cortisol. Cushing 
Syndrome can also be caused by adrenocortical tumours, by a more benign condition 
known as bilateral adrenal hyperplasia or by treatment with high doses of glucocorticoid 
hormones (iatrogenic). Treatment of adrenal tumors often requires unilateral or bilateral 
adrenalectomy to surgically remove one or more adenomatous nodules. Although 
iatrogenic adrenocortical-dependent and pituitary-dependent Cushing’s are separate 





1.6.2 Addison Disease 
Addison Disease, first described in the 1850s, is a comparatively rare disorder of the 
adrenal glands (Stewart 2011). It can develop either from a primary adrenal 
insufficiency or arise from a secondary disorder such as infection or hypopituitarism. 
Patients with Addison’s disease suffer from symptoms including defects in 
mineralocorticoid and glucocorticoid production, postural hypotension and generalized 
weakness, leading to adrenal crisis. These symptoms can lead to excessive salt loss or 
hypoglycemia which can be fatal (Mazilu and McCabe, 2011b). 
 
1.6.3 Congenital Adrenal Hyperplasia  
Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive inheritable 
disorders which cause dysfunction in the cortisol synthesis pathway. Generally speaking, 
adrenal hyperplasia is a consequence of increased level of ACTH in the absence of 
normal negative feedback from glucocorticoids on the HPA axis (Table 1.2). The most 
frequent form of this disorder, which is seen in more than 90% of the cases, is the 
mutation in 21-hydroxylase. Steroid 21-hydroxylase (also termed as CYP21 or P450c21) 
is a cytochrome P450 enzyme located in the cellular endoplasmic reticulum. It converts 
17-hydroxyprogesterone to 11-deoxycortisol, the precursor of cortisol, in the zona 
fasciculata. In patients with 21-hydroxylase deficiency, cortisol and aldosterone 
synthesis is impaired. The adrenal cortex is stimulated by an elevated level of 
corticotropin, and the production of adrenal androgens (DHEA) is abnormally increased 
which causes precocious puberty in males and virilisation in females. Mineralocorticoid 
deficiency causes salt wasting. For example, females with severe and classical CAH 
produce excessive androgens prenatally and are born with external ambiguous virilized 
genitalia. Male patients with CAH suffer from premature puberty. Three quarters of the 
patients are unable to secrete sufficient aldosterone to maintain homeostatic sodium 




Direct detection of genetic mutations allows the prenatal diagnosis and treatments of 
affected female fetuses to minimize the possibility of genital virilization. Moreover, 
affected children can be identified by neonatal screening of hormones prior to the 
development of salt-wasting crises, which could reduce the severity and mortality of this 
disease. The primary types of clinical treatments are glucocorticoid and 
mineralocorticoid replacements. Currently more novel and effective treatments are being 
developed including genetic and cellular therapies (Speiser and White, 2003; White, 
2001). 
 
1.6.4 Adrenal Hypoplasia Congenita (AHC) 
Adrenal Hypoplasia Congenita (AHC), resulting from a primary adrenocortical disorder, 
has an annual incidence of 1:12,000 births (Stewart 2011). AHC has two distinct forms: 
1) a miniature adult form, which is characterized by a small adrenal, no fetal zone and 
early death normally within the first few days after birth; 2) a cytomegalic form, which 
is only present in males and characterized with a larger adrenal, a persistent fetal zone 
after birth, the delayed puberty and vacuolated adrenocortical cells. AHC is believed to 
be associated with mutations in SF-1 or DAX1, although 40% of the patients have a 

















Gene/enzyme CYP21 CYP11B1 CYP11B2 CYP17 HSD3B2 StAR 
Alias P450c21 P450c11 P450aldo P450c17 3β-HSD  
Subtype Classic Non-classic      
incidence 1:14,000 1:500 1:100,000 Rare Rare Rare Rare 
        
Hormones        
Glucocorticoids ↓ nl ↓  ↓ ↓ ↓ 
Mineralocorticoids ↓  in SW nl ↑ ↓ ↑ ↓ ↓ 
Androgens ↑ ↑   ↓ ↓ ↓ 
        
Oestrogen     ↓ ↓ ↓ 
↑ Metabolites + 17-OHP + 17-OHP DOC, S B, 18-OHB DOC, B DHEA, 17∆
5
Preg None 
        
Clinical signs        
Ambiguous genitalia ♀  ♀  ♂ Severe in ♂, mild in ♀ ♂ 
Salt wasting crisis + in SW   +  + + 
Hypertension   +  +   
Na balance ↓ in SW nl ↑ ↓ ↑ ↓ ↓ 
K balance ↓ in SW nl ↓ ↑ ↓ ↑ ↑ 
Symbols:  + = present; ↓ = reduced quantity; ↑ = increased quantity; ♂ = male; ♀ = female. Abbreviations: nl = normal; SW = 
salt-water; P450 = cytochrome P450; 17-OHP = 17-hydroxyprogesterone; DOC = deoxycorticosterone; S = 11-deoxycortisol; 








1.6.5 Adrenocortical tumors 
Adrenocortical neoplasms of heritable and spontaneous types are common in human and 
some domestic species ranging from benign masses to adrenocortical carcinoma (ACC). 
Benign tumors are relatively common while ACC, albeit rare, are highly malignant. The 
prognosis of ACC is extremely difficult and often requires unilateral or bilateral 
adrenalectomy (Kim et al., 2009). Although the origin of adrenocortical tumors remains 
unknown, extensive analysis of tumor specimens indicates that the vast majority of cases 
of adrenocortical tumorigenesis involve both genetic and epigenetic mutations. Genetic 
changes include chromosomal alterations and aberrant telomere which accumulate 
during the tumor progression. Epigenetic changes result in increased proliferation and 
unstable phenotypic plasticity of adrenal progenitor cells. So far, the origin and 
transformation of adrenocortical tumors have been suggested to stem from a mutated 
adrenocortical cell or from the altered putative progenitor cells (Kim et al., 2009). 
Mutations in either cell-surface factors or their downstream effectors have been 
hypothesized to account for the occurrence of ACC. Oncology might to some degree 
recapitulate ontogeny in the adrenal cortex as in other tissues. Key transcriptional factors 
or signaling pathways involved in embryonic adrenal development and functional cell 
maintenance are often identified as being dysregulated in adrenocortical tumors. Hence a 
better understanding of signaling pathways and factors is required to exploit targeted 







1.7 Aim and hypothesis 
In mammals, the adrenal cortex secretes steroid hormones which arise from 
morphologically distinct zones that exhibit specialization of steroidogenesis. However, 
the underlying cellular mechanisms controlling the zonal development and postnatal 
maintenance of the definitive mouse adrenal cortex are incompletely defined. There are 
two distinct issues that need to be considered: a) the developmental origin of the 
definitive adrenal cortex and the establishment of functionally distinct zones and b) the 
mechanism through which the zones are replenished in the adults. The underlying theme 
of the present thesis is the development of techniques and genetic tools to identify the 
origins and fate of adrenocortical stem/progenitor cells as they relate to the maintenance 
of the definitive adrenal cortex.  
Cyp11b2 and Cyp11b1 are highly homologous genes and are physically close to each 
other. Although Cyp11b1 and Cyp11b2 are expressed in different cell types and encode 
distinct steroidogenic enzymes for different steroid production, these two genes might be 
regulated coordinately as a single genetic locus. Their expressions are determined by an 
unknown unique molecular mechanism at a critical point during progenitor cell 
differentiation to become zG or zF cells. Furthermore, there may exist plasticity or 
reversibility of Cyp11b1 and Cyp11b2 expressions within the genetic locus allowing one 
cell type to convert into the other.  
BrdU labeling in combination with histochemical markers provide one avenue to 
examine these hypotheses, which can also be verified by pilot studies undertaken with 
genetically-labelled mouse adrenal tissues or cells. The advantage of using mice is that 
many of the disease processes mentioned above have been modelled genetically in this 
species. The disadvantage is that the physical location and the fate of adult stem cells are 
not well defined in the mouse adrenal cortex. A primary requirement for these studies is 




expressed in a mutually exclusive pattern in zona fasciculata and glomerulosa cells 
respectively, a visual method of monitoring their independent expression levels would 
offer a convenient approach to the analysis of differentiation states of adrenocortical 
cells. In previous studies a mouse model of congenital adrenal hyperplasia has been 
developed by substituting part of the coding region of Cyp11b1 with a gene for a 
fluorescent protein (Mullins et al., 2009). This protein is expressed in a zona fasciculata-
specific manner within the mouse adrenal cortex. In a similar way a fluorescent marker 
for Cyp11b2 can be introduced. These independent markers for Cyp11b1 and Cyp11b2 
will identify the state of differentiation of an adrenocortical cell after cell proliferation. 
The main aims of the work reported in this thesis are: 
1) To analyse the acute and chronic effects of adrenal stimulations on the proliferation, 
distribution and fate of progenitor cells in the mouse adrenal cortex. Mouse 
adrenocortical progenitor cells are hypothesized to be located in the outer adrenal 
cortex. The mechanisms by which these progenitor cells proliferate in response to 
physiological and pathophysiological stimulation and differentiate into functionally 
different steroidogenic cells within the adrenal cortex is not known. 
2) To engineer a BAC construct of the mouse Cyp11b1/Cyp11b2 locus in which each 
gene is marked with an independent fluorescent reporter, allowing their expression 
pattern to be monitored. This construct will include promoter regions of both genes. 
Monitoring the differential expression of fluorescent reporters of Cyp11b2 and 
Cyp11b1 will facilitate investigations of the endogenous control of Cyp11b1 and 
Cyp11b2. 
3) To study the mutual and differential controls of fluorescent protein expression in 
adrenocortical cells in vitro and in vivo. By transfecting adrenocortical cell lines with 
the BAC construct, it should be possible to relate control of steroidogenesis with 
changes in gene expression. Genetically modified mice will be created in which the 
BAC construct is incorporated as a transgene or by homologous recombination of 




Cyp11b1 and Cyp11b2 in these mice should give greater insight of the critical 
mechanisms whereby the adrenal cortex is zoned into functionally distinct and 






Chapter 2-Materials and Methods 
 
2.1 Materials 
2.1.1 Chemicals and solvents 
Sigma (Sigma-Aldrich Company Ltd., Poole, U.K.) and BDH (BDH Laboratory 
Supplies, Poole, U.K.) supplied the chemicals, alcohols, acids and solvents which were 
of analytical quality. Bovine Serum Albumin (BSA, fraction V) and dimethyl sulphoxide 
(DMSO) were from Sigma. Phenol solution and TRIzol
 
reagent were from Invitrogen 
(Invitrogen Ltd., Paisley, U.K.); Phenol was redistilled and buffered with Tris-HCl to pH 
7.9. Agarose was purchased from Biowhittaker Molecular Applications, Inc. 
(Wokingham, U.K.) Oligodeoxynucleotide primers were from Eurofins MWG Biotech 
(Ebensburg, Germany). Radioisotopes were purchased from Millipore (Millipore, 
Molsheim, France). Kodak X-OMAT XAR-5 autoradiography films were supplied by 
Carestream Health Inc. (Rochester, NY, USA).  
 
2.1.2 Solutions 
Milli-Q deionized water (Millipore, Molsheim, France) was used to prepare all stock 
solutions which were autoclaved as required before use. Diethyl pyrocarbonate (DEPC, 








All restriction endonuclease enzymes and β-agarase were supplied by NEB (New 
England Biolabs, Hichin, UK) or Roche (Roche Diagnostics, GmbH, Mannheim, 
Germany). Taq DNA polymerase was from Thermo Fisher Scientific (Epsom, Surrey, 
UK), Phusion Hot Start DNA polymerase was from Finnzymes (Espoo, Finland), and 
Pfx DNA was from Invitrogen Ltd. T4 ligase, T4 kinase and Klenow enzyme were 
purchased from Promega (Southampton, UK). DNase-free RNase A and Proteinase K 
were from Sigma. BP clonase™ II and LR clonase™ II Plus enzyme mix were included 
in the MultiSite Gateway
®
 Pro kit from Invitrogen. Superscript II reverse transcriptase 
was from Invitrogen. RNase inhibitor and RQ1 RNase-free DNase were from Ambion 
(Huntingdon, U.K.) All the enzymes were stored and used according to manufacturers’ 
instructions. 
 
2.1.4 Reagents and buffers 




Table 2.1. General reagents and buffers 
Reagents and buffers Recipes Uses 
Luria Bertani (LB) 
medium 
0.5% (w/v) yeast extract, 1% (w/v) 
tryptone, 1% (w/v) NaCl, pH was 




0.5% (w/v) yeast extract, 2% (w/v) 
tryptone, 0.05% (w/v) NaCl, 2.5 mM 
KCl, pH was adjusted to 7.0 with 5 M 
NaOH, 10 mM MgCl2, add glucose to 







25 mM Tris-HCl pH8.0, 10 mM EDTA, 











147.21 g potassium acetate and 57.5 ml 
glacial acetic acid per 500 ml (i.e.  final 




TAE buffer (50X 
stock, Tris acetate) 
242 g Tris base, 57.1 ml glacial acetic 
acid and 100 ml 0.5 M EDTA (pH to 
8.0) per liter  
agarose gel 
electrophoresis 
TBE buffer (10X 
stock, Tris borate) 
108 g Tris base, 55 g boric acid, and 40 
ml 0.5 M EDTA (pH to 8.0) per liter 
pulse field gel 
electrophoresis 
(PFGE) 
6X DNA loading 
dye 
0.25% (w/v) bromophenol blue, 0.25% 
(w/v) xylene cyanol, 40% (w/v) sucrose 
load DNA samples to 
wells of agarose gels  
TE buffer 10 mM Tris pH8.0, 1 mM EDTA DNA reconstitution 
4% PFA 
4% (w/v) paraformaldehyde in PBS, 
adjust pH to 7.6 with 5 M NaOH   







137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 2 mM KH2 PO4 




10 mM Tris Cl pH7.6, 0.1 mM EDTA, 
100 mM NaCl 
DNA microinjection 
Lysis buffer 
10 mM Tris-HCl, pH 7.5, 10 mM 
EDTA, 10 mM NaCl, 0.5 % (w/v) SDS, 
filter to sterile  
preparation of 
genomic DNA from 
mammalian cell lines 
Tail buffer 
50 mM Tris pH8.0, 100 mM EDTA, 
100 mM NaCl, 1% (w/v) SDS 
preparation of 
genomic DNA from 
animal tissues 
Saturated NaCl 






0.25 M HCl 




0.5 M NaOH,  1.5 M NaCl 





1.5 M NaCl, 0.5 M Tris pH7.2, 1 mM 
EDTA 
gel treatment before 
transfer 
Southern blot:        
20X SSC 
175.3 g NaCl and 88.2 g sodium citrate 
per liter, adjust pH to 7.0 with citrate 
acid 
DNA transfer from gel 
to membrane blot 
Southern blot:   
Church & Gilbert 
pre-hybridization  
0.25 M Na2HPO4, 1 mM EDTA, 7% 
SDS 
membrane pre-
treatment for southern 
blotting 
 
Southern blot:   
Church & Gilbert 
wash solution 1 
 
20 mM Na2HPO4, 1 mM EDTA, 5% 
SDS 
 







Southern blot:  
Church & Gilbert 
wash solution 2 
20 mM Na2HPO4, 1 mM EDTA, 1% 
SDS 





1% (w/v) SDS, 0.1XSSC, 40 mM Tris 
pH7.6 
stripping probes from 
membranes 
 
2.1.5 Bacterial strains 
DH5α and DH10B were Escherichia coli (E. coli) strains obtained from Life 
Technologies, Inc. (Invitrogen, Paisley, U.K.). DY380 was a genetically-modified 
DH10B bacterial strain (Lee et al., 2001). One Shot
® 
Mach1™ T1R E. coli strain was 
included in the MultiSite Gateway
®
 Pro kit from Invitrogen.  
Table 2.2. Genotype of E.coli bacterial strains 
Strain Genotype 
Use and Optimal 
Incubation Temperature 
DH5α 
F– Φ80lacZΔM15 Δ(lacZYA-argF) U169 
recA1 endA1 hsdR17 (rK–, mK+) phoA 
supE44 λ– thi-1 gyrA96 relA1 
general vector host, 
37°C 
DH10B 
F– mcrA Δ(mrr-hsdRMS-mcrBC) 
Φ80lacZΔM15 ΔlacX74 recA1 endA1 
araD139 Δ(ara leu) 7697 galU galK rpsL 
nupG λ– 
BAC and PAC host, 
37°C 
DY380 
F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80dlacZ 
M15 ΔlacX74 deoR recA1 endA1 araD139 
Δ(ara, leu) 7649 galU galK rspL nupG 
[ λcI857 (cro-bioA) <> tet] 





F– Φ80lacZΔM15 ΔlacX74 hsdR(rK–, mK+) 
ΔrecA1398 endA1 tonA 









Ampicillin, chloramphenicol and kanamycin were obtained from Sigma. Hygromycin B 
and zeocin were purchased from InvivoGen (San Diego, CA, USA). The stock 
concentrations and working concentrations of these antibiotics for bacterial cells are 
indicated in Table 2.3. 
Table 2.3. Selection concentrations of antibiotics 




Selection of BACs in 
DH10B/DY380 cells 
Ampicillin 
100 mg/ml in dH2O, sterilised 
by filtering through 0.2μm 
sterilizing filter, stored at -
20°C 
100 μg/ml 50 μg/ml 
Chloramphenicol 
25 mg/ml in 100% ethanol, 
sterilised by filtering through 
0.2μm sterilizing filter, stored 
at -20°C 
25 μg/ml 12.5 μg/ml 
Kanamycin 
25 mg/ml in dH2O, sterilised 
by filtering through 0.2μm 
sterilizing filter, stored at -
20°C 
50 μg/ml 25 μg/ml 
Hygromycin B 
Commercial solution (ant-
hm-1, InvivoGen), 100 mg/ml 
in HEPES buffer stored at -
20°C 
200 μg/ml 100 μg/ml 
Zeocin 
Commercial solution (ant-zn-
1, InvivoGen), mg/ml in 
HEPES buffer stored at -20°C 






2.1.7 Cloning vectors 
Living colour vectors pEGFP-N1 and pmCherry-N1 were obtained from Clontech 
(Basingstoke, U.K.). Plasmids (pAS5’Kan3’, Pas5’Zeo3’, 11BKO-hygro BAC, p2A-
mCherry-pA and p2A-EGFP-pA) were provided by Dr. Linda Mullins in Molecular 
Physiology group. ASBAC vector was a kind gift from Prof. K. Parker.  
 
2.1.8 Commercial kits 
Commercial kits used and their suppliers are indicated in Table 2.4. 
Table 2.4. Commercial kits 
Commercial kit Supplier Use 
GenElute™ HP Plasmid MaxiPrep 
kit 
Sigma 
preparing plasmid DNA 
from bacterial host cells 
Nucleobond BAC100 kit 
Macgerey-Nagel, 
Germany 
preparing BAC DNA 
from bacterial host cells 
Gel DNA Recovery Kit Anachem, UK 
recovering DNA from 
agarose gel 
MultiSite Gateway® Pro Kit Invitrogen 
generating expression 
vectors 
RNeasy Mini Kit 
Qiagen (Crawley, 
U.K.) 
preparing RNA from 
cells or tissues 
Superscript II Reverse 
Transcription Kit 
Invitrogen 
making cDNA from 
RNA samples 
ImmPRESS™ Anti-Mouse Ig 
(peroxidase) Polymer Detection Kit 
Vector Laboratories, 
Burlingame, CA 
second antibody for a 
detection system in IHC 
ImmPRESS™ Anti-Rabbit Ig 
(peroxidase) Polymer Detection Kit 
Vector Laboratories, 
Burlingame, CA 
second antibody for a 





Various antibodies were used for immunohistochemistry (IHC), Immunofluorescence 
(IF), Immunocytochemistry (ICC) and enzyme-linkage immunoabsorbent assay (ELISA) 
experiments. The supplier information and the working dilution of antibodies were listed 
in Table 2.5. 
Table 2.5. Suppliers and working dilutions of antibodies   
Antibody Supplier/Reference Working Dilution 
mouse anti-11β-hydroxylase 
monoclonal 
Gift from Celso Gomez-Sanchez 
(1A4) (Wotus et al., 1998) 
1:8,000 for IHC 
rabbit anti-aldosterone 
synthase polyclonal 
Gift from Celso Gomez-Sanchez 
(Ab2085) (Wotus et al., 1998) 
1:100 for IHC 
mouse anti-ki67 monoclonal NCL-Ki67-MM1, Novocastra 1:200 for IHC 
sheep anti-BrdU polyclonal 20-BS17, Fitzgerald Industries 1:2,000 for IHC 
mouse anti-Oct4 
monoclonal 
C10, Santa Cruz Biotechnology 1:800 for ICC 
rabbit anti-GFP polyclonal A11122, Molecular Probes 
1:500 for IHC 
1:200 for ICC 
sheep anti-aldosterone 
polyclonal 
Gift from Emad Aldujaili (Al-
Dujaili et al., 2009b) 
1:15,000 for ELISA 
rabbit anti-corticosterone 
polyclonal 
Gift from Emad Aldujaili (Al-
Dujaili et al., 2009a) 






2.1.10 DNA markers 
All DNA markers were purchased from NEB, including 1 kb DNA ladder, 100 bp DNA 
ladder, 2-log DNA ladder, LMW (low molecular weight) DNA ladder, Midrange I and 
Midrange II PFG makers (Table 2.6, Fig. 2.1).  
Table 2.6. The size of each band in DNA markers 
DNA Marker Band Size 
1 kb DNA ladder 0.5, 1, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0, 10.0 kb 
100 bp DNA ladder 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1200, 1517 bp 
2-log DNA ladder 
0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.2, 1.5, 2.0, 3.0, 4.0, 
5.0, 6.0, 8.0, 10.0 kb 
LMW DNA ladder 25, 50, 75, 100, 150, 200, 250, 300, 350, 500, 766 bp 
Midrange I PFG 
marker 
15.0, 33.5, 48.5, 63.5, 82.0, 97.0, 112.0, 130.5, 145.5, 160.5, 
179.0, 194.0, 209.0, 227.5, 242.5, 257.5, 276.0, 291.0 kb 
Midrange II PFG 
maker 
24.0 & 24.5, 48.5, 72.5 & 73.5, 97.0, 121.0 & 121.5, 145.5, 169.5 
































Fig. 2.1. Electrophoresis of DNA markers showing distinct bands of 
various sizes  
A, 1 kb DNA ladder; B, 100 bp DNA ladder; C, 2-log DNA ladder; D, LMW DNA 





2.1.11 Tissue culture 
Cell cultures were maintained in a Hera Cell Incubator (Heraeus Instruments GmbH, 
Hanau, Germany) in a humidified environment with 5% CO2 at 37°C. Manipulation 
procedures were performed inside a laminar flow hood (Hera Safe Culture Hood, 
Heraeus). All surfaces inside the hood and all materials to be put inside the hood were 
sprayed with 70% (v/v) ethanol (BDH) before use to prevent bacterial and fungal 
contamination. 
Tissue culture plasticware was purchased from Corning (Corning Life Sciences, Corning, 
NY) and IWAKI (Aberbargoed, Mid-Glamorgan, U.K.). Gibco-BRL (Life Technologies 
Ltd., Paisley, U.K.) provided most of the tissue culture reagents including Dulbecco’s 
modified Eagle’s Ham’s F12 (DMEM/F12, 1:1) medium, Knockout DMEM™, 
Dulbecco’s Minimal Essential Medium Nutrient Mix F12K medium, α-MEM, 




, Hank’s Balanced 
Salt Solution (HPSS), and GlutaMax™-I. Heat-inactivated horse serum, heat-inactivated 
FBS, LIF for ES cell growth, non-essential amino acids (NEAA), L-glutamine and 
trypsin-EDTA were also from Gibco-BRL. DMSO, β-mercaptoethanol, gelatin, collagen 
Type IV, retinoic acid, forskolin, ACTH and cAMP were obtained from Sigma. Fetal 
bovine serum (FBS) for mouse ES cell culture was supplied by Hyclone (Logan, Utah, 
U.S.A.). NuSerum™ and ITS Plus (Insulin +Transferrin +Selenium) were supplied by 
BD Sciences (Bedford, MA, U.S.A.). 
 
2.1.12 Mouse strains and husbandry 
All mice used in this PhD project were housed and bred at the Biomedical Research 
Resource facility, Chancellor’s Building, the University of Edinburgh. They were ear-
notched for identification by genotyping. The maintenance, breeding and experimental 
studies of mice were performed with the project licence held by Professor John Mullins 




maintained in a stabilised environment with free access to water and food with 12hr 
light/dark cycles, and they were fed with commercial standard mouse chow purchased 
from Special Diets Services (Witham, U.K.). 
The C57BL/6 inbred mouse strain was used in all the animal experiments, and the 
oocytes for pronuclear microinjection procedures to generate transgenic founders were 






All the standard manipulation methods of nucleic acids described in this chapter were 
performed according to the Molecular Cloning Laboratory Manual (Sambrook et al., 
1989). All the commercial experimental kits and reagents were used in accordance with 
the manufacturers’ instructions and data sheets.  
 
2.2.1 DNA preparation 
2.2.1.1 Alkaline lysis method for High-copy plasmid/ low-copy BAC DNA 
minipreps 
A single bacterial colony was inoculated in 5 ml of LB medium containing the 
appropriate concentration of required antibiotics (Table 2.3) and was grown in a constant 
shaker (Innova 4000 Incubator Shaker, New Brunswick Scientific, Jencons-PLS, 
Leighton Buzzard, U.K.) at 200 × g  overnight (~16 hr). The incubation temperature 
varied according to bacterial host strains: 37°C was optimal for DH5α and DH10B 
strains and 32°C was used for DY380 strain. The cultured bacterial cells were spun 
down at 12,000 × g for 5 min in a microcentrifuge (Biofuge Pico, Heraeus). The 
supernatant was discarded and the pellet was votexed in 250 μl of ice-cold resuspension 
solution supplemented with 100 μg/ml RNase A. After resuspension, 250 μl of lysis 
solution was added and mixed thoroughly by inverting the tubes 5 times; the mix was 
left at room temperature (RT) for no more than 5 min. Then 250 μl of ice-cold 
neutralisation solution was added to the viscous bacterial lysate and mixed well by 
inverting the tubes, and left on ice for 10 min. The mixture became clear as white cell 
precipitate formed. Tubes were centrifuged for 20 min at 12,000 × g at 4°C to pellet 
down the cell debris and chromosomal DNA. The clear supernatant (~700 μl) containing 
desired plasmid or BAC DNA was then transferred to a new 1.5 ml microfuge tube. 500 
μl isopropanol was added, mixed by inversion, and then centrifuged at 12,000 × g for 30 




1 hour. Then 5 μl of 10 mg/ml RNaseA (Roche) was added, and tubes were mixed and 
incubated at 37°C for 1 hour. DNA was then extracted with the phenol-chloroform 
extraction method: 300 μl of phenol was added to RNaseA-treated DNA sample with 
mixing on a rotator for 15 min before centrifugation at 12,000 × g for 3 min at RT; the 
aqueous phase was transferred to a fresh tube and 300 μl of phenol: chloroform: isoamyl 
alcohol (25:24:1) was added with mixing on a rotator for 15 min before centrifugation at 
12,000 × g for 3 min; the aqueous phase was transferred to a fresh tube and 300 μl of 
chloroform: isoamyl alcohol (24:1) was added before mixing on a rotator for 15 min and 
centrifugation at 12,000 × g for 3 min. The aqueous phase was transferred to a fresh tube, 
and DNA was precipitated by adding 600 μl of 100% ethanol with mixing by inversion. 
Samples were incubated at -20°C for 20 min, and then centrifuged at 4°C for 20 min at 
12,000 × g. The DNA pellet was washed in 70% ethanol, and spun again. The DNA 
pellet was air dried at RT for 10 min and then resuspended in 50 μl of TE buffer. The 
prepared plasmid or BAC DNA was ready for downstream applications and was kept at 
-20 °C or -80°C for long-term storage. 
 
2.2.1.2 Spin Column method for High-copy plasmid DNA minipreps and 
maxipreps 
Minipreps or maxipreps for plasmid DNA were performed with GenElute™ HP Plasmid 
MiniPrep or MaxiPrep kit from Sigma (see Table 2.4) following the manufacturer’s 
instructions. 3 ml of plasmid-containing E.coli (minipreps) or 200 ml of plasmid-
containing E.coli (maxipreps) was cultured overnight (~16 hours) at 37°C with required 





2.2.1.3 Low-copy BAC DNA purification (NucleoBond BAC 100 Kit) 
BAC DNA was a kind of low-copy plasmids. 250-500 ml of overnight culture was 
inoculated with appropriate antibiotic selection. The BAC DNA preparation was 
performed using NucleoBond BAC 100 Kit (see Table 2.4) according to manufacturer’s 
instructions. A column chromatography step was included to purify BAC DNA. 
 
2.2.1.4 Genomic DNA preparation from mouse ear notches  
Ear notch samples were collected from mouse pups at weaning, placed in sterile 1.5 ml 
microfuge tubes and kept at -20°C for genomic DNA extraction. The ear sample was 
digested with 100 μl of Tail Buffer and 6 μl of 10 mg/ml Proteinase K overnight (12-18 
hr) at 55°C. 4 μl of 20 μg/ml RNase A was added and mixed well before one-hour 
incubation at 37°C. The RNase A-treated sample was extracted with phenol-chloroform 
method as described in Section 2.2.1.1. Genomic DNA was precipitated by adding 100 
μl of isopropanol or 200 μl of 100% ethanol. Alternatively, genomic DNA was 
precipitated directly from the RNase A-treated sample without phenol extraction by 
adding 50 μl of saturated NaCl, and after vortexing, 300 μl of 100% ethanol was added 
to the milky mixture to precipitate DNA. After centrifugation at 12,000 × g for 20 
minutes at 4°C, DNA pellets were washed with 100 μl of 70% ethanol followed by a 
further spin for 10 min at RT. The genomic DNA pellet was air dried at RT for 10 min 
and then resuspended in 50 μl of TE buffer overnight at 4°C. The genomic DNA 
samples were stored at -20°C. 
 
2.2.1.5 Genomic DNA preparation from tissue samples  
Approximately 20 mg of the mouse tissue samples (tail, spleen, liver, kidney or ovary) 
were dissected with sterile scissors, and digested with 600 μl of Tail Buffer and 35 μl of 




added and mixed well before incubation at 37°C for 1 hr. The RNase A-treated sample 
was extracted with phenol-chloroform method as described in Section 2.2.1.1. The 
genomic DNA pellet was precipitated and resuspended following the same method 
described in Section 2.2.1.4.  
 
2.2.1.6 Genomic DNA preparation from mammalian cell lines  
When cells in 6-well plates reached confluence, they were trypsinised and centrifuged at 
1,000 × g for 5 min. The cell pellet could be kept at -80°C for further use. Starting with 
1x10
6 
cells, 300 μl of Lysis buffer and 30 μl of 10 mg/ml Proteinase K were added to the 
cell pellet and the mixture were incubated at 55°C in a rotation rack overnight (12-18 hr). 
The digestion mixture were treated with 20 μl of 20 μg/ml RNase A at 37°C for 1 hr. 
DNA was extracted by mixing with 150 μl of saturated NaCl, and was precipitated with 
900 μl of 100% ethanol. DNA was pelleted by centrifugation at 12,000 × g for 30 min at 
4°C, and then washed in 300 μl of 70% ethanol with a further spin for 10 min at RT. The 
genomic DNA pellet was allowed to air dry at RT for 10 min, and resuspended in 50 μl 
of TE buffer overnight at 4°C. The genomic DNA samples were stored at -20°C. 
 
2.2.2 DNA manipulation and modification 
2.2.2.1 Restriction digestion of DNA 
Generally, restriction endonucleases from NEB or Roche were used to digest DNA. The 
choice of buffer and incubation temperature varied from one enzyme to another. To 
reduce the star activity of restriction endonucleases, DNA was digested with no more 
than 10% (v/v) enzyme. Typically reactions were performed at 37°C for 1-16 hr 
depending on the amount and type of DNA to be digested and depending on the purpose. 
The enzyme reaction was stopped by heat inactivation at 65°C for 20 min. When double 




the same time if there was a compatible buffer or sequentially if not. After digestion 
with the first enzyme, the enzyme was inactivated, and DNA was precipitated and 
resuspended in nuclease-free water before adding the second enzyme. The efficiency of 
DNA restriction digestion was checked by DNA electrophoresis (see Section 2.2.3.2). 
 
2.2.2.2 Ligation of DNA fragments 
T4 DNA ligase from Promega was used for DNA ligation for blunt-ended and sticky-
ended cloning, and the ligations were performed according to the manufacturer’s 
instructions. The ratio of vector: insert for each reaction was optimised first. The ligation 
reaction was incubated at 16°C for 2-16 hr. Blunt-ended cloning required a longer 
incubation time than sticky-ended cloning. After ligation, the reaction mixture was 
transformed into chemically-competent E.coli cells (see Section 2.2.4.2) to check the 
ligation efficiency. 
 
2.2.2.3 DNA sequencing 
The DNA sequencing service was provided by the Medical Research Council (MRC) 
Protein Phosphorylation Unit in the University of Dundee. DNA templates and 
sequencing primers were prepared according to instructions at 
http://www.dnaseq.co.uk/products.html. Sequencing results were analysed with the 
program Chromas 2.33 (Technelysium Pty Ltd). Sequences were aligned using BLAST 






2.2.2.4 Recovery of DNA fragment from agarose gels 
Bands of different sizes were separated after gel electrophoresis (see Section 2.2.3.2). 
Bands of interest were visualized under UV light, excised with a scalpel blade and 
transferred to a microfuge tube. DNA of interest was extracted with Gel DNA Recovery 
Kit (ANACHEM, UK) according to manufacturer’s instructions.  DNA fragments were 
stored at -20°C for downstream molecular applications. 
 
2.2.2.5 Recovery of large DNA fragments by agarase digestion 
Commercial DNA recovery kits were not suitable for the isolation of large DNA 
fragments. Instead, β-agarase I from NEB was used to digest agarose releasing trapped 
DNA in the agarose gel slice. The optimal temperature for β-Agarase I activity is 42°C, 
so only low melting point agarose was suitable for digestion. DNA fragments were 





Lonza, Rockland, ME, U.S.A.). Excised bands were equilibrated twice in the fresh 1X β-
agarase I buffer d for 30 min at 4°C. The remaining buffer was discarded, and the gel 
slice was weighed. One volume of 1X β-agarase buffer was added, and the gel sample 
was melted completely at 65°C for 10 min with mixing. The molten agarose sample was 
cooled to 42°C, and incubated with 1 U β-Agarase I per 200 μl of agarose sample. This 
procedure was used to digest up to 200 µl of 1% low melting point agarose, and the 
amount of enzyme was adjusted accordingly for larger volumes of agarose sample. After 
incubation at 42°C for 2 hr, molten samples were centrifuged at 12,000 × g for 5 min to 
remove any undigested agarose monomer. The supernatant was then carefully 
transferred to a fresh microfuge tube, and centrifuged again for 10 min. The supernatant 
was cooled on ice to check if the agarase treatment had been successful. The extracted 




2.2.2.6 DNA fragment preparation for pronuclear microinjection 
The DNA fragment for pronuclear microinjection was isolated as described in 2.2.2.5 
and then dilaysed against microinjection buffer for two hours at RT. Aliquots (100 µl) of 
extracted clean DNA sample was placed on a Millipore 0.05μm filter which was floating 
in a sterile large Petri dish filled with microinjection buffer. The dialysed DNA samples 
were collected into sterile microfuge tubes. DNA integrity was checked by 
electrophoresis and dialysed DNA sample was compared with a similar quantity of 
unlinearised DNA. DNA concentration was measured by Nanodrop spectrophotometry. 
Dialysed DNA fragments for further pronuclear microinjection procedures should be 
acceptable in terms of concentration and integrity. 
 
2.2.3 DNA detection 
2.2.3.1 Quantitation of nucleic acids  
The concentration of DNA or RNA was assessed with the Nanodrop spectrophotometer 
(Thermo, Wilmington, USA). 2 μl of ddH2O was used to normalize the machine and to 
make initial blank measurements. Then 2 μl of DNA or RNA sample was loaded to the 
surface of the apparatus and was then rapidly measured. The OD260:OD280 ratio, 
OD260:OD230 ratio and the concentration of the sample were calculated automatically. 
 
2.2.3.2 Agarose gel electrophoresis  
DNA molecules were separated on 0.8-2% (w/v) agarose gels (SeaKem LE). The 
percentage of agarose was chosen according to the sizes of DNA fragments to be 
separated. Gels were made using electrophoresis-grade agarose in 1X TAE buffer with 
ethidium bromide (0.5μg/ml). Electrophoresis was performed in 1X TAE buffer using a 




EPS-301 (Amersham Pharmacia Biotech). The speed of electrophoresis was generally 1-
3 V/cm. Typically DNA samples and DNA markers were loaded with 6X loading dye. 
DNA in the agarose gel was visualised under a UV light box (302nm, UVP 
Transilluminator TM36, UVP Inc., San Gabriel, CA). The images were captured with a 
Kodak EDAS 290 digital camera system and analysed with Kodak Scientific Imaging 
System Software (Eastman Kodak Company, Rochester, New York, U.S.A.). 
 
2.2.3.3 Pulse-field gel electrophoresis 
The apparatus for Pulse field gel electrophoresis (PFGE) was supplied by Bio-Rad (Bio-
Rad Laboratories, Inc., Hemel Hempstead, U.K.). Typically 0.8-1% agarose gel 
(SeaKem LE) without ethidium bromide was made with 0.5X TBE buffer. DNA 





 agarose, Lonza, Rockland, ME, U.S.A.) and loaded into the 
slots in the gel and allowed to set at RT. The horizontal level was adjusted to correct 
angle for the gel cast. Either PFG I midrange or PFG II midrange DNA markers (see Fig. 
2.1) were loaded for every gel. Gels were run in 0.5X TBE buffer with cooling (14°C) 
by a Cooling Module and with buffer circulated by a pump of variable speed normally 
set to 60-70. PFGE gels were typically run at 6 V/cm for 22 hr with a pulse time of 1-20 
sec (Chet DRII Drive Module). If appropriate, DNA in PFGE gel after running was post-
stained in ethidium bromide-containing 0.5X TBE buffer and visualised under UV light. 
 
2.2.3.4 Oligodeoxynucleotide primer design 
Optimal oligodeoxynucleotide primer pairs for input DNA were designed with a widely 
used online program Primer3: http://frodo.wi.mit.edu/. Another online program 
OligoAnalyzer 3.1 was used to analyse the primers checking for possible hairpin, self- 




(Integrated DNA Technologies, Coralville, IA, 
http://eu.idtdna.com/analyzer/Applications/OligoAnalyzer/). NCBI BLAST was used to 
check the specificity of primers. 
 
2.2.3.5 Polymerase chain reaction (PCR) 
Polymerase chain reactions (PCRs) were performed with a Veriti
® 
96-well Thermal 
Cycler (Applied Biosystems, Foster City, CA) or a PTC-200 DNA Engine
® 
Peltier 
Thermal Cycler (MJ Research). Several DNA polymerases were used in this study but 
the most common one was Taq DNA Polymerase from Thermo Scientific. The optimal 
choice of DNA polymerase was based on interactions between primer pairs and DNA 
templates, and on the purpose of PCR reactions. A typical PCR amplification cycle 
included denaturation, annealing and elongation steps. The annealing temperature was 
based upon the melting temperature (Tm) of a specific primer pair, which was calculated 
by the online program OligoAnalyzer 3.1 (Integrated DNA Technologies, Coralville, IA). 
The optimal Mg
2+
 concentration varied between 1.5 mM and 5 mM. But in most cases 
an Mg
2+
 concentration of 1.5 mM produced satisfactory results. Normally the amount of 
DNA templates was 10 ng-100 ng for mouse genomic DNA and 0.1 ng - 15 ng for 
plasmid DNA. All solutions were thawed on ice, gently vortexed and briefly centrifuged 
before use. The PCR products were stored at -20°C. 
 
2.2.4 Bacterial cell manipulation 
2.2.4.1 Preparation of chemically-competent E.coli DH5α cells 
Chemically-competent E.coli DH5α cells were prepared using ice-cold CaCl2. A single 
fresh DH5α colony was inoculated into 5 ml of LB medium without antibiotics and then 
grown at 37°C overnight in a shaker at 200 × g. The next morning, 100 ml of LB 




cells, and was shaken vigorously at 37°C for 2-3 hr until the Optical Density at λ 600nm 
(OD600) reached 0.4-0.6. DH5α cells were transferred to two pre-chilled 50 ml BD 
Falcon tubes and placed on ice for 10 min. They were centrifuged at 3,000 × g for 15 
min at 4°C in a bench top centrifuge (Megafuge 3.0R, Heraeus). The supernatant was 
discarded and 1 ml of pre-chilled 0.05 M CaCl2 solution was added to resuspend the 
bacteria pellet by gentle pipetting. It was then placed on ice for 30 min and centrifuged 
again as before. The supernatant was discarded and 2 ml of pre-chilled solution 
containing 15% glycerol (v/v) in 0.05 M CaCl2 was added to gently resuspend the pellets. 
The resuspended cells were placed on ice for 10 min and then split as 100 μl aliquots 
into pre-chilled microfuge tubes. The aliquots of chemically-competent cells were frozen 
promptly and stored at -80°C if not to be used immediately. 
 
2.2.4.2 Transformation of chemically-competent bacterial cells 
Chemically-competent bacterial cells were only used for transforming high-copy 
plasmid DNA or DNA ligation mixture. A 100 μl aliquot of chemically-competent cells 
was defrosted on ice for 10 min. 1-10 μl of DNA (≤ 50 ng) was added to the competent 
cells, mixed gently and placed on ice for 30 min. The mixture was then incubated in a 
42°C water bath for exactly 90 seconds and cooled on ice immediately for 2 min. 1 ml of 
SOC medium was added and the transformant was recovered at 37°C with gentle 
shaking for 1-2 hr before plating out on a LB Agar plate with appropriate antibiotic 
selection. 
 
2.2.4.3 Preparation of electrocompetent E.coli DH10B cells 
A single E.coli DH10B colony was inoculated into 5 ml of LB medium without any 
antibiotics and incubated at 37°C overnight. The pre-culture was diluted 1:100 to 




with shaking at 37°C. When OD600 of the E.coli culture reached 0.6, the 250 ml culture 
was chilled on ice for 15 min and split into five pre-chilled 50 ml BD Falcon tubes.  
E.coli cells were centrifuged at 3,000 × g for 15 min at 4°C in a bench top centrifuge. 
The supernatant was discarded and the cell pellet was resuspended in 25 ml of ice-cold 
ddH2O by vortexing. The suspension was spun at 3,000 × g  for 10 min at 4°C, and this 
wash step was repeated. Bacteria pellets from the 5 Falcon tubes were resuspended in 10 
ml of ice-cold 10% (v/v) glycerol in ddH2O by gentle pipetting. These resuspension 
were combined together and centrifuged again for 10 min as before and the supernatant 
was discarded and the pellet was washed again. The final pellet was resuspended in 500 
μl of 10% (v/v) glycerol in ddH2O, and separated into 50 μl of electrocompetent cell 
aliquots on ice. These aliquots were used promptly or frozen immediately at -80°C for 
future use. 
 
2.2.4.4 Transformation of electrocompetent bacterial cells 
Electrocompetent bacterial cells were used for BAC DNA transformation. A 50 μl 
aliquot of cells was defrosted on ice for 10 min. 1-5 μl of DNA (1-5 μg BAC) was 
mixed with cells gently and placed on ice for 10 min before transferring to a pre-chilled 
2 mm gap cuvette. The cuvette was then placed in the chamber of an Easyject 
Electroporation System, and the Electroporation was pulsed using settings described in 
Table 2.7. The cell suspension was resuspended with 1 ml of SOC medium as soon as 
the electroporation pulse was triggered. The transformants were recovered at 37°C (or 
32°C for DY380 strain) with gentle shaking for 1 hr before plating out on a LB Agar 
plate with appropriate antibiotic selection. 
Table 2.7. Settings of electroporator for E.coli transformation 
Cuvette size Voltage Capacitance Resistance 




2.2.5 Mammalian cell culture and manipulations 
2.2.5.1 Cell culture 
All the cell lines used in this study were maintained in 5% CO2 in a humidified Hera 
Cell Incubator (Heraeus) at 37°C. The culture-dish for mouse ES cells was coated with 
0.1% gelatin before cell seeding. Optimal growth conditions and properties of various 
cell lines were described in Table 2.8. 
Table 2.8. Optimal growth conditions and properties of various cell lines 
Cell Line Culture Medium Cell Description 
NCI-H295R 
DMEM/F12 medium + 2.5% NuSerum™  
+ 1% ITS Plus + antibiotics 




DMEM F-12K medium + 2.5% FBS + 
15% horse serum + antibiotics 
Mouse (Mus musculus) 
adrenal tumor cell line  
JM8A3 ES 
Knockout DMEM™ + 15% FBS + 2mM 
GlutaMax™-1 + 1mM NE Amino Acids + 
1,000 U/ml LIF + antibiotics 
Mouse (Mus musculus) 
“Agouti allele-repaired” 
ES cell line with a 
C57BL/6N background 
 
2.2.5.2 Expansion, Freezing and thawing of cell lines 
Generally cells were passaged every 3-4 days when they reached 80% confluency. 
Growth medium was aspirated from the cultured cells. Cells were washed in PBS twice 
and treated with pre-warmed 1-2% Trypsin-EDTA solution (1% for mouse ES cells, 2% 
for other cell lines) to trypsinise the cells (1 ml for 25 cm
2
 Surface Area). Cells were 
then incubated at 37°C for 3-5 min until they detached from the plate. Trypsinisation 
was stopped by adding two volumes of serum-containing medium, and the detached 




then transferred into a sterile 15 ml tube (Corning). The cell suspension was centrifuged 
at 1,000 × g for 5 min at RT (Biofuge Primo, Heraeus). The supernatant media was 
carefully removed by aspiration. The cell pellet was resuspended with 1 ml of pre-
warmed growth medium and seeded into a prepared culture dish as required. Cell 
density was estimated with a hemacytometer (Assistant, Germany) using a Nikon TMS-
F inverted microscope (Jencons-PLS). The growth medium was changed every 2 or 3 
days depending on cell type.  
To freeze cells, cell pellets were resuspended in freshly-made and filtered freezing 
medium (90% growth medium + 10% DMSO). The cell suspension was aliquoted 
(approximately 1x10
6
 cells) into cryovials (NUNC, Corning). The aliquots were frozen 
at -80°C overnight and then stored in liquid nitrogen (Taylor-Wharton K Series 
Cryostorage System, supplied by Jencons-PLS).   
Frozen cells were thawed in a 37°C water bath, and then transferred into a 15 ml tube 
containing 10 ml of warm growth medium. Cells were centrifuged at 1,000 × g for 5 min, 
resuspended and seeded onto plates as described above. The next morning, most of the 
cells had attached to the plate, and the medium was changed to eliminate any traces of 
DMSO. 
 
2.2.5.3 Kill curve determination of Hygromycin B 
1x10
5
 cells were seeded onto six wells of a 6-well plate (Corning), and left to settle 
overnight. The medium was replaced with 2 ml of growth medium containing different 
concentrations of Hygromycin B listed in Table 2.9. The growth medium was changed 
daily to remove the dead cells and the cell viability was monitored. The optimal 
concentration of Hygromycin B was defined as the minimum concentration which could 





Table 2.9. Kill curve of Hygromycin B for various cell lines 
 H295R Y-1 JM8A3 ES 
Concentration 1 50 μg/ml 100 μg/ml 50 μg/ml 
Concentration 2 100 μg/ml 200 μg/ml 100 μg/ml 
Concentration 3 200 μg/ml 400 μg/ml 150 μg/ml 
Concentration 4 300 μg/ml 500 μg/ml 300 μg/ml 
Concentration 5 400 μg/ml 600 μg/ml 400 μg/ml 
Concentration 6 500 μg/ml 800 μg/ml 500 μg/ml 
Optimal Concentration 100 μg/ml 200 μg/ml 150 μg/ml 
 
2.2.5.4 Introduction of foreign DNA into mammalian cells 
2.2.5.4.1 Transient transfection of mammalian cells using Liposome 
Transient transfection of cells was performed with Lipofectamine™ 2000 reagent 
(Invitrogen) following the manufacturer’s instructions. The day before transfection, 1- 2 
x10
5
 cells were seeded onto each well of a 24-well plate (Corning) containing 1 ml of 
growth medium without antibiotics.1 μg of foreign DNA diluted in 50 μl of serum-free 
OptiMEM (Gibco) and 2.5 μl of Lipofectamine™ 2000 reagent diluted in 50 μl of 
serum-free OptiMEM were mixed thoroughly, and incubated at RT for 20 min. This 
DNA/Liposome mix was added to each well of 24-well plate, and cells were incubated 
at 37ºC in a humidified CO2 incubator. Medium was replaced with 1 ml of growth 
medium 4-6 hr later. The transfected cells were maintained for 18-48 hr prior to testing 





2.2.5.4.2 Stable transfection of mammalian cells by electroporation 
Cells growing in a T75cm
2
 flask were washed, trypsinised and counted as described in 
Section 2.2.5.2. Approximately, 8x10
6
 cells were centrifuged again and resuspended in 
780 μl of PBS. 20 μg of linearised and purified transgene DNA (1μg/μl) was mixed 
gently with the cell suspension and incubated at RT for 5 min. The 800 μl mix was then 
transferred to a 4 mm gap cuvette (Bio-Rad) and electroporated using a GenePulser™ 
Xcell electroporator (Bio-Rad). The pulse settings were described in Table 2.10. After 5 
min incubation at RT, the recovered cells were immediately plated onto a 10 cm-dish 
containing 10 ml of warm growth medium without antibiotics and incubated at 37ºC. 
When generating stable-transfected cell clones, medium was replaced with fresh 
selection medium 48 hours after the electroporation. 
Table 2.10. Pulse settings for stable transfection of mammalian cells using 
a GenePulser™ Xcell electroporator 
Cuvette Size Voltage Capacitance Resistance 
4 mm 250 V 500 μF NA 
 
 
2.2.6 RNA preparation and detection 
2.2.6.1 RNA isolation (Trizol Reagent) 
Total RNA was extracted from cultured cells and animal tissues using TRIzol
®
 Reagent 
(Life Technologies, Invitrogen) according to the manufacturer’s instructions. During 
sample homogenization or lysis, TRIzol maintained the integrity of RNA, disrupted cells 
and dissolved cell components.  For cultured cells, 1 ml/well of TRIzol solution was 
added to a 6-well plate (~10
6
 cells / well) to lyse the cells. For tissue RNA extraction, 1 
ml TRIzol /100 mg pre-weighed frozen tissue was added together with a metallic 




disruptor (Hann, Germany). The cell lysate was then homogenized by pipetting several 
times before the addition of 200 μl of chloroform. The mixture was shaked by hand 
vigorously for 15 seconds and left at RT for 3 min. It was then centrifuged at 12,000 × g 
for 15 min at 4°C, and the aqueous phase (~500 μl) was transferred to a fresh tube. 500 
μl of isopropanol was added and mixed thoroughly. The mixture was incubated at 4°C 
for 10 min before a further spin. The supernatant was discarded and the RNA pellet was 
washed in 75% (v/v) ethanol in RNase-free H2O. The centrifugation was repeated as 
before. The RNA pellet was air-dried at RT for 10 min, and resuspended in 100 μl of 
RNase-free H2O with incubation at 55°C for 10 min. After measuring the concentration 
of RNA by Nanodrop Spectrophotometry and checking the integrity of RNA on a 1% 
agarose gel, RNA sample was immediately stored at -80°C. 
 
2.2.6.2 RNA extraction (Qiagen RNeasy Micro Kit) 
RNeasy Micro Kits (Qiagen) were used to prepare RNAs for quantitative real-time PCR 
in this study. The RNA isolation was performed according to the manufacturer’s 
instructions. 
 
2.2.6.3 Reverse transcription PCR (RT-PCR) 
Superscript II reverse transcriptase (Invitrogen) was used to make cDNA from total 
RNA sample following the manufacturer’s instructions. Generally, RNA samples were 
incubated with random primers or oligodT (Invitrogen) and dNTPs at 65°C for 5 min, 
and then cooled on ice before adding 5X First-Strand Buffer, 0.1M DTT and enzyme. 
After gentle pipetting, samples were then incubated at 42°C for 50 min. The reaction 





2.2.6.4 Semi-quantitative Reverse Transcription PCR (qRT-PCR) 
cDNA samples from equivalent amounts of RNAs were prepared as described in 2.2.6.3. 
PCRs were performed with cDNA templates and all the amplicons were loaded in the 
same agarose gel. The gene expression level of different RNA sources was compared 
based on the intensity of appropriate bands in the agarose gel. 
 
2.2.6.5 Quantitative real-time PCR 
Total RNA was isolated from different cells as described in Section 2.2.6.2, and the 
generation of cDNAs as real-time PCR templates was carried out according to Section 
2.2.6.3. The quantitative real-time PCR was performed using the Roche UPL (Universal 
Probe Library) system. It comprises a fluorogenic probe, which is an oligonucleotide 
attached with a reporter fluorescent dye and a quencher dye. When the probe is intact, 
the fluorescence emitted by the reporter dye is greatly reduced by the quencher through 
fuorescence resonance energy transfer (FRET). Primers were designed using the online 
Roche Assay Design Centre application (https://www.roche-applied-
science.com/sis/rtpcr/upl/index.jsp?id=UP030000). If possible, primer pairs were chosen 
to span exon junctions that would not recognize genomic DNA. Each primer pair was 
presented with a specific probe in the Roche UPL system. The Light Cycler
®
 480 Probes 
Master Mix was also provided in the system. For all quantitative PCR experiments in 
this study, real-time PCR was carried out using a Light Cycler
®
 480 (Roche). Each 
cDNA sample was measured in triplicates. The concentration of each sample was 
calculated from a standard curve by the Light Cycler
®
 480 Software automatically. The 
values were then normalised against the house-keeping gene (β-actin, 18S) to illustrate 






2.2.7.1 Southern blotting hybridization 
2.2.7.1.1 Preparation of blot membranes  
BAC DNA and genomic DNA of animal tissues were prepared using methods described 
in Section 2.2.1. Generally 10 μg of genomic DNA was digested with an appropriate 
restriction enzyme at 37°C overnight. The digested DNA was precipitated and 
resuspended in a small volume of TE buffer. These DNA fragments were then resolved 
on a 0.8% agarose gel containing ethidium bromide dye. The electrophoresis was 
performed overnight at 30V and the gel was photographed under UV light with a 
transparent ruler. Afterwards, the gel containing separated DNA fragments was washed 
in depurination solution for 10 min, and incubated in denaturation solution for 30 min. A 
brief rinse in dH2O was necessary between these steps. The DNA was then washed twice 
in neutralisation solution for 20 min. Southern blotting capillary transfer was performed 
to transfer the DNA fragments onto a charged nylon membrane (Southern, 1975). The 
transfer apparatus was assembled on a glass plate suspended over a reservoir of 20X 
SSC buffer. 2 pieces of 3MM paper were pre-soaked in 20X SSC and placed on the 
glass plate so the end of the bottom paper over-hung the buffer reservoir. Another piece 
of soaked 3MM paper and the denatured gel were placed on the wick. A sized 
positively-charged Nylon membrane (Roche) was soaked in 20X SSC buffer and 
carefully placed on the gel (ensuring there were no air bubbles between the wick layers 
by rolling a sterile pipette over it). Two more pieces of wet 3MM paper were placed top 
of the membrane with stacks of absorbent paper over the wick secured with an added 
weight. The capillary transfer of DNA to the membrane was carried out for 24 hr. The 
membrane was removed from the apparatus and baked at 80°C for 2 hr. Membranes 





2.2.7.1.2 Preparation of radiolabelled hybridization probes 
20-50 ng of DNA in TE buffer was radiolabelled by random priming and incorporation 
of [α-
32
P]-dCTP (PerkinElmer Life Sciences). The reaction was set up in a screw-top 
tube containing an Amersham Ready-To-Go DNA labelling bead (GE Healthcare, UK). 
Unincorporated nucleotides were removed by passing the reaction mixture through a 
ProbeQuant™ G-50 micro column (GE Healthcare). All procedures followed the 
manufacturer’s instructions.  
 
2.2.7.1.3 Hybridization 
Membranes (see Section 2.2.7.1.1) were pre-hybridised in 25 ml of pre-hybridization 
solution for 1 hr at 65°C in an evenly rolling hybridization bottle.  The radiolabelled 
probe (denatured by boiling for 5 minutes and then cooled quickly on ice for 5 minutes) 
was added to the pre-hybridization mixture. The membrane blot was incubated with the 
probe in the hybridization buffer overnight at 65°C. The hybridization mixture was 
discarded and the membrane blot was washed twice in wash buffer 1 for 15 min first and 
then in wash buffer 2 for 10 min. The level of radioactivity was monitored with a 
Counter during the wash processes and washing was stopped when the radioactivity 
reached background levels. The membrane was then wrapped in Saran wrap, placed in 
an X-ray cassette and exposed to X-ray film (Kodak) at -80ºC for 2 to 14 days 
depending on the specific activity of probes and the copy number of labelled nucleic 
acids in the genomic DNA. The exposed X-ray film was developed in a dark room using 
an autoradiographic film processor. 
 
2.2.7.2 Colony in situ hybridization 
In situ hybridization was used to screen the positive recombinant E.coli colonies. A 




streaked on this membrane, and the agar plate was incubated at 32°C overnight. The 
membrane blot with inoculated bacterial cells of different colonies was then denatured 
and hybridised as described above in Section 2.2.7.1.  
 
2.2.8 Histological analysis of cells and tissue sections 
2.2.8.1 Fixation of cultured cells 
Fixation should immobilize antigens while retaining cellular and subcellular structures. 
In this study, cultured cells were routinely fixed with 4% (w/v) paraformaldehyde (PFA). 
Growth medium was aspirated from the culture dish and cells were briefly washed in 
PBS twice. Cells were treated with 4% PFA and incubated at RT for 10-15 min. Fixed 
cells were then rinsed in PBS twice for 5 min each, and kept in fridge (4°C) until 
required. 
 
2.2.8.2 Oil Red O staining of cells 
Oil Red O dye (Sigma, Sudan Red 5B, C.I. 26125, C26H24N40) stains for neural 
triglycerides and lipids, the steroidogenic substrate, in cells on unfixed or frozen sections. 
Oil Red O stock solution was prepared in isopropanol and filtered (0.2 μm) before use. 
The cultured cells were fixed with 4% PFA as described in Section 2.2.8.1 and washed 
in ddH2O twice. 60% (v/v) isopropanol was added to the fixed cells and incubated at RT 
for 5 min. After discarding the alcohol, the cells were left to dry completely before the 
addition of Oil Red O working solution (60% stock solution in distilled water). The cells 
were incubated with Oil Red O dye for 10 min at RT, and rinsed four times in ddH2O 
immediately to remove the remaining traces of Oil Red O dye. Images (100x 
magnification) were acquired under the Nikon TMS-F inverted microscope (Jencons-





2.2.8.3 Immunofluorescence of cultured cells 
Cultured cells were fixed as described in Section 2.2.8.1. Permeabilisation of fixed cells 
is required for intracellular epitopes of antigens to be accessed by antibodies. Fixed cells 
were permeabilised using detergents (eg 0.2% NP-40, 0.2% Tween 20, 0.2% Triton X-
100) in blocking buffer (10% Goat serum + 1% BSA in PBS), and incubated at RT for 
20 min. Cells were washed in PBS twice for 5 min each and incubated with primary 
antibody diluted in blocking buffer at 4°C overnight. Cells were then washed in PBS 
three times and finally incubated with secondary antibody diluted in blocking buffer in 
the dark. Two methods for secondary antibody detection were used: firstly, cells were 
incubated with fluorochrome-conjugated secondary antibody (i.e. Goat anti Rabbit 
Alexa 488, 1:200, Sigma) for 1 hr in the dark; secondly, a Tyramide Signal 
Amplification detection system was used including the incubation with Goat anti Rabbit 
peroxidase (1:200, Vector labs) for 30 min and the incubation with TSA Plus kit (1:50, 
PerkinElmer) for 10 min in the dark. The secondary antibody solutions were discarded 
and cells were washed in PBS three times for 5 min each in the dark. Finally cells were 
counter stained with PI (Propidium Iodide) or DAPI for 10 min in the dark, and mounted 
with a drop of mounting medium (PermaFluor
®
 Aqueous Mounting Medium, Thermo 
Scientific). The mounted slides were covered with foil and stored at 4°C until image 
analysis. 
 
2.2.8.4 Adrenal tissue fixation and processing for wax-embedded sections 
Animals were killed and adrenal glands were dissected and collected into a microfuge 
tube containing 10% buffered formalin immediately. Adrenal tissues were generally 
fixed for 24 hours at RT and then transferred into 70% (v/v) ethanol, and stored at 4°C 
until embedding in paraffin wax and processing further. The aim of paraffin embedding 




thin sections to be cut on a microtome. In this study, adrenal glands were processed on 
an automated tissue processor which was routinely managed by technicians in histology 
facility based in QMRI of the University of Edinburgh. The paraffin processing is 
achieved mainly by removing water from the tissue and replacing with paraffin wax, 
which consists of dehydration, clearing, infiltration and embedding steps.  
 
2.2.8.5 Wax embedding and sectioning of adrenal glands 
Following tissue processing, adrenal tissues were embedded in molten paraffin wax and 
allowed to set. Adrenals were orientated and solid wax blocks were prepared for cutting 
sections. 4-5 μm sections of adrenal glands were cut from the wax blocks with a paraffin 
microtome. Adrenal sections were floated in a heated water bath (42°C) and nice flat 
sections were mounted onto microscope slides. Slides were then dried in a warm air 
oven at 50°C overnight. 
 
2.2.8.6 Haematoxylin staining of paraffin sections 
Paraffin sections were dewaxed in xylene for 5 min and transferred to a second xylene 
bath for 5 min. Sections were then rehydrated in alcohol series: 100%, 100%, 95%, 70% 
(20 seconds each) and rinsed in tap water. Nuclei were stained by immersing rehydrated 
sections in haematoxylin for 1-5 min followed by wash in water. Slides were then rinsed 
in acid alcohol for 1-10 sec and then in water. Nuclei colour was changed to blue by 
rinsing the slides in Scott’s tap water for 30 sec followed by rinsing in water. Sections 
were dehydrated in another alcohol series: 70%, 95%, 100% and 100% (20 seconds 






2.2.8.7 Immunohistochemistry of paraffin sections 
2.2.8.7.1 Single immunolocalisation 
Paraffin sections were processed and cut as described in section 2.2.8.4 and 2.2.8.5. 
Sections were deparaffinised and rehydrated using xylene and graded alcohols (referred 
to Section 2.2.8.6). Antigen retrieval was necessary for paraffin sections to unmask the 
antigens in the samples. It was performed by pressure cooking in 0.1M Citrate buffer 
(Sigma) for 5 min at 95°C, followed by cooling for 20 min. Endogenous peroxidase in 
sections was blocked with 3% hydrogen peroxide in methanol followed by rinsing in tris 
buffered saline (TBS) for 5 min. Non-specific binding of antibody was prevented by 
incubating sections in blocking buffer (typically 20% normal horse serum + 5% BSA + 
80% TBS) for 30min at RT, and then washing twice in TBS for 5 min. Primary antibody 
was diluted (see Table 2.5) in blocking buffer, Antibody dilution was optimised prior to 
immunohistochemistry. Sections were incubated with primary antibody solution 
overnight at 4°C. There were two methods used in this study for peroxidase secondary 
antibody detection. The first method was to incubate the sections with species-specific 
ImmPRESS anti-Ig (peroxidase) Polymer Detection Kit (Vector Laboratories, 
Burlingame, CA, USA) for 30 min at RT. The second method was to incubate with 
species-specific anti-IgG biotinylated antibody (1:500, Vector labs) followed by another 
incubation of Streptavidin HRP (horseradish peroxidase) (1:1000, Vector labs). DAB 
chromogen system substrate (Vector labs) was specific to HRP and it developed a brown 
colour. An alternative colour detection system was akaline phosphatase (AP)-linked 
secondary antibody with Fast Blue salt (Sigma) substrate to develop a blue colour when 
antigen was present. A combination of these two detection systems was used for double 





2.2.8.7.2 Double immunolocalisation 
Detection was performed sequentially. For example, detection for Ki67 was followed by 
detection for BrdU when the double immunolocalisation of Ki67 and BrdU were 
performed. Two different colour detection systems were required as described earlier in 
Section 2.2.8.7.1, typically including peroxidase-linked secondary antibody with DAB 
substrate to develop brown colour and akaline phosphatase-linked secondary antibody 
and Fast Blue salt substrate to develop blue colour. After Ki67 was stained, another 
antigen retrieval step for BrdU was essential to remove all the antibodies and enzymes in 
the Ki67 detection whilst preserving the brown colour staining signal. Slides were 
microwaved for 2.5 minutes in boiling citrate buffer pH6. 
 
2.2.8.8 OCT-embedding and cryosection of frozen tissues using cryostat 
Cryostat is essentially a microtome inside a freezer. Cryosections are widely used to 
perform rapid microscopic analysis of a specimen in pathological studies. Animals were 
killed and tissues (i.e. adrenal glands) were dissected and embedded in OCT compound 
(Tissue Tek, Miles Inc., USA) in a metal mould. It was then snap frozen on dry ice and 
stored at -80°C until ready for cryosections. 
Frozen tissues in OCT-embedded moulds were placed in the chamber of cryostat (Leica 
CM 1900) and equilibrated to the temperature of -20°C for 30 min. 7 μm frozen sections 
were cut and placed onto Superfrost Micro slides (VWR International). Cryosections 
were air-dried at RT for 5-10 min and immediately stored at -80°C before use. Sections 





2.2.8.9 Microscope imaging 
Immunohistochemical slides were viewed under a light microscope (Axioskop, Carl 
Zeiss), and images of sections were captured with KS300 software (Carl Zeiss) and a 3-
CCD JVC colour video camera. Fluorescence images were captured and photographed 
using Nikon Eclipse Ti inverted fluorescent microscope, Zeiss Axiovert 200M 
fluorescent microscope and Zeiss LSM 510 Meta confocal microscopy. Images were 
subsequently processed using ImageJ (NIH Image, Bethesda, MD) and Photoshop CS 
(Adobe Systems Inc., San Jose, CA) software. The area of different regions in mouse 
adrenal sections was measured with a digital image analysis software MCID basic 7.0 
(Imaging Research, Amersham, UK). 
 
2.2.9 Quantitative analysis of steroids 
2.2.9.1 Solid phase of steroid extraction  
The medium was collected from cultured mouse adrenocortical tumor Y1 cells and was 
stored at -20°C before analysis. Free and conjugated steroids were isolated from samples 
of medium by solid phase extraction as described previously (Al-Dujaili, 2006). Sep-Pak 
C-18 cartridges (Waters Corp, Milford, MA, U.S.A.) were connected to a syringe and to 
a vacuum manifold. The cartridges were pre-treated with 5 ml of 100% methanol to 
activate the silicon beads in the columns, and then washed with 5 ml of dH2O. 500 μl of 
defrosted culture media sample were passed through the cartridges, and the cartridges 
were washed with 1 ml of dH2O. Absorbed conjugated steroids were eluted with 2 ml of 
40% methanol. All the flow-through in the previous steps was discarded. Free 
aldosterone was eluted with 3 ml of 55% methanol and corticosterone was eluted with 
3ml of 65% methanol. Each eluate was collected separately in glass test tubes and was 
dried under a stream of oxygen-free nitrogen in a Techne-Dri-Block
®
 heater at 45°C for 
4-6 hr. The dried steroid samples in glass tubes were covered with parafilm and kept in 





2.2.9.2 Measurement of steroid levels by Enzyme-linked immunosorbent assay 
(ELISA) 
The levels of aldosterone and corticosterone (B) in different samples were measured by 
ELISA as described previously (Al-Dujaili et al., 2009b). These assays follow a 
competitive-binding principle in which competition happens between antigens in 
sample/standards and antigens on pre-coated microwell plates for specific binding sites 
on steroid antibodies. Antibody that binds to antigen on coated plates is then quantified 
by incubation with a secondary peroxidase-linked antibody. Peroxidase activity is 
measured colourimetrically. 
Dried steroid samples in glass tubes were resuspended in 500 μl of assay buffer (0.05 M 
PBS, pH 7.4, with 0.1% BSA). 96-well plate (Greiner microloan
®
 plate) was coated with 
200 μl of aldosterone- or B-conjugate in coating buffer (0.025 M PBS, pH 7.4) at a 
dilution of 1:1,000 in each well, and then covered and placed at 4°C overnight. The next 
morning, conjugate not bound to plastic plates was discarded and plates were washed 
three times with 250 μl of wash buffer (0.02 M PBS, pH 7.4, with 0.05% Tween 20). 
The wells were then blocked by adding 200 μl of blocking buffer (0.025 M PBS, pH 7.4, 
0.5% BSA) to each well. Plates were covered with parafilm and incubated at 37°C for 1 
hr. Blocking buffer was then discarded and 50 μl of samples or standards, and 100 μl of 
primary antibody solution (see Table 2.5) was added to each well. The plate was covered 
and incubated at RT for 2 hr. The unbound primary antibody solution was washed off 
four times as before. 100 μl of horseradish peroxidase (HRP)-linked secondary antibody 
(Aldosterone donkey anti-sheep, 1:10,000; Corticosterone goat anti-rabbit, 1:10,000; 
diluted in assay buffer; Invitrogen) was added to each well. The plate was covered and 
incubated at RT for 1 hr, and then washed four times as before. The bound HRP-
conjugate was detected by adding 100 μl of freshly-made substrate solution (0.2 M 
sodium acetate/citrate buffer pH 4.2, 250 μg/ml tetramethylbenzadine in DMSO, 0.5% 




substrate solution. After 10-15 min incubation in the dark at RT, the reaction was 
stopped by adding 50 μl of 1 M H2SO4. The colour of the solution in the wells was 
changed from blue to bright yellow. The absorbance was measured on Plate Reader at 
450 nm. Assay ZAP software was used to process ELISA absorbance values to calculate 
the concentrations of aldosterone and corticosterone against the standard curves. 
 
2.2.10 Statistical analysis 
The statistical tests including paired t-test, unpaired t-test, and two-way analysis of 
variance (ANOVA) were performed using Minitab Statistical software (release 16, 
Minitab, State College, PA). Quantitative real-time PCR data of genes of interest were 
normalised against those of internal control genes in Microsoft Excel software (Office 
2007). Statistical significance was determined using GraphPad Prism 5 (Graphpad 










Chapter 3-Cell proliferation and turnover in the 




3.1.1 Pulse-chase studies tracing adrenocortical cell lineages 
The establishment and maintenance of the adult adrenal cortex have been discussed 
briefly in Section 1.5. The adult adrenal cortex is a dynamic endocrine organ where the 
senescing cells are constantly replenished with newly divided and differentiated 
daughter cells (Chang et al., 2011). Adrenocortical development is dependent upon 
tightly-controlled cell proliferation and differentiation. Both extra-adrenal peptide 
hormones and intra-adrenal transcriptional factors are thought to be indispensible for the 
crucial regulatory processes. Adrenocortical cell turnover has been studied extensively 
during the past decades and most studies support the cell migration theory which was 
first raised in 1883 by Gottschau  reviewed in Kim and Hammer’s paper (Kim et al., 
2009). Numerous investigations relied on the autoradiography of labelled thymidine. It 
was indicated that adrenocortical cytogenesis occurred in an outer region of the adrenal 
cortex that might be the location of adrenocortical stem or progenitor compartments. 
Cell kinetic studies by Zajicek in 1986 (Zajicek et al., 1986) provided quantitative data 
on cell proliferation and migration within the rat adrenal cortex. However, the 
differentiation of newly-divided steroidogenic cells in the mouse adrenal cortex has not 
been clearly and convincingly defined yet. 
The approaches using radiolabelled [
3
H]-thymidine and thymidine analogue 5’-bromo-
2’-deoxyuridine (BrdU) incorporations have suggested a concept that adrenocortical cell 




inwards to form radial strips (Chang et al., 2011; Kataoka et al., 1996; Mitani et al., 
2003; Mitani et al., 1995; Zajicek et al., 1986). Enucleation experiments and studies on 
different transgenic mouse models provide further evidence for the theory that cell 
proliferation followed by centripetal movement maintains the adult adrenocortical cell 
population. This is strikingly illustrated by the appearance of an adrenal cortex with 
radial blue stripes of β-galactosidase staining in a transgenic mouse model where the 
mosaic expression of lacZ is under the control of Cyp21 promoter (Chang et al., 2011; 
Morley et al., 1996).  
Previous studies of BrdU pulse labelling in the adrenal cortex (Mitani et al., 1999, 2003; 
Miyamoto et al., 1999) showed that BrdU-labelled cells were pushed inwards. It is 
suggested that displaced cells differentiate into functional adrenocortical cells but lose 
the capacity to proliferate, and that the initial BrdU pulse of labeling includes a stem cell 
population. To maintain the stem cell population in a subcapsular niche, one daughter 
cell would remain in situ in an undifferentiated state whilst the other would have the 
potential for further cell division and terminal differentiation to become a functional 
steroidogenic cell. This hypothesis has been tested by counting the labelled cells and by 
marking the positions of pulse-chase labelled proliferating cells in the rat adrenal cortex, 
where the zona glomerulosa and the zona fasciculata are clearly delineated and separated 
by an intermediate zone of non-steroidogenic cells (McEwan et al., 1996; Miyamoto et 
al., 1999; Stachowiak et al., 1990) . In theory, a similar mechanism could be applied to 
the mouse adrenal cortex.  However, the analysis of how this might occur in mice is 
complicated because there is no clearly-defined intermediate zone in this species. Chang 
et al. (manuscript submitted for publication) have used a BrdU pulse-chase technique to 
analyse cell fate after proliferation. The relative positions of BrdU positive cells at 
various periods of time after proliferation are tracked in the mouse adrenal cortex. Cells 
with BrdU-labelled nuclei cluster in a subcapsular region in adrenal cortex immediately 
after BrdU injection (Fig. 3.1A). This subcapsular region in mice is analogous to the 
zona intermedia in rats and it is defined as outer zona fasciculata (OzF). Three weeks 




subcapsular position, many have been displaced. This is also seen as a change in slope of 
the cumulative frequency graph around the OzF region (Fig. 3.1B). Interestingly, BrdU 
label-retaining cells appear to have migrated outwards and inwards suggesting that zona 
glomerulosa and fasciculata cells are recruited from a common pool of cells located at 
the boundary between zG and zF. Chang et al., ibid, also demonstrated that acute ACTH 
treatment caused an increase in subcapsular cell proliferation, and some BrdU-labelled 
cells that remained in the zona glomerulosa retained the capacity to proliferate 
(manuscript submitted for publication). The increased cell proliferation by acute ACTH 
treatment pushed cells to displace outwards (towards the capsule) and inwards (towards 
the medulla). 
Potentially, the same BrdU pulse-chase labelling strategy could be applied to detect 
adrenocortical cell proliferation and turnover in response to other physiological or 
pathophysiological stimulations. In this Chapter, acute effects of angiotensin II and 
chronic control of cell turnover in Cyp11b1-null mice (Mullins et al., 2009) were tested 
and described. In these experiments, the localization of the nuclear antigen Ki67, a 
ubiquitous nuclear protein, has been used to mark cells actively undergoing cell 
proliferation. Ki67 is present during all active phases of the cell cycle (G1, S, G2, and 
mitosis), but not in the G0-phase and is therefore a good marker of the proliferating cell 
fraction (Muskhelishvili et al., 2003). Ki67 immunostaining presents a pattern similar to 
BrdU immunostaining in mouse adrenals immediately after BrdU injection. In the BrdU 
pulse-chase labelling experiments, Ki67 labelling indicates the location and number of 
proliferating cells while BrdU labelling indicates fate of cells after proliferation. Ki67 
and BrdU dual-labelled cells might indicate the location and number of adrenocortical 
progenitor cells that have maintained their positions and retained the abilities to 
proliferate. 
Pulse-chase tracing of the steroidogenic lineage would help to determine whether 
distinct adrenocortical zones are maintained by bidirectional cell movement from a 




migration from the capsule, or by independent stem/progenitor cell populations within 
each zone. 
 
Fig. 3.1. Distribution of BrdU-labelled cells in the mouse adrenal cortex 
after single BrdU injection 
The average distance from capsule to the cortex/medulla boundary is divided into 100 
centiles. Each labelled cell position is presented and ranked by the value between 0 and 
100. The capsular cells are regarded as position 0, while the innermost cortical cells are 
defined as position 100. The rank distribution measurement is described in detail in 
Section 3.2.5.  
(A) Labelled cells clustered in a subcapsular region immediately after single BrdU 
intraperitoneal injection (Time zero pulse, Blue).  
After three-week chase period (Red), labelled cells had been displaced outwards and 
inwards away from the subcapsular region where BrdU-labelled cells clustered at 
Time zero.  
(B) Individual data points have been pooled and ranked according to their positions in 
the adrenal cortex. Cortical position is plotted on a log scale to discriminate 
positions of individual cells in the narrow region of the zona glomerulosa. The 
dotted line is defined as the zona glomerulosa/fasciculata interface with a position 
value around 20.  
In contrast to the distribution plot of BrdU-labelled cell at Time zero (Blue), the 
labelled cells after three-week chasing (Red) had displaced in two directions: 
outwards towards the zona glomerulosa and inwards towards the zona fasciculata. 






3.1.2 Effects of Angiotensin II on adrenocortical cell proliferation 
Angiotensin II is a predominant physiological regulator of growth and steroidogenic 
activity of zG cells. Hypertrophic responses to dietary sodium restrictions or to long-
term angiotensin infusions are postulated to result from cell hypertrophy and cell 
hyperplasia in zG (Engeland et al., 1996; McEwan et al., 1995, 1996). In the present 
study, acute effects of angiotensin II injection were measured at 4 h because previous 
studies have demonstrated the proliferative responses to acute ACTH injection was 
maximal at this time point, 4 h (Miyamoto et al., 1999).   
 
 3.1.3 Effects of ACTH on adrenocortical cell proliferation and turnover 
Acute ACTH injection has been shown to increase cell proliferation at the zona 
glomerulosa/fasciculata interface in both rat and mouse adrenals 4 h after treatment. 
Long-term ACTH treatment causes cell hypertrophy and cell hyperplasia, and alters cell 
distribution in each of the adrenocortical zones (Nussdorfer, 1986; Stachowiak et al., 
1990). Under the chronic ACTH stress, the sustained increase in corticosterone 
production is considered to result from a combination of cell hypertrophy, cell 
hyperplasia and reduced apoptosis (Menzies R et al., 2010). Effects of congenital 
adrenal hyperplasia caused by null mutation of Cyp11b1 are described in this Chapter. It 







All the experimental animal work presented in this study was carried out with the animal 
licence and under the regulations described in Section 2.1.12. 
 
3.2.1 Establishment of methodology of BrdU and Ki67 dual 
immunohistochemical staining  
Osmotic mini-pumps, supplied by ALZET
® 
(model 2002, 0.5 μl/ hr, Alzet, Palo Alto, 
CA) were filled with 200 μl of filtered BrdU solution (100 mg/ml in 50% DMSO and 50% 
H2O), and then equilibrated in 0.9% saline overnight in a 37°C water bath. The next 
morning, these Alzet osmotic mini-pumps were implanted by Dr. Christopher Kenyon 
subcutaneously into 6 female virgin mice under anaesthesia. An area of back fur was 
shaved and the skin was wiped with 70% (v/v) ethanol, then a small incision was made 
and enlarged to make a pocket using forceps.  One osmotic mini-pump containing BrdU 
solution was inserted and the wound was closed with clips. After 7 days of BrdU 
infusion, mice were killed. The adrenal glands were removed and fixed in 10% buffered 
formalin. Paraffin-embedded sections were carefully prepared as described in Section 
2.2.8.4 and 2.2.8.5, and were stained for BrdU and Ki67 double immunohistochemistry 
following protocols described in Section 2.2.8.7. 
 
3.2.2 Adrenocortical cell proliferation in response to acute Angiotensin II 
stimulation 
Two groups of mice (N=8 each) were infused with BrdU pulse for one week and then 
left  for a further  6 week chase period before animals were sacrificed for tissue 
collection. Mice of control group were injected subcutaneously with 100 µl of saline 




containing saline (500ng). Four hours later, mice were decapitated and the adrenals were 
dissected and fixed in 10% buffered formalin for histology analysis. 
 
3.2.3 Cell proliferation in the adrenal cortex of Cyp11b1-null mice 




 and homozygous 
Cyp11b1
-/-
) were pre-treated with a one-week BrdU infusion followed by a 6 week-
chase period before they were killed. The adrenal glands were removed and fixed in 10% 
buffered formalin for histology. Mice used in this study were described in Mullins et al 
(Mullins et al., 2009).  
 
3.2.4 Counting of labelled adrenocortical cells 
Stained adrenal sections were examined under a Zeiss Axioskop 2 compound 
microscope. Longitudinal adrenal sections with a prominent medulla region were 
randomly selected for each adrenal gland. Images were captured with a Nikon Coolpix 
995 or JVC 3 CCD digital camera, and were analyzed with KS 300 or MCID digital 
imaging software. 
All tissue sections were analyzed in a single-blind fashion. Cells with round nuclei in the 
adrenal cortex were regarded as adrenocortical cells. Cells with narrow nuclei were 
considered to be fibroblasts or vascular endothelial cells and were excluded from 
analysis for this experiment. Since the thin zona reticularis was difficult to distinguish in 
the experimental mouse strains being used and the thin X-zone was irregularly aligned in 
some of these virgin female mice, the major part of the mouse adrenal cortex comprising 
the zona glomerulosa and the zona fasciculata in each section was manually divided into 
three zones under the consistent rule: the outermost zona glomerulosa (zG), the 
boundary intermediate outer zona fasciculata (OzF) and the columnar inner zona 
fasciculata/reticularis (IzF).  Cell size was assessed by dividing the field area by the total 




unlabelled (BrdU negative, Ki67 negative); BrdU single labelled (BrdU positive, Ki67 
negative); Ki67 single labelled (BrdU negative, Ki67 positive); dual labelled (BrdU 
positive, Ki67 positive). Within each field, numbers of cells in each category were 
calculated as a percentage of the total number of cells. The averaged percentages and 
cell sizes for individual mice were plotted by zone and by treatment. 
 
3.2.5 Ranking of labelled adrenocortical cells by cell distribution 
Using ImageJ software, the cortical position of every labelled cell (single or dual) was 
recorded within each section. The radial distance (d) of labelled cells from the edge of 
the capsule was expressed as a percentage of the width (w) of the cortex.  
The cortical position of labelled cells was plotted in two ways: bar graphs and 
cumulative distribution curves. Bar graphs showing the average number of cells were 
plotted for BrdU-labelled, Ki67-labelled and dual-labelled cells. The average distance 
from capsule to the cortex/medulla boundary is divided into 100 centiles. Each labelled 
cell position is presented and ranked by the value between 0 and 100. The capsular cells 
are regarded as position 0, while the innermost cortical cells are defined as position 100. 
For every adrenal section, the number of cells located in each 5-centile box was 
expressed as a percentage of the total number of labelled cells across the whole 
adrenocortical section. The cumulative distribution curves of labelled cells were plotted 
by genotype and by BrdU or Ki67 labelling. Data was normalized for difference in cell 
numbers between genotypes. The rank number for each labelled cell was calculated as a 






3.2.6 Data statistical analysis 
The statistical tests involved in the BrdU pulse-chase labeling experiments include 
paired t-test, General Linear Model (GLM) of analysis of variance (ANOVA) and two-
way ANOVA, which were performed with Excel and Minitab Statistical software 
(release 16, Minitab, State College, PA). All data was presented as Mean ± SEM from 






3.3.1 Establishment of methodology for BrdU and Ki67 dual 
immunohistochemical staining  
A well-defined zona intermedia comprising undifferentiated and lipid-depleted cells as a 
layer between zona glomerulosa and zona fasciculata is seen in rat but not mouse 
adrenal glands. Cell morphology was used to identify and distinguish zona glomerulosa 
(zG), outer zona fasciculata (OzF) and inner zona fasciculata (IzF). As indicated in Fig. 
3.2, cells at the zona glomerulosa/fasciculata interface (OzF) in the mouse adrenal cortex 
had an intermediate phenotype: smaller than zona fasciculata cells but larger than zona 
glomerulosa cells with neither columnar nor glomerular appearance. Cells in the inner 
zona fasciculata (IzF) were larger columnar cells and zona glomerulosa (zG) cells were 


















Fig. 3.2. A typical cross section of wild-type female mouse adrenal cortex 
Paraffin sections of adrenals were cut (thickness = 5μm) and stained with hematoxylin 
following methods described in Section 2.2.8.4-2.2.8.6. Capsule and different cortical 
zones are clearly indicated. (A) 10X objective lens magnification. (B) 40X objective 
lens magnification. Panel B represents the field of the square box in panel A.  
C, capsule; zG, zona glomerulosa; OzF, outer zona fasciculata; IzF, inner zona 






BrdU and Ki67 dual immunohistochemical staining of mouse adrenal sections was 
optimized for the method of antigen retrieval and for the dilution of primary antibody. 
The optimal dual immunohistochemical staining procedure is described in Section 
2.2.8.7. The distribution of Ki67-labelled cells in WT mouse adrenal cortex is illustrated 
in Fig. 3.3A. Proliferating cells were defined as Ki67 positive. Under normal 
physiological and pathophysiological conditions, very few Ki67-positive cells were 
identified and were mainly located within the outer adrenal cortex. As was shown in Fig. 
3.3B-C, BrdU-positive and Ki67-positive cells were detectable and clearly distinguished 
by the optimised method for dual immunohistochemistry. BrdU-labelled cells were seen 
throughout the mouse adrenal cortex. Dual labelled cells were generally more numerous 
in the zG and OzF than IzF indicating that some BrdU-positive cells in the outer cortex 
retained the potential to proliferate whereas those cells displaced inwards during the 
































Fig.3.3. Location of Ki67-labelled cells and BrdU-labelled cells in the 
mouse adrenal cortex after one-week BrdU infusion and one-week chase 
Paraffin sections of mouse adrenals pre-treated with one-week BrdU infusion and one-
week chase were cut (thickness = 5μm) and stained dually with Ki67 and BrdU antibody 
following methods described in Section 2.2.8.4-2.2.8.7. 
(A) Ki67 immunohistochemistry, 400X magnification. 
(B-C) BrdU and Ki67 dual immunohistochemistry, 100X magnification 
(D) BrdU and Ki67 dual immunohistochemistry, 400X magnification 
Ki67-positive is indicated by brown nuclear immunostaining while BrdU-positive is 
identified by blue nuclear immunostaining. Arrows in Black and Red indicate Ki67- 
and BrdU-labelled cells, respectively.  
Group 1, 2, 3 and 4 represent Ki67-labelled, BrdU-labelled, dual labelled and 
unlabelled adrenocortical cells, respectively.  
M, medulla; zG, spherical-clustered zona glomerulosa; OzF, outer zona fasciculata; IzF, 

















3.3.2 Adrenocortical cell proliferation in response to acute Angiotensin II 
stimulation 
Potential progenitor cells and differentiated cells in adrenocortical zones were assessed 
for their expression of Ki67 and BrdU. It was hypothesized that acute ANG II treatment 
would stimulate cell proliferation and cause some BrdU-positive cells to re-enter the cell 
cycle as shown previously for acute ACTH treatment. As expected, cell size in the IzF 
was significantly greater than the OzF and greater than the zG (Fig. 3.4). Acute ANG II 
treatment did not affect cell size.  
The number of cells with immunostained nuclei was expressed as a proportion of the 




 cell number in IzF was 
larger than OzF and larger than zG indicating that although most BrdU-positive cells had 
been displaced to IzF, a significant number of these cells remained in the outer part of 









cells in the OzF were significantly larger than zG and larger than IzF indicating that OzF 
is the main proliferative region of the adrenal cortex. Acute ANG II treatment had no 
significant effects on the number of immunostained cells in any of the adrenocortical 
zones indicating that neither cell proliferation nor cell turnover was affected. However, a 
comparison of individual Ki67-labelling indices in both control and ANG II-treated mice 
showed wide variations within each group (Fig. 3.6). Thus small differences in cell 








Fig. 3.4. Effects of acute ANG II stimulation on cell size in different 
adrenocortical zones 
Two groups of mice (N=8 each) previously infused with BrdU for one week followed 
by 6 week chase were treated separately with AII or saline vehicle as described in 
Section 3.2.2. Paraffin sections of adrenals were cut (thickness = 5μm) and dual-stained 
with Ki67 and BrdU antibody as described in Section 2.2.8.4-2.2.8.7. Cell area (cell 
size) was measured according to the methods described in Section 3.2.4. 
Cell size: IzF > OzF > zG. There was no significant change in cell size in any zone after 
acute ANG II treatment (P > 0.05).  
All data is expressed as Mean± SEM (N=8). X-axis represents the treatments and the 
unit of Y-axis is μm
2 
per cell. 
Ang II (Red), angiotensin II-treated;  
Control (Blue), saline-treated;  
zG, zona glomerulosa;  
OzF, outer zona fasciculata;  














Fig. 3.5. Acute ANG II stimulation has no effect on cell proliferation or 
turnover in any of the adrenocortical zones. 
Two groups of mice (N=8 each) previously infused with BrdU for one week 
followed by 6 week chase were treated separately with AII or saline vehicle as 
described in Section 3.2.2. Paraffin sections of adrenals were cut (thickness = 5μm) 
and dual-stained with Ki67 and BrdU antibody as described in Section 2.2.8.4-
2.2.8.7. Within each field, numbers of cells in each category were counted and 
calculated as a percentage of the total number of cells (see methods in Section 
3.2.4).  
Ki67 staining and BrdU staining indicate cell proliferation and cell turnover after a 
6-week chase period. The distribution of BrdU-positive and Ki67-positive cells 
throughout the adrenal cortex of mice treated with saline (Blue) or angiotensin II 
(Red) was assessed. X-axis represents the treatments and the Y-axis is the 
percentage of labelled cells in each category. There were no significant changes in 
cell counts of any subpopulation of cells after acute ANG II treatment (P > 0.05). 
All data is expressed as Mean± SEM (N=8). zG, zona glomerulosa; OzF, outer zona 


































Fig. 3.6. Cell proliferation in the adrenal cortex is highly variable within 
control group mice and within angiotensin II–treated mice.  
Two groups of mice (N=8 each) previously infused with BrdU for one week 
followed by 6 week chase were treated separately with AII or saline vehicle as 
described in Section 3.2.2.  
Paraffin sections of adrenals were cut (thickness = 5μm) and dual-stained with Ki67 
and BrdU antibody following methods described in Section 2.2.8.4-2.2.8.7.  
The numbers of Ki67-positive adrenocortical cells were counted, and the averaged 
percentage of Ki67-positive adrenocortical cells for each mouse within both groups 
was calculated and plotted according to the methods described in Section 3.2.4 and 
3.2.6.  
X-axis represents the treatment groups and the Y-axis is the percentage of Ki67-
positive cells. Values shown are individual data for the adrenal cortex across all 




3.3.3 Cell proliferation in the adrenal cortex of Cyp11b1-null mice 
 
Mullins (Mullins et al., 2009) generated a mouse model in which the function of 
Cyp11b1 to produce corticosterone was disrupted. Cyp11b1-null mouse represented a 
model of congenital adrenal hyperplasia (CAH) which exhibited glucocorticoid 
deficiency, mineralocorticoid excess and female infertility problems. The hypothalamo-
pituitary-adrenal (HPA) axis in Cyp11b1-null mice is activated because of a lack of 
negative feedback control by corticosterone (Mullins et al., 2009).  
To fully characterise the Cyp11b1-null mice as a model of CAH in the 
pathophysiological aspect, histological examinations and cell proliferation studies were 













 (WT)) were treated 
with one-week BrdU infusion followed by a six-week chase. These mice were then 
assessed for the adrenocortical distribution of BrdU-positive and ki67-positive cells. 
Adrenocortical hypertrophy was evident in Cyp11b1 HOM null mice (Fig. 3.7). The 
width of the adrenal cortex in HOM mice was larger than that in HET and WT mice. 
The average cross-sectional cell size (cell area) is shown in Fig. 3.8. Cells in the IzF 
were larger than those in the OzF and zG. Cell size in all adrenocortical zones of HOM 
null mice was significantly greater than that of HET and WT controls (***, P < 0.001). 
Moreover, cell hypertrophy was particularly seen in IzF where gene Cyp11b1 is 

















Fig. 3.7. Adrenocortical cells of wild-type (WT), heterozygous (HET) and 
homozygous (HOM) Cyp11b1-null mice 
Three groups of different genotyped mice (WT, HET, HOM) were separately treated with a one-
week BrdU pulse followed by a 6-week chase period as described in Section 3.2.3.  
Paraffin sections of adrenals were cut (thickness = 5μm) and stained dually with Ki67 and BrdU 
antibody following methods described in Section 2.2.8.4-2.2.8.7.  
Cells of HOM Cyp11b1-null adrenal cortex are clearly larger than those of HET and WT 
controls. Brown and blue nuclear staining indicates the Ki67-labelled and BrdU-labelled cells, 
























Fig. 3.8. Cell hypertrophy is seen in adrenals of wild-type (WT), 
heterozygous (HET) and homozygous (HOM) Cyp11b1-null mice 
T Three groups of different genotyped mice (WT, HET, HOM) were infused with a one-
week BrdU pulse followed by a 6-week chase period as described in Section 3.2.3.  
Paraffin sections of adrenals were cut (thickness = 5μm) and stained dually with Ki67 
and BrdU antibody following methods described in Section 2.2.8.4-2.2.8.7.  
Cell area (cell size) was measured according to the methods described in Section 3.2.4. 
X-axis represents the animal genotypes and the unit of Y-axis is μm
2 
per cell. 
.The average cross-sectional area of cells: IzF> OzF> zG.  
Cell size in adrenal cortex: Cyp11b1-null homozygous> heterozygous> wild-type 
control in all the three adrenocortical zones, particularly in the inner zona fasciculata 
(***, P < 0.001).  
Values shown are mean± SEM (N=5 adrenals).  







































) nuclei in three separate regions (zG, 
OzF and IzF) were counted in adrenal sections of wild type (WT), heterozygous (HET) 
and homozygous Cyp11b1-null mice (HOM). Quantitative analysis of labelled cell 
numbers revealed that distribution patterns of different cell subsets were similar in WT, 
HET and HOM Cyp11b1-null mice (Fig. 3.9). Six weeks after BrdU infusion, BrdU-
labelled cells were found distributed throughout the adrenal cortex indicating that mature 
cells originating from cells that incorporated BrdU during the first pulse week have 
migrated and differentiated into zona glomerulosa and zona fasciculata cells. Ki67-
labelled cells were located mainly in the outer adrenal cortex. Cell proliferation (Ki67 
index) in OzF was greater than that in zG and IzF suggesting that a pool of 
adrenocortical stem/progenitor cells might locate specifically in OzF. BrdU and Ki67 
dual-labelled cells also remained mostly in the outer adrenal cortex which implied that a 
specific population of cells within this region labelled with BrdU six weeks previously 
retained the ability to re-enter the cell cycle and to proliferate.   
Statistical analysis of cell counts (Fig. 3.9-3.10) showed that pulse-chased BrdU-positive 
cells in WT and HET mice had migrated inwards and were widely distributed 
throughout the cortex. A significant number of cells labelled with BrdU were retained in 
the zG of HOM Cyp11b1-null mice. Compared with WT and HET controls, numbers of 
Ki67-labelled and dual-labelled cells were significantly increased in the outer adrenal 
cortex of HOM Cyp11b1-null mice (***, P < 0.001).  
The distribution of labelled cells in the adrenal cortex after 6-week chase period was 
plotted against the distance from the capsule on a semi-log scale (Fig. 3.11). There was 
no significant difference of the distribution pattern of Ki67-labelled cells between 
Cyp11b1 WT, HET and HOM null mice. The difference in slope of cumulative 
frequency graph for BrdU-labelled cells was emphasized. It was confirmed that most of 
the BrdU-labelled cells displaced inwards during the chase period from the origin 




BrdU-labelled cells appeared to be bidirectional in the adrenal cortex of Cyp11b1 HOM 
null mice. Cells were displaced from zG/zF interface towards the zona glomerulosa as 







Fig. 3.9. Cell proliferation and migration in the adrenal cortex of wild-type 
(WT), heterozygous (HET) and homozygous (HOM) Cyp11b1-null mice 
Three groups of different genotyped mice (WT, HET, HOM) were infused with a one-
week BrdU pulse followed by a 6-week chase period as described in Section 3.2.3. 
Paraffin sections of adrenals were cut (thickness = 5μm) and stained dually with Ki67 and 
BrdU antibody following methods described in Section 2.2.8.4-2.2.8.7.  
Within each field, numbers of cells in each category were counted and calculated as a 
percentage of the total number of cells (see methods in Section 3.2.4). BrdU and Ki67 
labelling indices in adrenocortical zones of WT, HET and HOM Cyp11b1-null mice were 
assessed and compared. X-axis indicates genotypes and the Y-axis is the percentage of 
labelled cells. Compared with WT and HET mice, HOM Cyp11b1-null mice showed a 
significant increase of proliferating cells in the outer region of adrenal cortex (***, P < 


























































X-axis－Relative cortical position (%) 
Fig. 3.10. Effects of wild-type (WT), heterozygous (HET) and homozygous 
(HOM) Cyp11b1 null mutations on the distribution of BrdU- and Ki67-
labelled cells in the adrenal cortex 
Three groups of mice of different genotype (WT, HET, HOM) were infused with a one-
week BrdU pulse followed by a 6-week chase period as described in Section 3.2.3. 
Paraffin sections of adrenals were cut (thickness = 5μm) and stained dually with Ki67 
and BrdU antibody following methods described in Section 2.2.8.4-2.2.8.7.  
Within each adrenal section, labelled adrenocortical cells were ranked separately by 
cell distribution. The rank number for each labelled cell was calculated as a percentage 
of the total number of cells within the pool and was plotted according to cortical 
position. The measurement of relative position of stained adrenocortical cells is seen in 
Section 3.2.5. 
X-axis represents the relative cortical position and the Y-axis is percentage of labelled 
cells in each category. Values are expressed as the mean (N=5 adrenals).  
Ki67-labelled cells (left panel) cluster around zG/zF interface (dotted line, Position 20). 
Pulse-chased BrdU-positive cells (central panel) are displaced from zG/zF interface.  
A greater number of BrdU-positive cells are found in zG rather than in zF in adrenals 
of Cyp11b1-null mice. The distribution of dual-labelled cells (right panel) also shows a 
greater cell number in zG of Cyp11b1-null mice.  
Blue, wild type; Green, Cyp11b1 heterozygote; Red, Cyp11b1 homozygote;  
+ve, positive; - ve, negative  
 









Fig. 3.11. Effects of wild-type (WT), heterozygous (HET) and homozygous (HOM) 
Cyp11b1 null mutations on the distribution of BrdU- and Ki67-labelled cells in the 
adrenal cortex 
Three groups of mice of different genotype (WT, HET, HOM) were infused with a one-week BrdU 
pulse followed by a 6-week chase period as described in Section 3.2.3. Paraffin sections of 
adrenals were cut (thickness = 5μm) and stained dually with Ki67 and BrdU antibody following 
methods described in Section 2.2.8.4-2.2.8.7. Within each adrenal section, labelled adrenocortical 
cells were ranked separately by cell distribution. The measurement of relative position of stained 
adrenocortical cells is seen in Section 3.2.5. X-axis represents the relative cortical position and the 
Y-axis indicates the rank position of labelled adrenocortical cells in each category. Values are 





Hypothalamic-pituitary-adrenal axis, renin-angiotensin-aldosterone system and cell-
specific transcriptional factors play important roles not only in the embryonic adrenal 
development but also in maintenance of the adult adrenal cortex. Neither the precise 
location of adrenocortical progenitor/stem cells nor the subsequent distribution of 
terminally-differentiated cells has been clearly and reliably defined, particularly in mice. 
In rats, adrenocortical cell proliferation is found to occur primarily within the 
subcapsular region. Many cytogenic studies have suggested that daughter cells after 
proliferation migrate inwards and replenish the rat adrenal cortex (Kim et al., 2009). It 
has been reported, in rats, that the number of proliferating cells in the zona intermedia is 
increased by acute ACTH treatment and varies with a circadian pattern (Miyamoto et al., 
1999). Dietary sodium restriction and continuous Angiotensin II infusion for two weeks 
cause the hypertrophy of the zona glomerulosa and cause an increase of proliferating 
cells at the glomerulosa/intermedia interface (McEwan et al., 1996).  
It is crucial to understand the mechanisms underlying the maintenance of the mouse 
adrenal cortex under physiological challenges or prolonged pathophysiological changes 
in mouse models of adrenal diseases like the congenital adrenocortical hyperplasia. 
Morrison et al. have established a lineage tracing technique which compares the relative 
positions of proliferating cells at timed intervals after single BrdU injection in the mouse 
adrenal cortex. It is suggested that, in mice, zG and zF cells are recruited from a 
common pool of quiescent cells located at the interface of the zG and zF. This interface 
region is defined as the OzF in the present study and is analogous to the zona intermedia 
in rats.  
Ki67 immunostaining has been used to mark cells actively undergoing cell proliferation 
with a pattern identical to that shown by BrdU immediately after BrdU injection. In the 
present study, BrdU was administered in a pulse-chase manner to indicate the fate of 




physiological or pathophysiological stimulation were predicted. Acute angiotensin II 
treatment was expected to stimulate the proliferation of responsive zG cells which were 
not terminally differentiated. However, unlike the acute ACTH treatment, angiotensin II 
had no significant effects on the cell proliferation or cell turnover in any of the mouse 
adrenocortical zones, and there are several reasons why we did not see any significant 
effect of acute angiotensin II treatment: first, the time course of effects of angiotensin II 
on cell proliferation has not been clearly established as it has for ACTH in the mouse 
adrenal cortex. Only the influences of continuous one- or two-week angiotensin II 
treatment on zG-specific cell proliferation have been reported; secondly, zG is a much 
smaller region than zF within the adrenal cortex and the number of newly-divided cells 
that appear to differentiate into zF cells is ten-fold larger than that into zG cells. Any 
effect of acute angiotensin II treatment in the mouse zona glomerulosa might be 
obscured by problems of distinguishing a responsive zG cell against an unresponsive zF 
cell when the zona intermedia is not clearly defined in mouse adrenal cortex; thirdly, in 
the present study, the cell proliferation event in adrenals of both control and angiotensin 
II-treated mice was highly variable within each group. Therefore, small effects of acute 
angiotensin II treatment would have been difficult to see.  
Under chronic stress or long-term exposure to excessive ACTH, glucocorticoid 
production in mice is stimulated in zF/zR because of the increased steroidogenic enzyme 
expression, adrenocortical cell hypertrophy and hyperplasia, and the reduced cell 
apoptosis. A similar adrenal phenotype was expected in Cyp11b1-null mice which have 
elevated levels of ACTH and progesterone due to the absence of 11β-hydroxylase 
enzyme (Mullins et al., 2009). The negative-feedback control of the HPA axis is 
impaired in the Cyp11b1 homozygous null mice causing the cell hypertrophy in all 
adrenocortical regions, particularly in IzF.   
Generally speaking, the balance between rates of cell proliferation and cell death 
governs the size of adrenal cortex. In the present study, cell apoptosis is not assessed. 




lower levels in adrenals of ACTH-treated mice and the number of apoptotic cells 
identified by TUNEL staining in the innermost region of the adrenal cortex was reduced 
by ACTH treatment. In this study, the relative contribution of cell size, proliferation or 
turnover to the adrenal hypertrophy and hyperplasia was investigated in Cyp11b1-null 
mice. Cell proliferation was increased in Cyp11b1-null mice particularly in OzF where 
adrenocortical stem/progenitor cells might be located.  
The number of BrdU-positive cells displaced into IzF of Cyp11b1-null mice is equal to 
or smaller than that of wild-type controls. This could be interpreted as evidence that the 
half-life of zona fasciculata cell is extended in Cyp11b1-null mice. A slower cell 
turnover could also explain why there appeared to be more BrdU-positive cells in the zG 
of Cyp11b1-null mice. Normally after BrdU infusion, BrdU-positive cells are observed 
to displace into zG during the first three weeks (Morrison et al, submitted for 
publication). Afterwards, this BrdU pulse is dispersed since the cell turnover in the 
narrow zG is quicker than the much wider zF. If cell turnover is slowed in Cyp11b1-null 
mice, the disappearance of BrdU pulse in zG will be delayed.  
The distribution of Ki67/BrdU dual labelled cells indicated that more BrdU-positive 
cells in zG had retained the potential to proliferate in adrenals of Cyp11b1-null mice. 
This raises the question of whether these cells are differentiated to the extent that 
Cyp11b2 is expressed and aldosterone is secreted. In previous studies under normal 
dietary circumstances, the expression of aldosterone synthase has often been shown to 
be discontinuous; not all cells with zG-cell morphology were positive for aldosterone 
synthase. Moreover, phenotypic characterisation found that aldosterone synthase 
expression was hardly detected in adrenals of Cyp11b1-null mice (Zhao X & Kenyon CJ; 
unpublished observations). The steroid profile of Cyp11b1-null mice is consistent with 
the idea that some zG cells may not be fully differentiated. Urinary aldosterone levels 
were reduced because excessive production of deoxycorticosterone (a weak 
mineralocorticoid) by zF cells supplants the need for aldosterone synthesis and 




In summary, studies described in this chapter provide valuable information about the cell 
division and cell displacement in the mouse adult adrenal cortex under physiological or 
pathophysiological stimulations. It is suggested that all adrenocortical zones are 
repopulated with cells originating from a common progenitor cell pool within the outer 
cortex followed by bidirectional migration from the zG/zF interface towards zG and zF. 
There is clear evidence that ACTH, both acutely and chronically, regulates the 
proliferation of the potential adrenocortical progenitor cells. However, it would appear 
that, after cell division, the differentiation of cells into aldosterone-secreting zG cells 
and glucocorticoid-secreting zF cells are separately controlled. Ultimately, what defines 
a zG or a zF cell is the mutually exclusive expression of Cyp11b2 and Cyp11b1. It seems 
likely that terminally-differentiated cells have lost the potential to divide and would 
express either aldosterone synthase or 11β-hydroxylase but not both. Intervening steps 
between the cell proliferation and the final differentiation have yet to be discovered, but 
studies with the H295R adrenocortical cells have identified a number of genes important 
for responses to angiotensin II and ACTH expressed earlier than Cyp11b1 and Cyp11b2 
(Romero et al., 2010; Romero et al., 2007).  
Control of the Cyp11b1/b2 locus is significant for the adrenocorticoid synthesis and the 
genetic control of cardiovascular disease. The means to discriminate between Cyp11b1 
and Cyp11b2 will be invaluable in tracking the stages of embryonic and adult stem cell 
differentiation and in studying pathophysiological states of Cyp11b1/b2 dysregulation. 
One approach would be to engineer a DNA construct in which Cyp11b1 and Cyp11b2 
are substituted by distinct fluorescent protein markers. It would be possible to monitor 
expression patterns of Cyp11b1 and Cyp11b2 under different physiological and 
pathophysiological conditions and to relate any changes back to their origin. The 
following chapters in this thesis describe how such a DNA construct was built and the 
methods used to assess the transcriptional control of these fluorescent proteins in vitro 





Chapter 4-Construction and in vitro characterisation 
of AS-mCherry-11B-EGFP BAC   
 
4.1 Introduction 
This chapter describes the construction and testing of a mouse BAC which has been 
engineered to express green and red florescent reporter proteins under the control of 
Cyp11b1 and Cyp11b2 promoters respectively. The techniques used to substitute 
fluorescent reporter sequence into the Cyp11b1/b2 locus and the methods used to assess 
functional activity of engineered BAC construct in adrenocortical cells in vitro are 
described. 
 
4.1.1 Fluorescent reporter and 2A peptide 
4.1.1.1 Fluorescent reporter 
The advent and use of fluorescent protein markers provide an opportunity to visualize, 
trace, monitor and quantify molecules with high spatial and temporal resolution in living 
cells, which allows the investigation of complicated biochemical events. The crucial 
fluorescent reporters are genetically-encoded proteins easily detected and imaged, and 
have been used as molecular tags in many applications. They can be used to replace any 
protein of interest via DNA vector construction, in order to analyze the location and 
movement of that protein, providing new insights into the cellular processes and protein 
functions within a cell (Lippincott-Schwartz and Patterson, 2003).  
The diversity of available fluorescent reporters has allowed an explosion of new tools 
for biological imaging. Several factors need to be considered when choosing the best 
fluorescent protein for imaging experiments (Shaner et al., 2005). The first requirement 




express efficiently and provide sufficient signal above the auto-fluorescence background 
to be reliably detected and imaged. Although all fluorescent proteins will photobleach 
upon extended excitation, they should be photostable during the desired experiment. 
Secondly, when the experimental images require quantitative interpretation, the intensity 
of fluorescent proteins should be insensitive to the environmental effects other than that 
being studied. Thirdly, as multiple labelling in a single cell is often required, the 
fluorescent proteins within a set should have minimal crosstalk in their excitation and 
emission wavelengths in the spectrum.  
Green fluorescent protein (GFP) from the jellyfish Aequorea victoria was first found to 
self-fluoresce under excitation. GFP was purified and its gene was subcloned into other 
organisms (Chalfie et al., 1994; Prasher et al., 1992; Tsien, 1998). Subsequent research 
of GFP creates many variants of different colours with different absorbance and 
emission spectra. Enhanced GFP (EGFP) is an important and most widespread GFP 
variant with improved folding and expression properties. Among all the red fluorescent 
protein variants, mCherry is considered to be the best red monomer for general purpose 





Table 4.1 Properties of fluorescent proteins of mCherry and EGFP 
Protein mCherry EGFP 
Source Lab Tsien. Clotech. 
Organism Discosoma sp. Aequorea victoria 
Excitation 
a
 (nm) 587 488 
Emission 
b 
(nm) 610 507 
Brightness (EC*QY) (mM*cm)^-1 16 34 
Photostability 
c
 13.1 23.9 
a, major excitation peak in the spectra; b, major emission peak in the spectra; c, fold 
improvement over fluorescein. This table is adapted from the report by Tsien (Shaner et 
al., 2005). 
 
4.1.1.2 2A peptide 
2A peptide has 20 amino acids in length. It is inserted between the coding sequences of 
any two genes in the multicistronic DNA constructs. 2A peptide can efficiently modulate 
the co-translational cleavage of artificial polypeptides (Szymczak et al., 2004). It is now 
a widespread practice to express multiple genes under the control of a single promoter in 
a so-called multicistronic construct. For the purpose of making genetically engineered 
animals, 2A peptide allows the expression of different proteins in a coordinated manner 
and reduces the cost of breeding multiple transgenic lines (Trichas et al., 2008). 2A 
could lead to reliable expression of multiple genes at equal levels in a wide range of 
biological systems, including mammalian cell culture, adult tissues and genetically-





4.1.2 BAC recombineering 
The traditional DNA-manipulating method is often limited by the availability of 
appropriate restriction cleavage sites in both cloning vectors and genomic DNA, and 
limited by the capacity for large DNA inserts. Bacterial artificial chromosome (BAC) is 
a DNA construct with an insert size of around 150-350 kb. During the past two decades, 
BACs have been used to generate long-range physical maps, to clone disease genes and 
to sequence the genome of a range of organisms including mice. Moreover, BACs are 
now being utilized for precision in genetic engineering and disease modelling, often 
involving transgenic manipulation of mice. As is known, the correct spatial and temporal 
expression of complex genes may be modulated by several upstream regulatory elements 
including the promoter sequence. BAC vectors are preferred for these kinds of genetic 
studies because they can accommodate much larger DNA sequences that include these 
upstream sequences. They carry less risk of DNA rearrangement and they have greater 
stability than other types of cloning vectors.  
Homologous recombination is a genetic rearrangement event in which nucleotide 
sequences are exchanged between two identical or similar DNA molecules. It is used in 
molecular biology to introduce mutations in target DNAs. A highly efficient defective 
phage λ-based homologous recombination system in E.coli has been developed which is 
termed BAC recombineering. This system has improved the efficiency of targeting and 
subcloning of linear BAC DNA through electroporation. DH10B, the original E.coli host 
strain for BAC vectors, has been engineered to include the defective λ prophage in 
DY380 substrain. The temperature-sensitive expression of gam, beta and exo proteins in 
defective λ prophage is under the rigid control of λ repressor (allele cI857) critical for 
the BAC recombineering system in DY380 cells (Muyrers et al., 1999; Narayanan et al., 
1999). More importantly, BAC recombineering is effective with DNA homology arms 
as short as 30-50 bp, which allows PCR-amplified fragments to be used to flank the 
targeting cassettes (Lee et al., 2001). BAC recombineering technology has greatly 
simplified the generation of large transgenic and gene-knockout DNA constructs 







During the past few years, an advanced recombinational cloning system termed 
Gateway
® 
cloning technology has set a new trend for molecular biological research, 
which allows cloning, transferring and  re-combining DNA fragments between different 
expression vectors (Bushman et al., 1985). Multisite Gateway
® 
cloning is a highly 
efficient system for assembling multiple DNA segments simultaneously into a single 
vector in a predefined order, orientation and reading frame. Gateway
® 
technology relies 
on the site-specific recombination reactions of phage λ, which can integrate into and 
excise out of the E.coli chromosome and shuttle between its lytic and lysogenic 
pathways (Landy, 1989).  
Site-specific recombination events happen at specific att sequences between phage DNA 
and bacterial chromosome, resulting in the strand exchanges of two pairs of DNA. The 
attB, attP, attL and attR sites are recombination sites utilized in Gateway
®
 technology. 
There are two crucial specific reactions involved in Gateway
®
 cloning: BP reaction and 
LR reaction (Fig 4.1).  First, a PCR product flanked with attB sites reacts with an attP-
containing donor clone to generate a central plasmid termed entry clone that usually 
carries attL sequences. LR reaction is between entry clones and a secondary plasmid 
named destination vector. The destination vector carries attR sequences to subclone 
DNA of interest into a final expression clone which is driven by the cytomegalovirus 
(CMV) promoter. The attL and attR sites after recombination are hybrid sequences 
comprising segments from parental vectors. There is no gain or loss of nucleotides 
during the Gateway
®
 cloning reactions. BP and LR reactions are reversible, and are 
catalyzed by different enzyme mixes. Depending on circumstances, prophage λ enters a 
lytic or lysogenic pathway. Donor clones, destination vectors and enzyme mixes (BP 
clonase and LR clonase) are commercially available in the Multisite Gateway
® 
Pro Kit 










Fig 4.1. BP reaction (A) and LR reaction (B) in Gateway® cloning 
Entry clones and expression clones are products of BP reactions and LR reactions 
respectively. Donor vectors, destination vectors and enzyme mixes (BP Clonase™ II 
and LR Clonase™ II) are provided in the Multisite Gateway
® 
Pro Kit from Invitrogen 












4.1.4 Murine adrenocortical Y1 cell line 
In vitro adrenocortical cell models have made great contributions to research on the 
adult adrenocortical cells. Primary culture of cells isolated from the adrenal gland 
requires the animal sacrifice, and cells have a limited lifespan with variable phenotypes 
after long-term isolation procedures. In contrast, adrenocortical cell lines allow the rapid 
Fig 4.2. Multisite Gateway® Pro 4-fragment recombination 
 Four PCR products flanked by different attB or attBr sites react with four different 
donor clones separately to generate four entry clones. The four entry clones together 
react with a destination vector via LR recombination reactions to create an expression 
clone containing four DNA elements of interest. This diagram is adapted from the 
Multisite Gateway
®










propagation of large numbers of functional cells with a constant phenotype without the 
need to kill animals. In vitro culture of adrenocortical cells has revealed considerable 
understanding of adrenocortical cell growth, maintenance of steroidogenic ability and 
responses to agonists (Rainey et al., 2004).  
The Y1 cell line is one such adrenocortical cell line. It was originally derived from an 
adult LAF1 (C57Lx A/HeJ) male mouse with an adrenocortical tumor (Rainey et al., 
2004). Cells isolated from this tumor lost their metastatic property after several passages 
of culture in vivo. They synthesized corticosterone in response to ACTH, suggesting this 
tumor might originate from the zona fasciculata of mouse adrenal cortex. The Y1 cell 
line was cloned from the culture-adapted murine adrenal tumor and is available from the 
American Type Culture Collection (ATCC).  
After prolonged incubation, Y1 cells lost the steroidogenic activity of 21-hydroxylase 
(CYP21) and gained the 20-keto-reductase activity, producing 20α-
dihydroxyprogesterone and 11β, 20α-dihydroxyprogeserone rather than corticosterone 
(Rainey et al., 2004). The Y1 cells can synthesize cholesterol de novo from acetate or 
glucose as substrate for steroidogenesis, and express genes encoding enzymes and 
factors important for steroidogenesis including CYP11A, CYP11B1, StAR, 3βHSD but 
not CYP11B2. Although wild-type Y1 cells respond robustly to ACTH stimulation, 
response can vary among different Y1 sub-clones after long-term incubation. 
Angiotensin II does not affect steroidogenesis in Y1 cells (Langlois et al., 1990). The Y1 
cell line is amenable to genetic manipulations. Gene transfection of Y1 cells has been 
used to investigate the actions of physiological agents on adrenocortical cell 
proliferation and steroidogenesis, and to study the regulation of steroidogenic gene 
expression.  
Y1 cells have been used in the present study to investigate the functional properties of a 







4.2.1 BAC recombineering using DY380 bacterial strain  
The E.coli strain DY380 cell used for BAC recombineering in this study was derived 
from DH10B strain by introducing a defective λ prophage (Lee et al., 2001; Liu et al., 
2003). Targeting cassettes with homology arms were created through conventional 
molecular cloning techniques and prepared by linearisation and DNA purification. The 
BAC recombineering efficiency is higher when the homology arms are longer. The BAC 
DNA was transformed into electrocompetent DY380 cells first. A 5 ml overnight culture 
was inoculated from a single isolated DY380 colony containing BAC DNA. The 
bacterial cells were cultured overnight at 32°C or lower with appropriate selection and 
then diluted 1:50 to make a 25 ml LB culture. This was incubated for 3-5 hr in a 32°C 
shaker until the OD600 reached 0.6 whereupon 10 ml of cultured cells were transferred to 
an autoclaved 100 ml Erlenmeyer flask, and incubated in a shaking water bath at 42°C 
for exactly 15 min. The remaining cells were put back into culture for 15 min at 32°C as 
un-induced negative control. Both heat-shock induced and un-induced cells were then 
placed in an ice/water bath to cool rapidly for one minute with gentle shaking, and were 
then transferred to 15 ml pre-chilled Falcon tubes and spun at 3,000 x g (0°C) for 5 min. 
Cell pellets were first gently resuspended in 1 ml of ice-cold water and then filled up to 
10 ml with ice-cold water. The tubes were inverted several times before centrifugation 
again as before. This washing process was repeated three times with ice-cold water. 
After the last spin, the supernatant was discarded and the competent DY380 cells 
containing BAC DNA were gently resuspended in 50 μl of ice-cold water on ice and 
transferred to a pre-chilled microfuge tube. Targeting cassette (1-5 μl of DNA, 1-10 ng) 
was added and mixed well with the competent cells, and then transferred into a 2 mm 
electroporation cuvette. The electroporation pulse was triggered (for conditions see 
Section 2.2.4.4) and the cells were recovered. The transformed bacterial cells was plated 





4.3.1 Generation of AS-mCherry-11B-EGFP BAC vector 
The starting material for these studies was a BAC clone (ASBAC, ~133kb) which has a 
125kb DNA insert of mouse origin and spans the entire Cyp11b2- Cyp11b1 locus 
(Appendix Fig. A1). ASBAC comprises 65kb endogenous DNA sequence upstream of 
Cyp11b2 (aldosterone synthase, AS) and 45kb endogenous DNA sequence downstream 
of Cyp11b1 (11β-hydroxylase, 11B). To most effectively recapitulate the endogenous 
expression of Cyp11b1 and Cyp11b2 during the development and maintenance of the 
mouse adult adrenal cortex, fluorescent imaging reporters mCherry and enhanced GFP 
(EGFP) were subcloned and introduced to target AS and 11B on the wild-type ASBAC, 
respectively. The combination of mCherry and EGFP was chosen because of the 
brightness of their signals and because there is no crosstalk in their excitation and 
emission wavelength (Fig. 4.3). This was confirmed in an adrenocortical cell 
environment by transiently co-expressing mCherry and EGFP under the control of CMV 
promoter in H295R cells. Bright-field images and fluorescent images of mCherry and 
EGFP are shown in Fig. 4.4. Signals were intense with no spectral overlap.  
 
 
Fig. 4.3. The spectra of mCherry and GFP proteins are well separated 













 cloning technology was applied to create the targeting cassettes containing 
mCherry or EGFP as the imaging reporter as outlined in Fig. 4.5A-B. Zeocin and 
hygromycin were also included for antibiotic selections in both bacterial and mammalian 
cells. After multiple BP reactions and LR reactions, AS expression clone and 11B 
expression clone were generated as targeting constructs to disrupt Cyp11b2 and 
Cyp11b1 on the ASBAC, respectively.  
bright field 
Fig. 4.4. Bright-field and fluorescence microscopic images of 
transiently transfected H295R cells   
Cells were co-transfected with CMV-driven EGFP plasmid (pEGFP-N1, 4.7kb) and 
CMV-driven mCherry plasmid (pmCherry-N1, 4.7kb) (Appendix Fig. A2). The 
fluorescence signals of EGFP and mCherry were intensive, and were clearly 










   
Fig. 4.5. Strategy of creating AS and 11B targeting constructs using 
Gateway cloning technology  







The Gateway recombinational system transferred PCR-generated DNA fragments 1-8 
(Fig. 4.6) into the corresponding donor clones (provided in the MultiSite Gateway® Pro 
Kit) producing entry clones 1-8 (Table 4.1). All DNA fragments created by PCRs were 
verified by DNA sequencing to eliminate any chance of DNA mutations, and the correct 
entry clones were also confirmed by restriction enzyme digestion and DNA sequencing. 
Table 4.2 Entry clones, DNA fragments, PCR templates and PCR primers 
Entry clone DNA fragment / length  PCR template PCR primer 
1 attB1-5’AS-attB5r / 819bp pAS5’Kan3’  EC1for, EC1rev 
2 attB5-2AmCherrypA-attB4 / 
1646bp 
p2A-mcherry-pA  EC2for, EC2rev 
3 attB4r-Zeo-attB3r / 1282bp pAS5’Zeo3’  EC3for, EC3rev 
4 attB3-3’AS-attB2 / 613bp pAS5’Kan3’  EC4for, EC4rev 
5 attB1-5’11B-attB5r / 746bp 11BKO-hygro 
BAC  
EC5for, EC5rev 
6 attB5-2AEGFPpA-attB4 / 
1626bp 
p2A-EGFP-pA  EC6for, EC6rev 
7 attB4r-Hygro-attB3r / 1945bp 11BKO-hygro 
BAC 
EC7for, EC7rev 
8 attB3-3’11B-attB2 / 664bp 11BKO-hygro 
BAC 
EC8for, EC8rev 
AS 5’ homology arm (759 bp) spans exons 1-2 of Cyp11b2; AS 3’ homology arm (555 
bp) spans exons 8-9 of Cyp11b2; 11B 5’ homology arm (743 bp) spans exons 1-2 of 
Cyp11b1; 11B 3’ homology arm (606 bp) spans exons 8-9 of Cyp11b1. 
All the PCR templates are DNA vectors described in Section 2.1.7. The vector maps of 
entry clones 1-8 are displayed in Appendix Fig.A3-A6. Sequences of PCR primers are 








Entry clones 1-4 were combined into a destination clone to create AS expression clone 
through LR reactions, while entry clones 5-8 were combined to create 11B expression 
clone via LR reactions (Fig. 4.5). The AS expression clone had four fragments: AS 5’ 
homology arm; 2A-mCherry CDS; zeocin CDS; AS 3’ homology arm. The 11B 
expression clone contained: 11B 5’ homology arm; 2A-EGFP CDS; hygromycin CDS; 
11B 3’ homology arm. The vector maps of AS and 11B expression clones are given in 
Appendix Fig. A7. 
AS expressing clone (pAS5’-mCherry-Zeo-3’) and 11B expressing clone (p11B5’-
EGFP-Hygro-3’) were identified by BamHI digestion and PstI digestion (Fig. 4.7A-D). 
Clone NO.2 was chosen as the correct AS targeting construct and clone NO.4 was 
chosen as the correct 11B targeting construct. Both AS expression clone and 11B 
expression clone were further confirmed by DNA sequencing and verified through the 
transient transfection assay in H295R cells. The expression of mCherry and EGFP were 
clearly detected in transfected H295R cells indicating that cDNA sequence of mCherry 
or EGFP reporter in the targeting construct was in frame with the 5’ and 3’ homology 
arms (Fig. 4.7E-F).   
Fig. 4.6. Electrophoresis of DNA fragments generated by PCRs 
PCR templates and primers are listed in Table 4.1.  
Lane M is 100bp DNA marker. The sizes of PCR fragments 1-8 (F1-F8) are 819bp, 
1626bp, 1282bp, 613bp, 746bp, 1646bp, 1945bp and 664bp. 
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Fig. 4.7. Identification of AS expression clone and 11B expression clone 
(A) PstI digestion of AS expression clone (pAS5’-mCherry-Zeo-3’). The correct bands 
are 4007bp, 2442bp, 914bp, 722bp, 649bp, 525bp and 201bp. Lane M is 100bp DNA 
ladder. (B) BamHI digestion of AS expression clone. The correct bands are 4013bp, 
3330bp and 2117bp. Lane M is 1kb DNA ladder. Lane 1-4 represents clone candidate 
NO.1-4. Clone NO.2 is chosen for further construct building. 
(C) BamHI digestion of 11B expression clone (p11B5’-EGFP-Hygro-3’). The correct 
bands are 3998bp, 3380bp and 2801bp. (D) PstI digestion of 11B expression clone. 
The correct bands are 4007bp, 2493bp, 1640bp, 892bp, 526bp, 420bp and 201bp. Lane 
M is 2-log DNA ladder. Lane 1-9 represents clone candidate NO.1-9. Clone NO.4 is 
chosen for further construct building.  
(E) Fluorescence image of verified AS expression clone expressing mCherry driven by 
CMV promoter. (F) Fluorescence image of verified 11B expression clone expressing 

















The resultant AS and 11B targeting constructs were linearised with SacII and HindIII 
(see Appendix Fig.A7 for restriction sites). The BAC recombineering strategy outlined 
in Fig. 4.8 was used to engineer a modified BAC construct named AS-mCherry-11B-
EGFP BAC. Targeting of Cyp11b1 gene in ASBAC was followed by targeting of 

















Fig. 4.8. Outline strategy for the generation of AS-mCherry-11B-EGFP BAC 
using BAC recombineering  
Targeting of 11β-hydroxylase in ASBAC vector is followed by targeting of aldosterone 
synthase. The final double knockout BAC vector contains mCherry and EGFP reporters 
driven by endogenous Cyp11b2 and Cyp11b1 promoters and regulatory apparatus, 
respectively.  
AS 5’-2A-mCherry-PGK-zeo-3’ 








Colony PCRs were employed to screen the correct recombinational AS-mCherry-11B-
EGFP BAC clone using a panel of 6 PCRs to determine the presence of targeting 
fragments and the absence of endogenous Cyp11b2-Cyp11b1 loci. The locations of 
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Fig. 4.9. Locations of PCR screening primers  
The colony PCR screening strategy is based on the rule that the correct homologous 
recombinants should be positive for PCR1 (ASK5’), PCR2 (ASK3’), PCR3 (11BK5’) 
and PCR4 (11BK3’), and be negative for PCR5 (ASWT) and PCR6 (11BWT).  
PCRs 1-4 are BAC transgene-specific PCRs and PCRs 5-6 are endogenous gene-specific 
PCRs. 
(A) ASBAC. (B) AS-mCherry-11B-EGFP BAC.  
Sequences of PCR primer pairs and length of PCR products for each PCR reaction are 
seen in Appendix Table A2. 
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The AS-mCherry-11B-EGFP BAC clone was selected based on the strength and 
reproducibility of the positive signal by PCR. Finally the optimal AS-mCherry-11B-
EGFP BAC clone was identified by PCR1-6 (Fig. 4.10), and was further confirmed by 
BamHI digestion (Fig. 4.11) and DNA sequencing. 
 
 




















Fig. 4.10. Verification of the correct AS-mCherry-11B-EGFP BAC clone 
by colony PCRs 
 PCRs 1-4 are BAC transgene-specific PCRs and PCRs 5-6 are endogenous gene-
specific PCRs. The desired BAC clone was positive for PCR1-4 and negative for 
PCR5-6. ASBAC was used as control DNA.  
M, 2-log DNA marker 
Sequences of PCR primer pairs and length of PCR products for each PCR reaction 
are seen in Appendix Table A2. Locations of PCR primers are seen in Fig. 4.9. 
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Fig. 4.11. Confirmation of the correct AS-mCherry-11B-EGFP BAC 
using BamHI digestion 
 ASBAC is used as control BAC.  
The left figure is the band patterns after BamHI digestion of AS-mCherry-11B-
EGFP BAC (lane 1) and ASBAC (lane 2) predicted by Vector NTI software. 
Compared to ASBAC, AS-mCherry-11B-EGFP BAC has two additional DNA 
bands of 6383bp and 2801bp (red arrow) while it lacks two DNA bands of 7363bp 
and 4034bp (green arrow).  
The right figure shows the band patterns of AS-mCherry-11B-EGFP BAC candidate 
(lane 1) and ASBAC (lane 2) digested with BamHI which are identical to that 













4.3.2 Production of AS-mCherry-11B-EGFP transgenic Y1 cell line 
Y1 cell line is a mouse adrenocortical tumor cell line already described in Section 4.1.3. 
The wild-type Y1 cells (passage 11) were characterized both morphologically and 






Fig. 4.12. Wild type (WT) Y1 cell line characterized under normal culture 
conditions 
(A) Morphology of Y1 cells at passage 11. Cells were flat and columnar of zona 
fasciculata cell-like. (B) Y1 cells were stained with Oil Red O to indicate the presence of 
lipid droplets (see Section 2.2.8.2.) (C) WT Y1 cells were characterized by RT-PCR at 
the transcriptional expression level. Steroidogenic genes SF-1, StAR, 3β-HSD, cyp21, 
ACTH-R and cyp11b1 were expressed while cyp11b2 was not expressed in WT Y1 cells. 
β-actin was used as the internal control gene. Mouse adrenals and mouse embryonic 
stem cells were adopted as positive and negative control, respectively. RT-PCR primers 
are listed in Appendix Table A3. 
It was observed that Y1 cells under normal culture conditions grew as flat and adherent 
cells with the polyhedral and columnar shape. Lipid droplets in Y1 cells were stained 
with Oil Red O indicating Y1 cells could synthesize cholesterol de novo for 
steroidogenesis. RT-PCR assay identified the expression of key steroidogenic enzymes 






in Y1 cells including SF-1, StAR, 3β-HSD, Cyp21, ACTH receptor (ACTH-R) and 
Cyp11b1, while Cyp11b2 was not expressed in Y1 cells.  
To characterize the generated AS-mCherry-11B-EGFP BAC in vitro, this BAC vector 
was linearised with NruI and introduced into Y1 cells via electroporation. Transgenic 
clones incorporating the linear AS-mCherry-11B-EGFP BAC DNA were isolated under 
hygromycin selection for two weeks. Transgene-negative cells were killed gradually 
while positive cells propagated and formed individual cell clones. Finally 32 stable 
antibiotic-resistant clones were isolated and assessed by a panel of two PCRs (ASK5’, 
11BK5’) to determine the presence of AS-mCherry-11B-EGFP transgene (Fig. 4.13).  
       
 
      
 
     




Fig. 4.13. PCR screening analysis of isolated Y1 cell clones 
Stably transfected Y1 cell clones were screened for integration of the AS-mCherry-11B-EGFP 
BAC transgene by PCRs. Lane 1-32 represents results from individual Y1 cell clones NO.1-32. 
AS-mCherry-11B-EGFP BAC DNA was used as positive control (PC) for PCRs.  
(A) PCR screening with ASK5’for and ASK5’rev primers for AS-mCherry transgene. (B) PCR 
screening with 11BK5’for and 11BK5’rev primers for 11B-EGFP transgene.  
Sequences of PCR primer pairs and length of PCR products for each PCR reaction are seen in 
Appendix Table A2. Locations of PCR primers are seen in Fig. 4.9. 
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20 clones out of 32 candidates were positive for PCR screens indicating that they had 
incorporated the AS-mCherry-11B-EGFP transgene, among which clone 3, 6, 12, 24 and 
29 were selected for further assessment and characterization. Normally transgene 
expression is affected by integration sites and copy numbers. Foreign AS-mCherry-11B-
EGFP transgene was incorporated into the genome of Y1 cells in a random fashion, and 
different Y1 cell clones might have different integration sites and copy number of the 
transgene. To better characterize AS-mCherry-11B-EGFP BAC and select the optimal 
transgenic Y1 cell clone, the transgene expression was examined in clones 3, 6, 12, 24, 
and 29 by RT-PCR. Endogenous expression of SF-1, Cyp11b1 and Cyp11b2 genes were 
also examined (Fig. 4.14). Consistent with WT Y1 cells, all clones expressed SF-1 and 
cyp11b1 but not cyp11b2. Clones 3, 6, 12 and 29 expressed 11B-EGFP transgene (TG) 
transcript but not AS-mCherry TG transcript indicating that the promoter and all the 
regulatory apparatus contained in AS-mCherry-11B-EGFP BAC could direct the 
appropriate expression of  Cyp11b1 and the transcriptional machinery of Cyp11b2 was 




Fig. 4.14. Transcriptional expression of AS-mCherry-11B-EGFP transgene 
in Y1 cell clones 
β-actin was used as an internal control. Expression of endogenous SF-1 and cyp11b1 
genes was observed in all the five transgenic cell clones (No. 3, 6, 12, 24, 29). 
Expression of 11B-EGFP TG transcript was detected in clone 3, 6, 12 and 29. None of 
the transgenic clones expressed cyp11b2 or AS-cherry TG transcript.  




Transgenic cell clones 3, 6, 12 and 29 were further characterized for AS-mCherry-11B-
EGFP transgene expression at the protein level. The expression of EGFP and mCherry 
was examined by fluorescent microscopy (Fig. 4.15). All the four transgenic clones 
showed EGFP but not mCherry expression. The intensity of EGFP signals varied 
enormously between clones indicating the difference in transgene expression levels. The 
majority of cells in clone 3 and 29 showed little or no EGFP signal. The EGFP signal in 
clone 12 was weak, despite the evidence of physical integrity and the verified mRNA 
expression of transgene. Cells in clone 6 had a much higher fluorescent signal although 
the EGFP expression pattern appeared nonuniform and mosaic (Fig. 4.15). This 
phenomenon of instability and non-homogeneity of transgene expression in isogenic 
cells of clone 6 was confirmed in Fig. 4.16. It was assumed that stably transfected Y1 
cell clones might have accumulated cell-to-cell variations in transgene expression levels 








Fig. 4.15. Microscopic images of stably-transfected Y1 clones 
The expression of AS-mCherry-11B-EGFP transgene was examined in individual clones 
at the protein level. All images were captured with the same light intensity under bright 
field and with the same exposure time under fluorescence channel.  
(A) bright field. (B) merged channel of GFP and mCherry. (C) merged channel of GFP, 




Fig. 4.16 showed a single ‘snapshot’ analysis of transgenic clone 6 confirming the 
heterogeneous expression pattern of AS-mCherry-11B-EGFP transgene, which might 
result from: (i) the intrinsic fluctuations in transgene expression; (ii) the instability of 






To examine whether the nonuniformity of transgene expression was attributed to cell 
contamination in clone 6, clonal formation assay was performed. The cell suspension of 
clone 6 was diluted to achieve single-cell culture per well by plating in a 96-well plate. 
After two weeks, individual clones in each well were formed from the single cells. This 
clonal formation assay eliminated the chance of cell contamination between clones. 
Eventually, the transgene expression of newly-formed cell clones was checked (Fig. 
4.17).  The cell-to-cell mosaicism phenomenon was still observed in newly-formed 
single clones, confirming the nonuniform expression of AS-mCherry-11B-EGFP 
transgene not caused by the impurity of cells in transgenic clone 6.  
Fig. 4.16. Stability and homogeneity of AS-mCherry-11B-EGFP transgene 
expression in cells of clone 6 
Within the same cell population, EGFP expression was variable and some cells even 
expressed no EGFP. No cells expressed mCherry.  











Fig. 4.17. Mosaicism of transgene expression amongst cells cultured from single 
cells of clone 6. (A) bright field (B) merged channel of GFP and RFP
B
Fig. 4.17. Mosaicis  of transgene expression amongst cells cultured from 
single cells of transgenic clone 6  








The expression of AS-mCherry-11B-EGFP transgene and endogenous Cyp11b1 in clone 
6 was also identified by immunofluorescence. Cells of clone 6 were fixed with 4% 
paraformaldehyde (PFA), and stained with anti-CYP11B1 (11β-hydroxylase) antibody 
and anti-GFP antibody. The methodology of immunofluorescent detection of fixed cells 
was established (Fig. 4.18). All the cells in transgenic clone 6 were positive for 11β-
hydroxylase indicating uniform expression of CYP11B1 (Fig. 4.18-4.19). The variegated 
expression of AS-mCherry-11B-EGFP transgene was also detected by 






Fig. 4.18. Immunofluorescence labeling of 11β-hydroxylase in the cells 
of transgenic clone 6 
 Cell nuclei were counterstained with DAPI (blue). 11β-hydroxylase was detected 















Fig. 4.19. Immunofluorescent detection of 11β-hydroxylase and EGFP 
transgene in transgenic clone 6 
Cell nuclei were counterstained with DAPI (blue). 11β-hydroxylase was detected 
using Cy5-conjugated anti-CYP11B1 antibody (red). Exogenous EGFP reporter was 
labelled with Fluorescein-conjugated anti-GFP antibody (green).  
(A) Cy5. (B) Fluorescein. (C) Cy5 and DAPI. (D) Fluorescein and DAPI. (E) Cy5 and 











In summary, AS-mCherry-11B-EGFP transgenic Y1 cell line was generated and the 
optimal transgenic clone 6 was chosen for further expression studies of the transgene. 
Transgenic clone 6 was verified to nonuniformly and stably express EGFP but not 
mCherry consistent with the fact that Cyp11b1 but not Cyp11b2 was expressed in Y1 
cells.  
 
4.3.3 Responses of AS-mCherry-11B-EGFP transgenic Y1 cells to various 
stimuli 
 
Generally, steroidogenic gene expression and steroid production are positively regulated 
by ACTH or cAMP in Y1 cells. Also, forskolin, an activator of adenyl cyclase, has been 
widely used to study cAMP-induced steroidogenesis in adrenocortical cell lines (Rainey 
et al., 2004). Previous studies have shown clonal variations of Y1 cells in their 
responsiveness to ACTH, cAMP and forskolin stimulations (Frigeri et al., 2002). The 
effects of ACTH, cAMP and forskolin treatment on AS-mCherry-11B-EGFP transgene 
expression were therefore examined in transgenic Y1 cells of clone 6.  
Cells were maintained in the presence of ACTH (100nM), cAMP (1mM) or forskolin 
(10μM) for 24 h. Changes in cell shape were observed after cAMP or forskolin but not 
ACTH treatment (Fig. 4.20). Responding cells retracted the extended plasma membranes 
becoming spherical and attached less firmly to the culture surface. Morphological 
change was rapid and significant effects were observed after 30 min of incubation with 
cAMP or forskolin. Maximum effects were seen at 24 h (Fig. 4.20A). ACTH (100nM) 
had no visible effects on the morphology of AS-mCherry-11B-EGFP transgenic Y1 cells 






Fig. 4.20. Time course of ACTH, cAMP or forskolin effects on the 
morphology of AS-mCherry-11B-EGFP transgenic Y1 cells 
Microscopic images of transgenic Y1 cells were captured at 30 min, 1 h, 2 h, 6 h, and 24 
h after treatments. Cell rounding effects were observed as early as 30 min after cAMP 
(1mM) or forskolin (10μM) treatment and were maximal at 24 h. Cells showed no 
response to ACTH (100nM) stimulation.  














Fig. 4.20. Time-course of ACTH, cAMP and forskolin effects on the morphology of transgenic 
AS-mCherry-11B-EGFP Y1 cell . Microscopic imag s of transgenic Y1 cells 30 min, 1 , 4 h, 6 h, and 24 h 
after treatment. Cell rounding effects were observed as early as 30 min after cAMP (1 M) or forskolin (10μM) 




The AS-mCherry-11B-EGFP transgenic Y1 cells failed to respond to ACTH stimulation 
because the receptor for ACTH was not expressed in clone 6 (Fig. 4.21). It was shown 
that ACTH-R expression was generally lower in all transgenic Y1 cells compared with 





The expression of other mRNA transcripts in clone 6 cells after ACTH, cAMP and 
forskolin treatments are shown in Fig. 4.22. Clone 6 cells were incubated for 6 or 24 h 
with the presence of vehicle, ACTH (100nM), cAMP (1mM) or forskolin (10μM). 
Medium was removed and cellular RNA was recovered to quantify the expression of SF-
1, Cyp11b1 and EGFP transgene by real-time qPCR.  
As expected, ACTH had no significant effect on the expression of SF-1, Cyp11b1 or 
EGFP transcript after 6 h or 24 h of treatment. SF-1 mRNA was significantly increased 
by cAMP or forskolin at 6 h but returned to normal after 24 h treatment (Fig 4.22A) 
indicating that SF-1 transcript was not stable. Cyp11b1 mRNA was also significantly 
increased after 6 h of cAMP or forskolin treatment, and continued to rise to higher levels 
at 24 h (Fig 4.22B). After 6 or 24 h of cAMP or forskolin stimulation, expression of 
EGFP contained in the AS-mCherry-11B-EGFP transgene was significantly higher than 
Fig. 4.21. ACTH receptor expression in transgenic Y1 clones 
The expression of ACTH-R was assessed by RT-PCR in clones 3, 6, 12, 24 and 29 (see 
Section 4.3.2). β-actin was used as internal control gene. RNA sample from mouse 
adrenals was used as positive control. Clones 3, 6 and 24 did not express ACTH-R. 




unstimulated controls, although the degree of effects at 24 h was no greater than at 6h 
(Fig. 4.22C). Difference in the Cyp11b1 and EGFP expression are shown as a ratio in 
Fig. 4.22D. A lower ratio of EGFP to Cyp11b1 after 24 h of incubation with cAMP or 




Fig. 4.22. SF-1, Cyp11b1 and EGFP expression of AS-mCherry-11B-
EGFP transgenic clone 6 cells after ACTH, cAMP or forskolin treatment 
Results are presented as mean ± SEM from at least three independent experiments and 
levels of mRNA expression were normalised against 18s ribosomal RNA.  
Statistical differences from untreated controls were calculated by ANOVA (*, 
P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001).  










































































































































Fig. 4.22. Sf-1, Cyp11b1  and EGFP mRNA expression by clone 6  AS-mCherry-11B-EGFP 
transgenic Y1 cells in response ACTH, cAMP or forskolin
Results are presented as mean ±SEM from at least three independent experiments. mRNA values 
normalised against18s ribosomal  RNA.Statistacal d ifferences from the untreated controls. were 
assessed by ANOVA (*, P<0.05. **, P<0.01. ***, P<0.001. ****, P<0.0001).  Primer sequences for 




Since Cyp11b1 expression in AS-mCherry-11B-EGFP transgenic Y1 cells was increased 
by cAMP treatment, its effect on enzyme activity was checked.  The normal mouse 
adrenal cortex primarily produces corticosterone. As mentioned in Section 4.1.4, the 
main steroid products in cultured Y1 cells are 20α-dihydroxyprogesterone and 11β, 20α-
dihydroxyprogeserone as the 20-keto-reductase is activated in Y1 cells. To estimate the 
effects of cAMP treatment on activities of 11β- hydroxylase and aldosterone synthase 
encoded by Cyp11b1 and Cyp11b2, clone 6 cells were incubated with the addition of 
deoxycorticosterone (DOC), the intermediate substrate for corticosterone and 
aldosterone. The concentrations of corticosterone and aldosterone in media were 
measured by ELISA.  
Fig. 4.23 showed that cAMP-treated cells converted more DOC to corticosterone 
indicating that Cyp11b1 had been successfully translated into functional enzyme 11β- 
hydroxylase. The synthesis of aldosterone was much less than that of corticosterone 
even with the addition of DOC reflecting the fact that Y1 cells expressed very low levels 
of Cyp11b2. As expected, aldosterone synthesis was not affected by cAMP treatment 
which was consistent with the previous result that cAMP did not affect Cyp11b2 













































































Fig. 4.23. Effects of cAMP stimulation on 11β- hydroxylase and 
aldosterone synthase activities in transgenic Y1 clone 6 cells 
 
Corticosterone and aldosterone in the media of cells was purified before cAMP 
treatment or at 24 h after treatment with the addition of deoxycorticosterone (DOC). 
Results are mean ± SEM from three independent experiments.  







In the present study, an AS-mCherry-11B-EGFP BAC vector was successfully generated 
using Gateway
® 
cloning technology and BAC recombineering. In this targeted BAC, 
Cyp11b2 and Cyp11b1 were genetically substituted with mCherry and EGFP reporters 
respectively. This 130kb BAC construct contained the entire Cyp11b2/b1 locus and 
65kb of upstream and 35kb of downstream flanking DNA, which it was hoped would 
contain all the endogenous promoters and regulatory apparatus required for the 
appropriate expression of Cyp11b2 and Cyp11b1 in cell culture and in transgenic 
animals. Ideally, the mCherry and EGFP coding sequences in the AS-mCherry-11B-
EGFP BAC should mark the expression of Cyp11b2 and Cyp11b1 localised to 
aldosterone-secreting zG and corticosterone-secreting zF cells respectively in mouse 
adrenals. Before the assessment whether mCherry and EGFP was expressed in an 
appropriately controlled manner in transgenic mice, the AS-mCherry-11B-EGFP BAC 
was first tested in vitro in mouse adrenocortical cells. 
Y1 tumor cell line was the only cell line of mouse adrenocortical origin available for 
testing. However, the characterization of AS-mCherry-11B-EGFP BAC transgene is 
limited in Y1 cells because Cyp11b2 is not normally expressed, thus EGFP but not 
mCherry signals are expected. The AS-mCherry-11B-EGFP transgene was linearised 
and introduced into Y1 cells in vitro via electroporation. Variegated EGFP expression in 
different transgenic clones was observed mainly ascribed to varied integration sites and 
copy numbers of transgene in the cell genome. Five clonal candidates were isolated and 
identified after appropriate selection and PCR screens. Clonal cell line 6 was assessed by 
fluorescent microscopy to be the optimal AS-mCherry-11B-EGFP transgenic Y1 cells 
with the highest expression of EGFP reporter. 
Transgenic cells of clone 6 stably expressed EGFP but not mCherry consistent with the 




EGFP contained in the transgene was nonuniform in clone 6 cells, ranging from 
homogenous expression to mosaic to even complete silencing. Theoretically, a stably 
transfected cell clone, once identified, is expected to express the transgene in all cells at 
constant levels. It has been reported that the phenotypic characterization of transgene 
expression shows remarkable differences between isogenic cell lines (Kaufman et al., 
2008; Liu et al., 2006). However, when clonal cell line 6 was purified and cultured from 
single cells, the mosaicism of transgene expression remained not attributed to cell 
contamination. It is not known whether this nonuniform pattern takes place at the 
transcriptional level or is a consequence of the instability of fluorescent reporter EGFP. 
The mosaic expression patterns of transgene and the progressive silencing are often 
thought to be triggered by epigenetic modifications of foreign DNAs, which are 
generally seen in genetically-engineered in vitro cell lines and organisms.  
The responsiveness of transgenic Y1 cells to stimulations of cAMP and forskolin was 
also examined. The induction of morphological changes in transgenic Y1 cells was 
observed as early as 30 min after the cAMP and forskolin treatment, and reached 
maximum after 24 h. This cell rounding effect has been linked to effects on 
steroidogenesis (Rainey et al., 2004). Forskolin and cAMP treatment have been shown 
to have significant effects on steroidogenic gene expression in transgenic Y1 cells. The 
expression of SF-1 mRNA was transiently increased after 6 h of cAMP and forskolin 
treatment. More sustained increases in the expression of transgene and Cyp11b1 were 
also observed, although the time course of their expression was not identical. EGFP 
expression levels at 6 h and 24 h were similar. The ratio of EGFP to Cyp11b1 expression 
level in stimulated cells was lower than unstimulated cells at 24 h. This may have 
resulted from the differences in the stability of transcripts. The transgene transcript 
might be responsive to physiological stimuli but be less stable than Cyp11b1 transcript. 
The effects of cAMP treatment on Cyp11b1 expression corresponded to the effects on 
11β-hydroxylase activity. The conversion of substrate DOC to corticosterone was 
increased by cAMP treatment, and aldosterone synthesis was not affected confirming a 




AS-mCherry-11B-EGFP transgenic Y1 cells did not respond to ACTH treatment either 
by showing a change in cell morphology or by increasing gene expression levels. 
Further analysis of several different transgenic clones showed variable levels of ACTH 
receptor expression. The resistance of clone 6 transgenic Y1 cells to ACTH treatment 
results from a complete lack of ACTH-receptor expression. It has been reported that Y1 
cells, similar to other tumor cells, accumulate mutations and clonal variants with 
different steroidogenic abilities when they are maintained in continuous culture for very 
long time.  
Comparisons between the data obtained from the microscopic observation, 
immunofluorescent detection, quantitative real-time PCR and ELISA have to be 
interpreted with caution as timing of the appearance of mRNA and protein is quite 
different, and the post-translational modifications might affect the half-life and the 
biological activity of the mature molecules.  
In conclusion, the AS-mCherry-11B-EGFP BAC construct was generated in which 
Cyp11b1 or Cyp11b2 is marked with an independent fluorescent reporter EGFP or 
mCherry respectively. This BAC construct was characterised in Y1 cells. Following 
stable integration of the AS-mCherry-11β-EGFP BAC construct into the Y1 cell genome, 
detection of EGFP signal demonstrated functional 11β-EGFP reporter activity, as would 
be expected for a reporter driven by the promoter region of an endogenous gene 
normally expressed in Y1 cells. However, the observed mosaic pattern of 11β-EGFP 
reporter expression failed to fully recapitulate the endogenous expression pattern of 
Cyp11b1, which would be normally expected to be expressed in all Y1 cells and was 
apparently expressed in all Y1 sub-lines generated. The characterization of mCherry 
reporter contained in the BAC transgene is limited because of the deficiency of Cyp11b2 






Chapter 5-Generation of AS-mCherry-11B-EGFP 
BAC transgenic mice 
 
5.1 Introduction 
5.1.1 Creation and application of transgenic mice  
The mouse species is an ideal animal model for functional and developmental studies, 
not only because the genomes of mouse and human are quite similar, but also gene-
manipulating techniques have greatly developed in recent decades allowing the 
introduction of new genetic material into the mouse germ line. 
In 1981, Gordon and Brinster (Brinster et al., 1981; Gordon and Ruddle, 1981) 
introduced a technique of making transgenic mice by transmitting foreign DNAs into the 
early-stage mouse embryos. Since then, the generation of transgenic mice has become 
routine and is commonly applied to the characterization of exogenous genes in vivo 
(Rulicke and Hubscher, 2000). The most popular method for creating transgenic mice is 
the direct microinjection of transgene DNA into one pronucleus of a fertilized egg. Mice 
are particularly suitable for microinjection because it is easy to obtain a relatively large 
number of oocytes from female mice. Superovulation is a process of drug-induced 
production of multiple eggs. Fertilized eggs for injection are harvested from the oviduct 
of superovulated females the next morning. The foreign DNA is injected into the male 
pronucleus in fertilized eggs normally preferred as it is larger and better positioned (Fig. 
5.1). The appearance of the male pronucleus is a time- and strain-dependent event. The 
transgene DNA is integrated randomly into chromosomes during chromosome 
replication. Microinjected DNA can persist in the form of free molecules for several 
days and, once integrated into a chromosome, the consequential offspring should contain 








The initial offspring carrying the transgene DNA are termed transgenic founder (GO) 
mice, which develop from the injected zygotes. The transgenic founder mice are 
subsequently bred with wild-type mice to identify germline transmission and to establish 
transgenic mouse lines. If the egg-donor female mice are of an inbred line, transgenic 
founders should be bred to the same background to maintain the pure inbred background. 
Ideally, the stably-integrated transgene is transmitted in a Mendelian fashion to the 
progeny. However, different transgenic founders can have different integration sites and 
copy numbers of transgene, and even mosaic germline patterns. Therefore each founder 
carrying the same transgene should be bred independently. Due to the different dose and 
position effects, every transgenic founder might have a different level of transgene 
expression.  
If the native expression pattern of a transgene is intended, the best strategy is to use large 
DNA constructs, such as BACs and YACs which can harbour the entire genomic locus 
of the transgene. Up to 300 kb of DNA fragments can be cloned into BAC vectors and 
injected into fertilized eggs (Shizuya et al., 1992).  
Fig. 5.1. Foreign DNA is microinjected into the male pronucleus of a mouse 
zygote.  
Mouse pronuclei are visualized using Differential Interference Contrast (DIC) optics.  








5.2.1 Pronuclear microinjection 
Pronuclear microinjection procedures were performed by Ailsa Travers at the Biology 
Resource Facility in the University of Edinburgh. The foreign linear DNA transgene was 
introduced into CBA/C3H F1 single cell-stage oocytes by pronuclear microinjection 
(Gordon and Ruddle, 1981, 1983). Four to six week-old female mice were superovulated 
by injecting 5 IU of PMSG (pregnant mare serum gonadotropin) first and injecting 5 IU 
of HCG (human chorionic gonadotropin) 48 hours later. These superovulated females 
were placed with fertile male mice for mating (ratio 1:1). The following morning, plugs 
were checked and fertilized eggs were collected from the oviduct of pregnant females. 
Single-cell oocytes were then removed from surrounding cumulus cells by 
hyaluronidase digestion and maintained in M16 medium in a 5% CO2 incubator. When 
the pronucleus of any oocyte was visible, DNA fragment of interest in the 
microinjection buffer (2μg/ml; 2pl/injection) was injected usually into the larger male 
pronucleus with a needle (<1μm diameter) and a glass holding pipette. Injected oocytes 
(optimally at the 2-cell stage) were maintained in M16 medium overnight before 
implanted into pseudopregnant mice which had been prepared by mating with 








5.3.1 Establishment of AS-mCherry-11B-EGFP transgenic founder mice 






Fig. 5.2. Scheme for creating transgenic founder mice  
Step 1: To linearise the transgene separating it from as much of the vector backbone 
as possible; 
Step 2: To collect one cell-stage embryos; 
Step 3: To inject the linear transgene into the male pronucleus of individual zygotes; 
Step 4: To implant the injected embryos into pseudopregnant female mice;  









The AS-mCherry-11B-EGFP BAC transgene was linearised with NruI. The intact 125kb 
transgene fragment was separated from a 5kb BAC vector backbone. The complete 
digestion of the transgene was verified by running a small aliquot (~ 1 μg) of the 
digested DNA sample on a pulse field gel electrophoresis (PFGE) gel (Fig. 5.3A). 
Agarase treatment was performed to recover the linear transgene DNA (125kb). The 
DNA sample was further dialysed against the microinjection buffer to remove any traces 
of contaminants which would otherwise affect the viability of zygotes. After DNA 
recovery and purification, the integrity and correct size of the transgene was confirmed 
on PFGE gel before the final dilution followed by the pronuclear microinjection. No 
DNA degradation was observed (Fig. 5.3B). 
 




Fig. 5.3. Preparation of linear AS-mCherry-11B-EGFP BAC transgene  
(A) AS-mCherry-11B-EGFP BAC construct was linearised with NruI producing a 125kb 
transgenic fragment and a 5kb BAC vector backbone (seen in red squares).  
Lane 1, uncut BAC DNA; Lane M, Midrange I PFG marker; Lane 2, fragments of 
AS-mCherry-11B-EGFP BAC after NruI digestion.  
(B) Pulse field gel electrophoresis of the transgene after DNA recovery and purification 
confirming the correct size and integrity of the linear transgene.  
Lane M1, Midrange I PFG marker; Lane M2, Midrange II PFG maker; Lane 1-2, 






























Linear AS-mCherry-11B-EGFP transgene was injected into the male pronucleus of 
individual mouse zygotes at the one-cell stage. The injected viable embryos (surviving 
to 2-cell stage after overnight incubation) were implanted into the oviduct of 
pseudopregnant female mice. After a period of 21-day gestation, 27 pups were born. Ear 
notch DNAs were isolated and tested for the presence of AS-mCherry-11B-EGFP 




















Among the 27 pups, only GO9 and GO16 were identified by PCR genotyping to be 
transgenic founder mice containing the entire fragment of AS-mCherry-11B-EGFP 
transgene (Fig. 5.5-5.6).  
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Fig. 5.4. Strategy for PCR screens of transgenic founder mice 
The PCR genotyping of transgenic founder mice is based on the rule that they should be 
positive for PCR1 (mCherry CDS), PCR2 (BAC1), PCR3 (BAC2), PCR4 (ASWT), PCR5 
(11BWT), PCR6 (ASK5’), PCR7 (ASK3’), PCR8 (11BK5’) and PCR9 (11BK3’).  
These primer pairs are distributed across the whole transgene. BAC1 and BAC2 are DNA 
sequences on the BAC vector backbone close to NruI restriction sites (both ends of linear 
transgene DNA). PCRs 1-3 and PCRs 6-9 are BAC transgene-specific PCRs, PCRs 4-5 are 
endogenous gene-specific PCRs. 
(A) ASBAC. (B) AS-mCherry-11B-EGFP BAC. Sequences of PCR primer pairs and length of 
PCR products for each PCR reaction are shown in Appendix Table A2. 
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Fig. 5.5. Identification of AS-mCherry-11B-EGFP transgenic founders  
Ear DNA samples of 27 pups were tested for the presence of transgene by PCR1 
(mCherry CDS) (see Fig. 5.4). GO9 and GO16 were found to be positive indicating 
these might be transgenic founders. All the others were negative. Lane M, DNA 
ladder; Lane 1-27, NO.1-27 candidate pups; AS-mCherry-11B-EGFP BAC DNA is 
the positive control (PC). The sequences of primers are given in Appendix Table A2. 
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Fig. 5.6. Verification of GO9 and GO16 as AS-mCherry-11B-EGFP transgenic 
founder mice 
GO9 and GO16 were verified by 8 PCR screens (PCR2-PCR9) with primers distributed 
across the entire transgene (see Fig. 5.4). GO9 and GO16 were positive for all the 
transgenic genotyping PCRs. The sequences of primers are given in Appendix Table A2.  
(A) Lane 1, GO9; Lane 2, GO16; Lane 3,  AS-mCherry-11B-EGFP BAC DNA as positive 
control; Lane 4, H2O 







GO9 and GO16 mice were further assessed by Southern blot hybridization. The CDS of 
mCherry was isolated from p2A-mCherry-pA plasmid (Fig. 5.7) and used as the 
Southern blot probe.  
 
                                  
 
 
Fig. 5.7. Preparation of cDNA probe for Southern blot analysis 
The southern blot probe contained 720 bp mCherry cDNA isolated from p2A-mCherry-
pA plasmid.  
(A) Vector map of p2A-mCherry-pA showing the restriction sites. (B)Double digestion 
of p2A-mCherry-pA using BamHI and EcoRI created two DNA fragments of 2.7 kb 
and 720 bp. (C) 720 bp mCherry cDNA was extracted an purified.  


















Genomic DNA was extracted from the tail biopsy of 7 candidate pups (GO 9, 10, 11, 14, 
16, 18, 27), and 10 μg of each DNA sample was digested with SspI overnight. SspI 
digestion of AS-mCherry-11B-EGFP transgene created an 11.2 kb DNA band 
containing mCherry cDNA which was identical to southern blot probe. Southern blot 
hybridization assay was then performed with mCherry probe to confirm GO9 and GO16 
as transgenic founders (Fig. 5.8). However, none specific fragment was detected in GO 9, 
10, 11, 14, 16, 18, and 27.  
 





Fig. 5.8. Verification of transgenic founder mice using Southern blot hybridization  
10 μg of tail DNA from each candidate pup GO9, 10, 11, 14, 16, 18, 27 was digested with SspI.  
(A) Assessment of SspI restriction digestion products. DNA bands of different sizes were well 
separated on a 0.8% agarose gel run overnight and were stained with ethidium bromide as 
described in Section 2.2.3.2 and 2.2.3.3.  
(B) MCherry probe was hybridized to DNA-binding membrane for Southern blot assay as 
described in Section 2.2.7. No specific band was detected from any candidate pups including GO9 
and GO16.  
Lane M, 2-log DNA ladder; Lane PC, AS-mCherry-11B-EGFP BAC DNA (1 μg, ~7x10
9 
copies) 
as positive control; Lane NC, ASBAC (1 μg, ~7x10
9 
copies) as negative control 
 
 


















5.3.2 GO9 and GO16 transgenic founders are mosaic 
It was hypothesized that GO9 (♂) and GO16 (♀) might be mosaic transgenic founders 
according to the results of genotyping PCRs with ear notch DNA and results of Southern 
blot assay with tail biopsy. To confirm this hypothesis, GO9 and GO16 were bred to 
wild-type C57Bl/6 mice separately. The germline transmission and mosaicism in GO9 
and GO16 were then determined.  
49 progeny in four litters were produced from the transgenic founder GO9 (♂) and were 
tested for the presence of AS-mCherry-11B-EGFP transgene by genotyping PCRs. None 
of the 49 progeny of GO9 was positive for the transgene (Fig. 5.9A-C). GO9 exhibited 
an extremely low rate of germline transmission indicating that few of the germ cells of 
GO9 incorporated the transgene.  
22 progeny in three litters were obtained from the transgenic founder GO16 (♀) and 
were also assessed for the presence of AS-mCherry-11B-EGFP transgene by PCRs. All 
the 22 progeny of GO16 were found to be negative for the transgene (Fig. 5.10A-C). 
Unfortunately, GO16 had to be terminated because of difficulties in birthing her pups. 
Founder GO16 failed to transmit the transgene through germline indicating that not all 




















   





Fig. 5.9. Genotyping of 49 progeny from transgenic founder GO9 by PCR 
All 49 progeny of GO9 were negative for transgene indicating no germline 
transmission of GO9 founder. 11BWT primers were used in PCR1 as an internal 
control. MCherry primers were used in PCR2 as transgenic genotyping.  
(A) Lane 1-14, F1 progeny 1-14 of GO9 founder; Lane 15, ear DNA of GO9 as 
positive control. (B) Lane 1-13, F1 progeny 15-27 of GO9 founder; Lane 14, ear DNA 
of GO9 as positive control. (C) Lane 1-22, F1 progeny 28-49 of GO9 founder; Lane 23, 
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Fig. 5.10. Genotyping of 22 progeny from the transgenic founder GO16 by 
PCR 
All 22 progeny from three litters were negative for the transgene indicating no germline 
transmission of GO16 founder. P 11BWT primers were as an internal control in PCR1. 
Primers of mCherry were used in PCR2.  
(A) Lane 1-7, F1 progeny 1-7 of GO16; Lane 8, ear DNA of GO16 as positive control; 
Lane 9, DNA of wild-type C57Bl/6 mouse as negative control.  
(B) Lane 1-10, F1 progeny 8-17 of GO16; Lane 11, ear DNA of GO16 as positive control. 







GO9 and GO16 were sacrificed for confirmation of the AS-mCherry-11B-EGFP 
transgene mosaicism. DNA samples of tail, spleen, liver and kidney tissues from GO9, 
and DNA samples of tail, spleen, liver, kidney and ovary tissues from GO16 were 
isolated and genotyped for the presence of the AS-mCherry-11B-EGFP transgene by 
PCRs (Fig. 5.11). The transgene was only present in tail tissue of GO9 but was present 
in all the tissues of GO16.  
Given the results of genotyping PCRs and southern blot assay, it was thus concluded that 
both GO9 and GO16, to some degree, were mosaic transgenic founder mice. GO9 had a 













10 μg of each DNA sample of various tissues of GO9 and GO16 was digested with SspI 
and hybridised with the mCherry probe (described in Fig. 5.7) for southern blot assay. 
However, no specific fragment was evidently detected in all the tissues. It was suggested 
that the majority of cells throughout those tissues of GO9 and GO16 were negative for 
the transgene confirming that GO9 and GO16 were mosaic (Fig. 5.12).  
Fig. 5.11. Mosaicism in GO9 and GO16 transgenic founders  
The mosaicism of GO9 but not GO16 was confirmed. 11BWT primers were used as 
an internal control in PCR1. Primers of mCherry were used in PCR2 for transgenic 
genotyping. Lane M, DNA marker; Lane 1-4 represent tail, spleen, liver and kidney 
of GO9; Lane 5-9 represent tail, spleen, liver, kidney and ovary of GO16. 
 
 
Fig. 5.11. Mosaicism in GO9 and GO16 transgenic founders 
Lane M, DNA marker; Lane 1-4 represent tail, spleen, liver and kidney of GO9; Lane 5-9 represent tail, 
spleen, liver, kidney and ovary of GO16. The mosaicism of GO9 but not GO16 was confirmed.



















Fig. 5.12. Analysis of mosaicism in GO9 and GO16 transgenic founders 
by Southern blot hybridization  
(A) DNA samples were digested with SspI. DNA bands were well separated on a 0.8% 
agarose gel run overnight and were stained with ethidium bromide as described in 
Section 2.2.3.2 and 2.2.3.3.  
(B) 720bp mCherry probe was hybridized to the DNA-binding membrane for Southern 
blot assay. No specific band is detected indicating both of GO9 and GO16 were 
mosaic. 
Lane M, 2-log DNA ladder; Lane 1, GO9 tail; Lane 2, GO9 spleen; Lane 3, GO9 liver; 
Lane 4, GO9 kidney; Lane 5, GO16 tail; Lane 6, GO16 spleen; Lane 7, GO16 liver; 
Lane 8, GO16 kidney; Lane 9, GO16 ovary;  
Lane 10, wild type C57Bl/6 mouse tail as negative control;  
Lane 11, 10 copies of AS-mCherry-11B-EGFP BAC transgene as positive control; 


















AS-mCherry-11B-EGFP transgene expression should be localized to adrenocortical cells 
that normally express Cyp11b2 and Cyp11b1. Accordingly, adrenals from GO9 and 
GO16 were checked for fluorescent reporter expression. Mouse adrenal glands have a 
high level of autofluorescence which could compromise observations of the expression 
of reporter proteins. Fluorescent signal of mCherry or EGFP was not observed in wild-
type C57Bl6 mouse adrenals (data not shown) or in the adrenals of GO9 (Fig. 5.13). 
Very dim red and green fluorescent signals for mCherry and EGFP could be seen in the 
adrenal sections of GO16 when sections were examined under the microscope.  
Unfortunately however, these fluorescent signals were at the limit of detection and were 
not captured in the printed images (Fig. 5.13).  Comparisons with wild-type C57Bl/6 
mouse adrenals indicated that the punctuate pattern of red and green fluorescence signals 








Fig. 5.13. Fluorescence images of adrenal sections of GO9 and GO16 
Unfixed frozen sections of adrenal glands were stained with DAPI and were assessed for the 
expression of AS-mCherry-11B-EGFP transgene. Autofluorescence was high in all sections. 
GO9 adrenal sections showed no expression of either fluorescent reporter. Very weak 










Fig. 5.13. Fluorescent icroscopic image  of adrenal ection  of found rs GO9 and GO16
Unfixed frozen sections of adrenal glands w re freshly stained with DAPI (nuclear labelling) and were 
assessed for the expression f AS-mCherry-11B-EGFP transge e by fluorescent microscopy. Wild type 
C57Bl6 mouse adrenals were negative (not shown). Autofluorescence background was high in all sections. 
GO9 adrenal sections showed no expression of either fluorescent reporter. Very weak fluorescent signals of 






Expression of AS-mCherry-11B-EGFP transgene in the adrenals of mosaic mouse 
founder GO16 was also checked  by RT-PCR (Fig. 5.14). Both of the AS-mCherry TG 
and 11B-EGFP TG transcript were expressed in GO16 adrenals indicating that GO16 
was a useful, albeit mosaic, transgenic founder of the AS-mCherry-11B-EGFP transgene. 
It can be inferred from the results that the AS-mCherry-11β-EGFP BAC contains the 
necessary regulatory elements to direct cell-specific expression of Cyp11b2 and 
Cyp11b1 in the adrenal cortex.  However, the apparently low levels of reporter 
expression compared to the endogenous genes could result either from a short half-life 
of the mCherry and EGFP fluorescent proteins in the adrenocortical environment, or the 
absence of more distal regulatory sequences from the BAC reporter construct such as 
enhancer of insulator sequences (see Discussion Chapter 7), or a combination of both.  
The precise reasons for this difference will require further investigation. 
 
 
Fig. 5.14. Expression of transgene and steroidogenic genes in tissues of 
GO16 founder compared with wild-type adrenals and transgenic Y1 cells 
RNA was extracted from the adrenal, kidney and liver tissues of founder GO16, from 
wild-type mouse adrenals, and from transgenic Y1 cells (see Chapter 4). β-actin is the 
internal control. Steroidogenic genes SF-1, cyp11b2 and cyp11b1 were expressed in all 
adrenocortical tissues. AS-mCherry TG and the 11B-EGFP TG were expressed in the 




The degree of mosaicism in adrenals of transgenic mouse founder GO16 was further 
analysed using immunohistochemical techniques that avoid problems of 
autofluorescence of adrenal sections. Adrenal cryosections were stained with anti-GFP 
antibody and diaminobenzidine (DAB) colour staining. Only a small proportion of zona 




Fig. 5.15. Mosaic staining of EGFP in GO16 adrenal cryosections 
Adrenal cryosections of GO9 and GO16 were cut and were immunochemically stained 
with anti-GFP antibody (DAB, brown, 1:500) and counterstained with hematoxylin (blue) 
as described in Section 2.2.8.6-2.2.8.8.  
No GFP staining was seen in GO9 adrenals. Patches of stained cells were seen in the 







The application of transgenic mice in biomedical research is now widespread and is 
most commonly used to define cis-acting DNA fragments which direct the tissue-
specific patterns of gene expression. The gene transfer techniques creating transgenic 
mice have already become well-established and standard procedures. 
An AS-mCherry-11β-EGFP BAC construct has been generated and characterized in the 
mouse adrenocortical Y1 cells. Detection of EGFP reporter expression suggests that the 
regulatory elements required to direct cell-specific Cyp11b1 expression in Y1 cells are 
present in the BAC construct. However, the mosaic pattern of reporter expression could 
result from random silencing of the transgene due to peculiarities of the Y1 tumor cell 
environment or the absence of more distal regulatory sequences required for full 
endogenous levels of expression.  Analysis in Y1 cells also had another disadvantage 
that it was not a suitable environment to assess the function of the AS-mCherry reporter. 
In order to better assess the presence of regulatory sequences in the AS-mCherry-11β-
EGFP BAC construct and also to develop a reporter system to monitor the differential 
state of the adult adrenal cortex, we attempted to establish a transgenic mouse model in 
which zona glomerulosa cells and zona fasciculata cells are genetically labelled with 
mCherry and EGFP reporter, respectively. We hoped to use these markers to monitor 
stages in the differentiation of adrenocortical stem/progenitor cells into functionally 
distinct mineralocorticoid- and glucocorticoid-secreting steroidogenic cells. 
The linear AS-mCherry-11B-EGFP transgene was purified and microinjected into 
(C57BL/6) mouse zygotes. 27 pups were born, among which only GO9 (♂) and GO16 
(♀) were verified to be AS-mCherry-11B-EGFP transgenic mice by PCR genotyping. 
However, the Southern blot assay failed to provide evidence for GO9 and GO16 as 
transgenic founders. It was thus hypothesized that GO9 and GO16 might be mosaic.  
To identify whether GO9 and GO16 founder mice can transmit the AS-mCherry-11B-




Towards the end of this PhD project, 49 progeny were obtained from founder GO9 (♂) 
and 22 progeny were produced from founder GO16 (♀). Unfortunately, none of these 
progeny was positive for the AS-mCherry-11B-EGFP transgene. Genotyping PCRs and 
Southern blot assays indicated a relatively high degree of mosaicism in GO9 and a 
relatively low degree of mosaicism in GO16. The ovary of GO16 was positive for 
transgenic genotyping suggesting GO16 could have contained positive germ cells. It was 
unfortunate that she had to be killed because of health issues. The expression pattern of 
fluorescent proteins in adrenals of GO9 and GO16 appeared to be mosaic indicating the 
transgene had been integrated into some but not all cells of these mice. Mosaicism is not 
uncommon in transgenesis particularly with BAC transgenes. This problem and possible 
solutions are discussed in more detail in Chapter 7. 
GO16 was verified to be a useful transgenic founder albeit mosaic because expression of 
the AS-mCherry-11B-EGFP transgene in the adrenals of GO16 was detected by RT-
PCR. Immunochemical detection using anti-GFP antibody on the adrenal cryosections of 
GO16 found that the exogenous EGFP expression faithfully recapitulated the 
endogenous Cyp11b1 expression in the adult mouse adrenal cortex. However, EGFP 
expression was detected only in a small proportion of zona fasciculata cells confirming 
the adrenals of founder GO16 were mosaic. Due to the lack of any robust anti-mCherry 
primary antibody, the mCherry expression in zona glomerulosa cells was not determined. 
GO9 and GO16 are mosaic founder mice due to the very late integration of AS-
mCherry-11B-EGFP transgene during mouse embryogenesis. Transgenic mice are made 
through the integration of transgene DNA into the mouse genome. The frequency of 
transgene integration is thought to be affected by several factors such as the DNA 
concentration, DNA purity, the general conditions of both the embryo donors and 
recipient mice, and the manual skills of the microinjection procedure. Moreover, the risk 
of shearing DNA molecules is strikingly increased when dealing with very large 
transgenes (>30 kb) such as BAC constructs. Polyamines can be added to the 




considered that the embryo viability might be severely reduced by the increased dosage 
of genes in the BAC constructs (Giraldo and Montoliu, 2001). In theory, founder mice 
transmit their transgene to 50% of their offspring. However, in practice, it is more 
frequently observed that only 10-30% of pups inherit the transgene. Founders can be 
highly mosaic and may exhibit very low frequencies of germline transmission of the 
transgene. Some tissues or cells in the founder mice carry the transgene while others do 





Chapter 6-Generation and in vitro differentiation of 




6.1.1 Genetic manipulations in embryonic stem cells 
Embryonic stem (ES) cells are derived from the inner cell mass of blastocysts and 
remain undifferentiated under appropriate culture conditions. ES cells are capable of 
undergoing differentiation into all cell lineages contributing to the embryogenesis and 
development of various tissues (Nishikawa et al., 2007). The genetic manipulation 
techniques in ES cells have rapidly developed during the past decades facilitating 
versatile biological studies such as gene function, mammalian development and the 
creation of mouse disease models. DNA transgenes are usually introduced into ES cells 
via electroporation in vitro. Altered mouse ES clones can then be injected into 
blastocysts to continue their development in the uterus of a pseudopregnant female 
mouse. The subsequent mouse chimeras may be able to transmit the genetic alterations 
in ES cells to their offspring (Frohman and Martin, 1989). The transgenes either 
integrate into the genome of ES cells randomly, or specifically at the target location by 
homologous recombination.  
The mouse ES cell line used in the present study was a subline, JM8.A, which is 
regarded as feeder-independent (Pettitt et al., 2009). These ES cells were isolated with a 
C57BL/6N genetic background and are thought to be highly germline-competent. The 
mutant Agouti allele in JM8.A ES cells has been corrected, re-activating the expression 
of a dominant coat colour gene agouti. The restoration of agouti to C57BL/6N mouse 




and offspring by coat colour. The breeding process to obtain pure inbred mouse 
background is thus simplified.  
 
6.1.2 Differentiation of ES cells towards the steroidogenic lineage in vitro 
As mentioned above, ES cells have multiple potentials to elucidate biological process 
such as embryogenesis at the cellular level. We know relatively little about the 
differentiation pathways of ES cells in culture and how these pathways are compared to 
those in the in vivo developing embryos. ES cells can differentiate into three primary 
germ layers under specific culture conditions in vitro: the ectoderm, the mesoderm and 
the definitive endoderm, which interact with each other to eventually form all the tissues 
and organs throughout the body. The general methods for ES cell differentiation in vitro 
include the embryoid-body (EB) formation, the culture of ES cells on feeders/matrices 
and the forced expression of critical growth factors (Nishikawa et al., 2007). The EB 
formation method “mimics” the virtual embryonic development in vivo. The ES cell 
cultures on feeders/matrices and the forced expression of critical growth factors are 
aimed directing ES cell differentiation into specific lineages. 
Mesenchymal stem cells (MSCs) are defined as cells with the potentials to give rise to 
multiple mesenchymal lineages such as adipocytes, osteocytes (Takashima et al., 2007) 
and steroidogenic lineages. Recently, MSCs have attracted more attention as a cell 
source for therapeutic applications. The method to differentiate ES cell into MSC was 
established by Era’s research group (Era, 2010; Kitagawa and Era, 2010; Takashima et 
al., 2007), in which leukemia inhibitory factor (LIF) was withdrawn from the serum-
containing culture medium, ES cells were cultured on collagen IV-coated dish and 
treated with retinoic acid (RA). 
As described previously, the steroid production and steroidogenic gene expression in 
adrenals or gonads are controlled primarily by the NR5A family orphan nuclear 




SF-1 was shown to drive ES cell differentiation towards the steroidogenic cell lineage 
(Crawford et al., 1997). Although this finding is pioneering, the steroidogenic capacity 
of transformed cells is very limited since progesterone is the only steroid product after 
adding a membrane-permeable substrate, 20α-hydroxycholesterol. Yazawa recently has 
found that SF-1 could induce the differentiation of bone marrow-derived mesenchymal 
stem cells (BM-MSCs) into steroidogenic cells with the aid of 8bromo-cAMP 
stimulation (Yazawa et al., 2009; Yazawa et al., 2006). The induction of SF-1 in MSC 
differentiation seems to involve chromatin structure alterations activating the expression 
of steroidogenic genes such as StAR and CYP17 (Miyamoto et al., 2011). However, 
similar treatment with other undifferentiated cells such as ES cells or embryonic 
carcinoma cells fails to induce cell differentiation because of unknown reasons. It is 
found that ES cells stop proliferation and die several days after the withdrawal of LIF in 
the culture medium (Miyamoto et al., 2011; Yazawa et al., 2011).  
A novel strategy has been developed in which ES cells are induced into steroidogenic 
cells via an intermediate stage of multipotent MSCs (Yazawa et al., 2011). ES cells are 
differentiated into MSCs before the activation of SF-1 expression which is controlled by 
ROSA-TET system (Takashima et al., 2007; Yazawa et al., 2011). The expression of 
various steroidogenic genes is detected, such as Cyp11a1, Cyp17, 3β-HSD, Cyp21, 
Cyp11b1 or ACTH-receptor. Corticosterone is the primary steroid secreted from these 
cells. Both the pattern of gene expression and the profile of secreted steroids are very 






6.1.3 Sonic hedgehog signaling during the adrenocortical development 
Several findings by Kim and colleagues suggest that Shh signaling serves to initiate 
adrenal development and to help maintain the adrenal cortex (Kim et al., 2009; Kim et 
al., 2008a; Kim et al., 2008b; Kim et al., 2003). Sonic hedgehog (Shh) is a 
paracrine/autocrine morphogen, a secreted signaling protein that contributes the 
progenitor cell renewal, proliferation, lineage specialization and patterning of various 
organs (Huang et al., 2010). Expression of Shh is detected in the developing mouse 
adrenal cortex suggesting that it is required for normal adrenal organogenesis (Ching 
and Vilain, 2009). Both the thickness of adrenal cortex and the adrenal size are 




 mice. Moreover, the progenitor-like nonsteroidogenic 
mesenchymal cells beneath the capsule respond to Shh signals (King et al., 2009).  
Shh protein is thought to become involved in the early cartilaginous differentiation of 
mesenchymal cells in the spine and the limb. It has been reported that MSCs express 
cartilage markers within 2 weeks after treatment with recombinant Shh protein (r-Shh) 
in vitro under the optimal culture conditions (Warzecha et al., 2006). Considering the 
critical importance of Shh in the adrenocortical development, I hypothesized that Shh 
protein might promote the in vitro differentiation of ES cells and MSCs towards the 







6.2.1 Karyotyping of transgenic ES clones 
Approximately 1x10
6
 mouse ES cells were passaged into a T25cm
2
 flask 2-3 days prior 
to karyotyping. At this time, cells were 70-80% confluent growing exponentially and fed 
with 5 ml of fresh growth medium. 200 μl of KaryoMAX Colcemid solution (10μg/ml, 
Invitrogen) was added to the culture medium to arrest chromosomes in the metaphase 
stage and cells were incubated in a 37°C incubator for 2 hours. Medium was aspirated; 
cells were rinsed with PBS twice and then trypsinised and centrifuged as described in 
Section 2.2.5.2. The cell pellets were resuspended in PBS and centrifuged as before. The 
supernatant was discarded and 5 ml of 0.56% KCl hypotonic solution was added 
dropwise to resuspend the cells. The cell suspension was incubated in a 37°C water bath 
for 10 min. Cells were spun and the pellets were resuspended in 5 ml of ice-cold fixative 
(methanol: glacial acetic acid=3:1). Fixative was added dropwise to the suspension and 
cells were mixed carefully before centrifuging at 1,000 x g for 5 min. The spin and 
resuspension step in fixative was repeated for 3 times. Cells were finally resuspended in 
1 ml of fixative. Using a glass pipette, cell suspension was added dropwise onto the 
slides (2 drops/slide) from a height of 20-30 cm. Slides were rinsed and cooled in 100% 
ethanol at -20°C before use. Finally the metaphase spreads on the slides were completely 
dried at RT before staining with Toluidine Blue or DAPI dye (Sigma). For each ES cell 
clone, 20-30 karyotyping spread images were captured under a Zeiss Axiovert 200M 
microscope using an oil emersion objective. Chromosome numbers were counted in 
each of the spreads manually. 
 
6.2.2 Fluorescent in situ hybridization analysis of transgenic ES clones 
Fluorescent in situ hybridization (FISH) analysis was performed by Ms. Shelagh Boyle 




6.2.2.1 DNA labelling by Nick translation 
The intact transgene BAC DNA was labelled using biotin-16-dUTP incorporation using 
a nick translation kit from Roche according to the manufacturer’s guidelines. DNase I 
(Invitrogen) and T4 DNA polymerase I (Invitrogen) were added to the reaction mixture, 
which was mixed thoroughly before being incubated for 90 min at 16°C. The reaction 
mixture was then immediately passed through Quick Spin columns (Roche) to remove 
unincorporated DNA probe and finally eluted with TE buffer. 
 
6.2.2.2 Detection of DNA label incorporation 
Labelled DNA probes in TE buffer were spotted onto the pre-soaked gridded membrane 
alongside 1, 2, 10 and 20 pg of labelled λ DNA standards (Roche). DNA was cross-
linked onto the membrane using UV crosslinker. The membrane was washed in buffer 1 
(0.1M Tris-HCl, 0.15M NaCl) for 1 min, and then blocked with 3% (w/v) BSA fraction 
V in buffer 1 for 15-30 min at 60°C. Streptavidin-alkaline phosphatase (AP, Roche) was 
diluted in buffer 1 (1:1000) and incubated for 10-30 min at RT. Two drops from bottle 
1-3 from the AP-ABC kit (Vector labs) was diluted in buffer 3 and added in a sealed 
plastic bag with the membrane. The colour reaction was observed within 10 min of 
incubation at RT. The concentration of DNA labelled probe was estimated by comparing 
with known DNA standards. 
 
6.2.2.3 Slide preparation for FISH 
Glass slides were cleaned and stored in 100% ethanol at -20°C. Suspension of fixed cells 
in ice-cold methanol: acetic acid (3:1) was dropped directly onto a microscope glass 
slide from a 20-30 cm height (see above). Slides with dropped cell samples were dried 




6.2.2.4 Hybridization and detection of FISH 
Labelled probes were mixed with salmon sperm DNA and mouse Cot-1 DNA 
(Invitrogen). DNA probes were then precipitated by the addition of 2 volumes of 100% 
ethanol, centrifuged and dried under vacuum before resuspension in hybridization mix 
(50% deionised formamide, 10% dextran sulphate, 1% Tween 20 and 2x SSC). The 
resuspended probes were then denatured by heating at 70°C for 5min and pre-annealed 
at 37°C for 15min.  
Slides which had aged for more than 2 days were treated with 100 μg/ml RNase A at 
37°C for 1h and then rinsed in 2x SSC and dehydrated through a series of aqueous 
ethanol solutions (70%, 90% and 100% ethanol). Slides were dried and heated at 70°C 
for 5 min and immediately denatured in 70% formamide (v/v) at 70°C for 1-1.5 min. 
Slides were transferred to ice-cold 70% ethanol for 2 min and then dehydrated with 90% 
and 100% ethanol as before.  
The dried slides were treated with pre-annealed DNA probes that had been spotted onto 
the warmed coverslips. Coverslips were sealed onto the slides with rubber solution and 
incubated overnight in a covered tray in a water bath at 37°C. The next morning, rubber 
solution was removed and the slides were washed four times in 2x SSC. Blocking buffer 
(4x SSC, 5% Marvel) was added to each slide and incubated for 5 min at RT.  
FISH signal detection was performed with sequential layers in the dark, including FITC-
conjugated Avidin (1:500, Vector), biotinylated anti-avidin (1:100, Vector) and a further 
layer of FITC-conjugated avidin. All slides were mounted in Vectshield mounting 
medium containing DAPI. Slides were kept in the dark at 4°C until image capturing to 







6.3.1 Creation of AS-mCherry-11B-EGFP transgenic mouse ES clones 
To use the AS-mCherry-11B-EGFP BAC construct in studying the mutual and 
differential controls of Cyp11b1 and Cyp11b2 expression in vitro, I attempted to create 
AS-mCherry-11B-EGFP transgenic mouse ES clones for in vitro cell differentiation. 
JM8.A ES cell line has been described in Section 6.1.1. The morphology of wild-type 
JM8.A ES cells (at passage 9) was shown in Fig. 6.1A, and the undifferentiated 
phenotype of these mouse ES cells was verified by immunofluorescence against Oct4 (a 





Fig. 6.1. The phenotype of wild type JM8.A mouse ES cells at passage 9 
(A) ES cells with homogenous morphology indicating an undifferentiated state 
(B) Uniform Oct4 expression. ES cells were fixed in 4% PFA and ES cell nuclei were 
stained with Fluorescein-conjugated Oct 4 marker (green) and counterstained with PI 






AS-mCherry-11B-EGFP BAC construct was linearised with NruI as before. The linear 
transgene was introduced into JM8.A mouse ES cells via electroporation. 59 stably-
transfected mouse ES clones were isolated after hygromycin selection for two weeks in 
culture. The positive transgenic ES clones were identified by a panel of four genotyping 
PCRs with primer pairs of ASK5’, ASK3’, 11BK5’ and 11BK3’ (Fig. 6.2). Clone NO. 
23, 32, 40, 45, 47 were selected as the optimal AS-mCherry-11B-EGFP transgenic ES 
clones for further assessment upon the strength and reproducibility of the positive signal 














         ASK5’for 
                      
        ASK5’rev 
                   
         ASK3’for                          ASK3’rev 
 
         11BK5’for 
                      
        11BK5’rev 
                   
         11BK3’for 
                      
        11BK3’rev 
                   
Fig. 6.2. PCR screening primers for AS-mCherry-11B-EGFP transgenic ES 
clones 
Screening strategy was based on the rule that transgenic ES clones should be positive 
for PCR1 (ASK5’), PCR2 (ASK3’), PCR3 (11BK5’) and PCR4 (11BK3’). PCRs 1-4 are 
BAC transgene-specific PCRs. PCR1-2 primer pairs are specific for AS-mCherry 
transgene while PCR3-4 primer pairs are specific for 11B-EGFP transgenes. 
(A) Wild-type ASBAC. (B) AS-mCherry-11B-EGFP BAC.  
Sequences of PCR primer pairs and length of PCR products for each PCR reaction are 
seen in Appendix Table A2. 
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Fig. 6.3. PCR genotyping of 59 antibiotic-resistant AS-mCherry-11B-EGFP 
transgenic ES clones 
59 transfected ES clones were expanded after two-week hygromycin selection, and were 
then screened for stable integration of the AS-mCherry-11B-EGFP BAC by genotyping 
PCRs following the strategy described in Fig. 6.2. PCR1-2 primer pairs are specific for 
AS-mCherry transgene while PCR3-4 primer pairs are specific for 11B-EGFP 
transgenes. Sequences of PCR primer pairs for each PCR reaction are seen in Table A2. 
PCR2 PCR1 
PCR3 
M 49 50 51 52 53 54 55 56 57 58 59PCH2O 
M 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 
M 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 
M   1   2   3   4   5   6  7   8  9  10 11 12 13 14 15 16 
PCR4 
M 42 43 44 45 4647 48 49 50 51 5354 55 56 575859 PCH2O 
M  21  22 23 24 25 26 27 28  29 30  31 32 33 34  35 36 37 40 41 
M  1  2   3   4   5  6  7   8  9 10 11 12 13 14 15 16 17 18 19 
 M 47 49 51 53 55 PC H2O 
M  2   5   8  10  12 15 19 23 25 32 34 36 40 42 45 
 M 47  49  51  53  55  PC H2O 




Karyotyping assay was performed on cell spreads of AS-mCherry-11B-EGFP transgenic 
ES clone 23, 32, 40, 45 and 47. All the five transgenic ES clones were shown to present 
a normal mouse karyotype having 40 chromosomes compared with wild-type mouse ES 




Fig. 6.4. Karyotyping of AS-mCherry-11B-EGFP transgenic ES cell clones 
of NO. 23, 32, 40, 45 and 47 Metaphase cell spreads of transgenic ES cell clones 
were prepared and karyotyped as described in Section 6.2.1. Wild-type (WT) JM8.A ES 







The site of DNA integration has a great impact on transgene expression. Integration 
close to the heterochromatic region such as centromeres or telomeres can silence 
transgene expression. Therefore, before any transgenic ES clones to be used for further 
studies, FISH analysis was performed to identify the transgene integration sites of 
individual ES clones (NO.23, 32, 40, 45 and 47). The intact AS-mCherry-11B-EGFP 
transgene was used as the hybridization probe for FISH. The location of endogenous 
Cyp11b2-Cyp11b1 locus was revealed. Wild-type ES cells had two fluorescent signals 
because the BAC transgene shared very large DNA sequences with the endogenous 
Cyp11b2-Cyp11b1 genetic locus. Compared with wild-type ES cells, all the five tested 
transgenic ES clones had a third fluorescent signal indicating the non-homologous 
transgene incorporation. The additional signal in ES clone 23, 40, 45 and 47 was very 
close to the centromere in another chromosome and the additional signal in ES clone 32 
was located in the euchromatic region of another chromosome (Fig. 6.5). For subsequent 











Fig. 6.5. FISH analysis of AS-mCherry-11B-EGFP transgene integration 
sites of in ES clones NO.23, 32, 40, 45 and 47 
Metaphase cell spreads were prepared as described in Section 6.2.1, and were hybridized 
with the intact AS-mCherry-11B-EGFP BAC DNA probe for FISH analysis (green 







6.3.2 Differentiation of transgenic mouse ES cells into transgenic mouse 
MSCs 
To investigate the specialization of steroidogenic zona glomerulosa cells and zona 
fasciculata cells in vitro, I attempted to induce the differentiation of AS-mCherry-11B-
EGFP transgenic ES cells into adrenocortical cells, in which zG cells and zF cells were 
labelled with fluorescent reporter mCherry and EGFP, respectively. 
To transform mouse ES cells into steroidogenic cells, they were first differentiated into 
MSCs, an intermediate cell type for adrenogonadal primordium using a method 
described by Nishikawa and colleagues (Takashima et al., 2007; Yazawa et al., 2011). 
AS-mCherry-11B-EGFP transgenic ES cells were cultured on Collagen IV-coated dishes 
with Differentiation Medium from Day 0. The Differentiation Medium was α-MEM 
supplemented with 10% FBS and 50μM beta-Mercaptoethanol (β-ME) without LIF.  
Transgenic ES cells were then treated with 1μM retinoic acid (RA) from Day 2 to Day 5. 
Consistent with previous reports, cell morphological alterations were robustly induced 
indicating differentiation into MSCs (Fig. 6.6). The expression of molecular markers for 
the mesenchymal cell lineage including PDGFRα, PDGFRβ and OB-CAD were induced 
by RA treatment, confirming the successful derivation of mouse MSCs from AS-








Fig. 6.6. Cell morphological changes during the differentiation of AS-
mCherry-11B-EGFP transgenic ES cells into MSCs 
Cells were cultured in Differentiation Medium and cultured on collagen IV-coated 
dishes, and were treated ± 1μM RA from Day 2 to Day 5. 
(A) Day 0. (B) Induction Day 2. (C) Control Day 5 (no RA treatment).  





















Fig. 6.7 RT-PCR analysis during the differentiation of AS-mCherry-11B-
EGFP transgenic ES cells  
Cells were cultured as described in Fig. 6.6. Oct4 is the marker for undifferentiated cells. 
PDGFRα, PDGFRβ and OB-CAD are markers for mesenchymal lineage. SF-1 and Shh 
are markers for adrenocortical cells. β-actin is the internal control.  
Primer sequences of RT-PCRs are listed in Appendix Table A3. 
D0, Day 0 
D2, Induction Day 2 
D5 RA-, Control Day 5 without RA treatment 
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6.3.3 Attempting to induce transgenic MSCs to differentiate into 
adrenocortical cells with Shh treatment 
 
As described in Section 6.1.3, sonic hedgehog (Shh) has been reported to promote the 
chondrogenic and neuronal differentiation of bone marrow-derived MSCs (Trzaska and 
Rameshwar, 2011; Warzecha et al., 2006). It was hypothesized that Shh could also 
promote the differentiation of MSCs towards the adrenocortical cells in vitro. 
Thereafter, the impact of Shh treatment on the ESC-derived MSCs was tested. AS-
mCherry-11B-EGFP transgenic MSCs were treated with 500 ng/ml recombinant sonic 
hedgehog protein (r-Shh) (R&D Systems, Minneapolis, MN, USA) for two weeks. The 
resulting cells were further treated with 8-Bromo-cyclic AMP (1mM) for another two 
days.  
Changes in cell shape were robustly induced after Shh treatment (Fig. 6.8). Shh-treated 
cells had a nonuniform morphology and did not have the appearance of adrenocortical 





Fig. 6.8. Effects of Shh and cAMP treatment on cell morphology of AS-
mCherry-11B-EGFP transgenic mesenchymal cells 
The transgenic ES cell-derived mesenchymal cells were maintained in differentiation 
medium as described in legend of Fig. 6.6, and then induced with 500 ng/ml of r-Shh 
protein for two weeks and with 8-br-cAMP (1mM) for another two days. Morphological 
changes were compared with the cells at day 0.  
(A) ESC-derived transgenic mesenchymal cells, Day 0.  
(B) Shh treatment (500ng/ml r-Shh protein), Day 7. 
(C) Shh treatment (500ng/ml r-Shh protein), Day 14. 
















The expression of mesenchymal cell markers such as PDGFRα and OB-CAD continued 
to be expressed after Shh and cAMP treatment. However, the expression of 
adrenocortical cell markers including SF-1 and Shh was not induced after Shh and 
cAMP treatment (Fig. 6.9). This indicated that ESC-derived mesenchymal cells could 
not be induced to differentiate into adrenocortical cells solely by recombinant Shh 











Fig. 6.9. Effects of Shh and cAMP treatment on gene expression of AS-
mCherry-11B-EGFP transgenic mesenchymal cells 
Experimental details are seen in legend to Fig. 6.8. PDGFRα and OB-CAD are 
markers for mesenchymal lineage. SF-1 and Shh are molecular markers for 
adrenocortical cells. β-actin is the internal control.  
Primer sequences of RT-PCRs are listed in Appendix Table A3. 
Adrenocortical cell induction from ESC-derived transgenic mesenchymal cells: 
(A) ESC-derived transgenic mesenchymal cells, Day 0.  
(B) Shh treatment (500ng/ml r-Shh protein), Day 7. 
(C) Shh treatment (500ng/ml r-Shh protein), Day 14. 
(D) Shh (Day 1-14) plus cAMP treatment (1mM 8br-cAMP, Day 15-16), Day 16. 


















As discussed in Chapter 3, mechanisms underlying the determination of adrenocortical 
zonation and function remain controversial. It is not known whether the expression of 
Cyp11b2 and cyp11b2 are mutually exclusive in terminally-differentiated zG and zF 
cells or if adrenocortical cells have the plasticity or reversibility to allow transition from 
one cell type into another. However, it is hypothesized that the differential expression 
pattern of Cyp11b2 or Cyp11b1 is critical during the differentiation of adrenocortical 
stem/progenitor cells to become specialized zG or zF cells. The AS-mCherry-11B-EGFP 
BAC construct is therefore a useful tool for studying the mechanisms of ES cell 
differentiation towards the adrenocortical lineage. By incorporating the AS-mCherry-
11B-EGFP transgene into the ES cell genome, any subsequent differentiation step 
involving Cyp11b2 and Cyp11b1 expression can be monitored by the fluorescent 
reporter proteins mCherry and EGFP respectively. Linear AS-mCherry-11B-EGFP 
transgene was introduced into the JM8.A mouse ES cells and transgenic ES clones were 
identified by genotyping PCRs. Karyotyping and FISH assays determined the optimal 
transgenic ES clones, in which the random integration site of AS-mCherry-11B-EGFP 
transgene was located in a euchromatin region. Chromosomal environment at the 
transgene integration site can significantly influence the transgene expression, a 
phenomenon called position effect variegation. For example, if the transgenic DNA 
integrates into heterochromatin, which is transcriptionally inactive, the transgene will 
not be expressed in the adult offspring.  
The AS-mCherry-11B-EGFP transgenic ES cells were successfully differentiated into 
mesenchymal stem cells by culturing ES cells on collagen IV-coated dishes and treating 
cells with pulse exposure of RA from Day 2 to Day 5, as identified by cell 
morphological changes and gene expression of molecular markers for the mesenchymal 




achieve the transformation of transgenic mesenchymal cells into adrenocortical-like cells 
in vitro. 
Shh, as a secreting signaling protein, has been shown to play an important role in the 
adrenal development in vivo. It has been demonstrated that the adrenal cortex in Shh-null 
mice is much smaller compared with wild types (Huang et al., 2010). However, it has 
been suggested that although Shh signal promotes the growth of both adrenal capsular 
and cortical cells, any remaining adrenal cortex in Shh-null mice was capable of 
undergoing the appropriate adrenal zonation and producing steroid hormones, indicating 
that Shh might be dispensable for the specialization of functional adrenocortical cells 
(Laufer et al., 2011). In other words, although the negative effects of Shh deletion on the 
adrenal cortex are dramatic, Shh does not directly or exclusively contribute to the cell 
maturation or maintenance of the adult adrenal cortex. Additional factors might be 
required before Shh can play its role in promoting the transdifferentiation of ESC-
derived mesenchymal cells into adrenocortical cells. Based on previous studies, MSCs 
do not acquire any steroidogenic functions without the expression of SF-1. Therefore it 
is perhaps predictable that Shh either with or without cAMP treatment did not initiate 





Chapter 7-Discussion and Prospectives 
 
7.1 Discussion 
Functionally and morphologically the adult mammalian adrenal cortex is divided into 
zones that separately control mineralocorticoid and glucocorticoid hormone activities. 
This separate control is mediated by the renin-angiotensin-aldosterone system which 
regulates the outer zona glomerulosa and the hypothalamo-pituitary-adrenal axis which 
regulates glucocorticoid production by the zona fasciculata. Although a functional 
distinction between glomerulosa and fasciculata cell types is characterised by mutually 
exclusive expression of aldosterone synthase and 11β-hydroxylase, embryological 
evidence suggests that all adrenocortical steroidogenic cells have a common origin. The 
present thesis is concerned with experiments designed to explain the processes of 
glomerulosa and fasciculata cell specialization. This is important for several reasons. 
Firstly, it will lead to a greater understanding of the physiological maintenance of salt 
and water homeostasis and metabolism; secondly, it may provide a rational basis for 
pathophysiological conditions where corticosteroid synthesis is dysregulated; thirdly, it 
may help define the molecular basis of adrenocortical tumour formation. 
Two approaches have been adopted from opposite angles: the start and end of cell 
differentiation.  BrdU incorporation has been used to label proliferating cells in the 
adrenal cortex of adult mice with a view to identifying their fate under experimental 
conditions. Pulse-chase studies were used to identify stem/progenitor cells and to mark 
their displacement to different zones within the adrenal cortex. From the opposite 
perspective, a BAC construct has been created in which the coding sequences of genes 
Cyp11b1 (11β-hydroxylase) and Cyp11b2 (aldosterone synthase) have been substituted 
with sequences for fluorescent reporter proteins. The aims here were to express the 
construct in adrenocortical cell lines to monitor in vitro responses in gene expression to 




construct has been incorporated transgenically or by homologous replacement. 
Expression of fluorescent reporters in vivo should (i) identify critical stages of 
adrenocortical differentiation; (ii) establish whether Cyp11b1 and Cy11b2 expression is 
sequential or mutually exclusive in adrenocortical cells and (iii) present evidence of co-
ordinated expression in extra-adrenal tissues. 
Immunocytochemistry was used to locate Ki67-positive nuclei in the adrenal cortex of 
adult mice. These positive cells clustered in a subcapsular region which formed the 
interface between glomerulosa and fasciculata cells, a pattern which is identical to the 
distribution of labelled cells immediately after an acute injection of BrdU or radioactive 
thymidine to mark cell proliferation in the mouse or rat adrenal cortex. It has been 
argued that some of these cells are stem/progenitor cells which are then maintained in 
the same niche, turning over slowly to maintain a stem cell population whereas other 
cells differentiate and are displaced into steroidogenic zones. In one week pulse / six 
week chase studies with BrdU, dual immunohistochemistry with BrdU and Ki67 
confirmed that some BrdU positive cells were retained at the Ki67 origin whilst others 
were displaced inwards and outwards. Interestingly the incidence of dual labelled cells 
was greatest at the zona glomerulosa/fasciculata interface indicating that BrdU-positive 
cells that appeared to have maintained their original position had a greater capacity for 
cell division than those that had been displaced. Miyamoto (Miyamoto et al., 1999) also 
noted a stimulated increase in cell proliferation with ACTH treatment particularly in 
cells on the fasciculata side of the interface although the ultimate fate of BrdU-positive 
cells was not confirmed. A bi-directional displacement of mouse adrenocortical cells has 
been described by Change et al. (manuscript submitted for publication) which was 
similar to observations made by Miyamoto in the rats. Chang et al., ibid, noted that 4h 
after an acute injection of ACTH, cell division was increased and BrdU-positive cells 
were displaced. Based on previous observations of long-term zone specific effects on 
cell proliferation of manipulating the renin-angiotensin system, one might have expected 
acute angiotensin treatment to selectively prompt proliferation and migration of cells 




described in chapter 3. Although there may have been technical reasons why this acute 
response was not detected here, it is notable that in the studies of Miyamoto et al 
(Miyamoto et al., 2000), a one-week activation of the renin angiotensin system was 
required to trigger an increase in BrdU-positive cells positioned towards the zona 
glomerulosa and that this increase appeared to be at the expense of proliferating cells 
positioned towards the zona fasciculata. Taken together these results could indicate that 
cell division is an HPA-regulated process which precedes differentiation. This 
hypothesis is supported by the analysis of cell turnover in a mouse model of congenital 
adrenal hyperplasia where adrenal hypertrophy is driven by glucocorticoid hormone 
deficiency which leads to failure of the negative feedback of the HPA system. These 
mice have chronic ACTH excess and a suppressed renin-angiotensin-aldosterone system 
due to excess production of an alternative mineralocorticoid hormone (DOC) from the 
zona fasciculata. Pulse-chase labelling with BrdU and dual immunohistochemistry for 
Ki67 and BrdU confirm the subcapsular origin of cells in the cortex and an overall 
increase in cell proliferation. However, despite suppression of aldosterone levels, a 
significant number of BrdU-positive cells are displaced outwards with a zona 
glomerulosa morphology in adrenals of CAH mice. Again this study indicates that zonal 
fate of cells is determined before functional differentiation is complete. For future 
studies, this window between the origin and fate of zona glomerulosa cells is one that is 
open to exploitation. 
The technique used to develop the successful mouse model of congenital adrenal 
hyperplasia involved homologous recombination of the Cyp11b1/b2 locus with a 
genetically-modified BAC construct. In the present study, an AS-mCherry-11B-EGFP 
BAC construct was built in which both Cyp11b1 and Cyp11b2 were substituted with 
fluorescent proteins, EGFP and mCherry, respectively. This BAC transgene was used to 
transfect adrenocortical cell lines and to create genetically modified mice which 
incorporated fluorescent reporters to label aldosterone synthase and 11β-hydroxylase. 
This BAC vector contained 65kb upstream and 35kb downstream flanking DNA 




expression of Cyp11b1/b2. It is significant that just 2kb upstream flanking sequence has 
been shown to be sufficient for the appropriate controlled expression of hCYP11B2 
(Clyne et al., 1997). In the present studies, Y1 cells transfected with the BAC transgene 
gave expression of EGFP (marker for Cyp11b1) in some cell lines which responded 
appropriately to treatment with cyclic AMP. Consistent with previous studies of Y1 cells, 
there was no expression of mCherry (reporter for Cyp11b2). This Y1 phenotype is just 
one of a number of differences (such as angiotensin and melanocortin receptors, calcium 
signalling, expression of 21-hydroxylase, 20-HSD enzymes) from normal mouse 
adrenocortical cells. The expression of EGFP was variable but whether this is another 
artefact of Y1 cells or a function of the transgene is not clear.  
It should be noted that Cyp11b1 expression on an individual Y1 cell basis has not been 
reported previously. If the mosaic pattern of expression is a property of the transgene, 
this might suggest that some important elements are missing from the BAC construct, 
such as distant insulators of the regulating Cyp11b2 /b1 locus. Insulators are defined by 
their ability to protect expressing genes from inappropriate signals of the surrounding 
environments (West et al., 2002). One type of insulator works by blocking interactions 
between enhancers and promoters. A second type prevents the activity of adjacent 
condensed chromatin which might otherwise silence the gene of interest. Insulator acts 
as a barrier against the spreads of heterochromatin which is very important for transgene 
expression against the position effect (Gaszner and Felsenfeld, 2006). Insulator activity 
has emerged as a major mechanism of controlling epigenetic gene expression. 
Theoretically, all cells from an individual line initially express the transgene at the same 
level. After a long period of cell culture or too many cell divisions, the transgene 
becomes subject to epigenetic silencing by condensed chromatin. At a given time point, 
the genetically identical transgenic cells might gain from different epigenetic changes, 
thus showing variable phenotypes (West et al., 2002). It is possible, therefore, that 
variegated or mosaic transgene expression in vitro in transgenic Y1 cells or in vivo in 




sequences of endogenous insulators on the transgene, which misdirects the expression of 
Cyp11b2/b1 reporters. 
Two methods were used to introduce the BAC transgene into the mouse genome: 1) by 
pronuclear microinjection for random integration of the BAC transgene; 2) by gene 
targeting whereby blastocysts are injected with ES cells in which the transgene has been 
homologously recombined. Both of these two methods have advantages and 
disadvantages. Gene-targeted mice would ensure that all regulatory sequences are 
present.  However, losing one copy of the endogenous gene may result in an undesirable 
phenotype. In the case of Cyp11b1-null mice, from a steroidogenic point of view, there 
was no evidence of haploinsufficiency. Pronuclear injection is the most common and 
convenient way to make transgenic mice. The native genes are intact but multiple copies 
of the transgene may be introduced. There are also risks of incomplete regulatory 
sequences, position-effect variegation of transgene expression, and disruption of the 
expression of normal genes unrelated to the transgene, which may be important for 
development. In practice, the expression level might not correlate with the copy number 
of integrated transgenes. If integrated into a transcriptionally inactive region of the 
mouse genome, the transgene expression might be silenced. Transgene silencing could 
be attributed to its integration site close to a repressor or to epigenetic modification (see 
above for Y1 cell mosaicism).  
BAC constructs such as the AS-mCherry-11B-EGFP BAC in this study are frequently 
used to genetically modify mice as they reflect the endogenous gene expression more 
accurately than other smaller plasmid vectors. BAC constructs of large size could 
harbour more distant upstream and downstream regulatory sequences containing 
enhancers and other locus control regions, increasing the chance that the spatial and 
temporal expression pattern of corresponding endogenous genes in vivo will be 
recapitulated. In addition, BAC constructs reduce the influence of position effects 




animal model also has several disadvantages including time-consuming vector 
construction, remaining expression variegation and low efficiency of transgenesis. 
In this PhD project, pronuclear injection was used to generate two mosaic AS-mCherry-
11B-EGFP founder mice. GO9 and GO16 were established without germline 
transmission indicating that not all cells were integrated with the transgene. 
Occasionally, mosaic transgenic founders will occur due to late integration of the 
transgene into the mouse genome. It may be that mosaic founder mice will never 
transmit the transgene to offspring, or the transgene might be transmitted at very low 
efficiency depending on how many germ cells have integrated the transgene. However, 
there are alternatives to pronuclear injection. Lois reported an alternative method using 
lentiviral vectors to create transgenic mice (Lois et al., 2002). Lentiviral vectors 
integrate into the mouse genomic DNA with high efficiency, a distinct advantage when 
compared with traditional pronuclear microinjection. It would allow more rapid 
transgene integration into the genome of fertilised eggs and reduce the possibility of 
transgenic mosaicism. 
Many of the drawbacks of random integration caused by microinjection could be 
circumvented by site-specific transgene recombination. During the past decade, the Cre-
loxP system combined with gene targeting strategies has proven to be very useful for 
gene knockout in specific tissues or cell types. The Cre recombinase gene driven by 
tissue/cell-specific promoter could conditionally delete the target gene flanked with two 
identical loxP sites (Kwan, 2002; Tronche et al., 2002). In addition, a few specific 
transgene “safe harbour” loci have been identified, such as the Rosa26 locus on mouse 
chromosome 6 (Irion et al., 2007; Masui et al., 2005; Soriano, 1999) and an intergenic 
Hipp11 (H11) locus on mouse chromosome 11 (Hippenmeyer et al., 2010). Rosa26 
locus allows global expression of a single-copy knock-in transgene driven by the CMV 
enhancer and the chicken β-actin promoter (pCA) (Muzumdar et al., 2007; Zong et al., 
2005). H11 locus also supports the high level of global expression of a single-copy 




recombination than Rosa26 locus (Hippenmeyer et al., 2010). Several mouse ES cell 
lines have been established containing the loxP-flanked Rosa26 locus or loxP-flanked 
H11 locus, which, combined with the loxP-flanked and lineage-specific Cre 
recombinase, generate highly-efficient conditional transgenic or knockout mice. For 
example, aldo-keto reductase 1B7 (Akr1b7) is a member of the aldose reductase family 
(AKR1B) highly expressed in the adrenal cortex. Akr1b7-Cre transgenic mice were 
created by random integration following pronuclear injection, and the Cre recombinase 
activity was analyzed by mating 0.5 akr1b7-Cre mice with ROSA26R reporter mice. It 
was found in the offspring that Cre recombinase was specifically expressed in the 
adrenal cortex and some specific structures of the kidney (Lambert-Langlais et al., 2009).  
All these novel technologies provide insights for generating AS-mCherry-11B-EGFP 
founder mice with higher efficiency in the future, such as site-specific integration into 
Rosa26 or H11 locus supported by Cre-loxP recombination system, allowing better 






7.2 Future Work 
The studies described in this thesis have provided novel observations on which to base 
further investigations of the early events that programme the differentiation of 
adrenocortical cells in the adult mouse adrenals. However, a number of experimental 
problems have been identified concerning methods of expressing reporters for Cyp11b1 
and Cyp11b2 genes which have still to be overcome. 
Pulse-chase labelling experiments indicated a window between the original asymmetric 
division of an adrenocortical stem cell and terminal differentiation into a steroidogenic 
zona glomerulosa or zona fasciculata cell. Several different approaches to discovering 
the processes underlying adrenocortical cell differentiation could be tested based on 
immunolocalisation of potential intermediary factors. Firstly, the distribution of cells 
which express factors that have already been shown to be critical in embryonic adrenal 
development should be investigated (see Section 1.4). Secondly, factors which are 
known to be enriched in extracts of adrenal zona glomerulosa and fasciculata tissues 
should be compared in aldosterone synthase-positive and 11β-hydroxylase positive cells, 
and/or in cells with the morphology but not the steroidogenic capacity of a glomerulosa 
or fasciculata cell (Nishimoto et al., 2012). Thirdly, techniques which have been 
successfully applied to other biological systems might be considered. For example, the 
key changes involved in maintaining cell turnover in epithelial cells of the intestine 
might be applied to the adrenal cortex. 
An important aspect of the present studies has been the confirmation that 
pathophysiological manipulations can exaggerate adrenocortical development in a zone-
specific manner. It follows that the processes defining zonation could be controlled in 
vivo by promoting or removing the need for mineralocorticoid or glucocorticoid 
hormone. However, one of the aims of the present study was to investigate whether 
embryonic stem cells or mesenchymal stem cells could be induced in vitro to 




glomerulosa or fasciculata cells. Based on my observations and those of others, the 
obstacle appears to be the expression of steroidogenic factor 1. Once circumvented, the 
next logical question would appear be to be how to direct cells to become glomerulosa 
or fasciculata like. These in vitro investigations will be informed by in vivo observations 
but it is perhaps significant that mesenchymal stem cells derived from adipose or bone 
marrow tissue are induced by Sf1 transfection to preferentially express either 
corticosteroids or androgens (Gondo et al., 2008). The implication is that transformation 
of embryonic stem cells into mesenchymal stem cells may preordain the type of steroid 
hormones produced when steroidogenesis is subsequently induced. 
Signaling molecules, growth factors and cell culture matrix are three important aspects 
in the cellular transdifferentiation-based engineering of adrenal cortex. As described in 
Section 1.4, Shh, bFGF, IGF, TGF superfamily and Wnt/β-catenin are signaling 
molecules or growth factors playing pivotal roles in adrenocortical development, 
maintenance and function. In the future, the combination of an extracellular ligand such 
as Shh involved in signaling pathways and chemical factors such as bFGF involved in 
intracellular pathways can be tested. Given the interactions between multiple factors and 
their effects on SF-1 regulation and function, four key transcriptional factors DAX1, 
WT1, PBX1 and CITED2 are considered for the effective induction. The forced 
expression of these four key transcriptional factors in combination with SF-1, and the 
use of small signalling molecule mimetics which reproduce the function of pathway 
signalling molecules such as Shh and Wnt/β-catenin, as well as the combination of 
ACTH and other growth factors mentioned above, could be tested to see which 
combination achieves the differentiation of MSCs into steroidogenic cells before 
launching into adrenal cell-based therapies. 
In an attempt to mark the selective expression of Cyp11b1 and Cyp11b2, embryonic 
stem cells were transfected with the AS-mCherry-11B-EGFP BAC construct. FISH 
analysis indicated that integration of the BAC transgene was randomly incorporated 




expression of reporter genes. In contrast, in previous studies with a very similar BAC 
clone with only a modified Cyp11b1 gene, homologous recombination was achieved and 
was the technique used to create the model of congenital adrenal hyperplasia (CAH) that 
was studied in chapter 3 (Mullins et al., 2009). An important difference in the 
preparation of CAH mice was that they were created using a mouse ES cell line with a 
different genetic background (E14TG2a, derived from mouse strain 129/Sv) that is more 
accepting of the modified BAC. It is perhaps significant that when investigating the role 
of genetic background on fertility of CAH mice, Dr. Linda Mullins (personal 
communication) identified multiple sequence differences at the Cyp11b1/b2 locus of 
C57BL/6 and 129 strains of mice. A priority in future would therefore be to repeat 
studies outlined in chapter 6 starting with ES cells E14TG2a (Hooper et al., 1987).  
Genetically modified mice will be created in which the AS-mCherry-11B-EGFP BAC 
construct is incorporated transgenically or by homologous replacement. In order to 
maximize the production of transgene-expressing transgenic mice, the BAC construct 
can be transgenically introduced to a site-specific transgene recombination locus such as 
the mouse genomic ROSA26 or H11 locus, which will eliminate the potential inhibitory 
effects from nearby genomic areas. The creation of AS-mCherry-11B-EGFP transgenic 
mice can also be achieved by injection of the transgenic ES cells (described in Chapter 6) 
into mouse blastocysts, in which the transgene integration site has already been 
determined.  
Problems associated with attempts to produce genetically modified mice with the AS-
mCherry-11B-EGFP BAC construct have already been discussed and various strategies 
to avoid these problems have been outlined. Once generated, the scope for further 
studies is extensive. For example, fluorescent activated cell sorting could be used to 
identify adrenal and extra-adrenal steroidogenic cell populations, investigations of  
physiological, cellular and molecular regulation of corticosteroid synthesis would be 
facilitated, the question of whether adrenocortical cells undergo transdifferentiation 




be explained, transplantation studies might be possible. The ultimate aim, however, 
would be to use animals expressing fluorescent reporter proteins to understand how 
dysregulation of corticosteroid synthesis is implicated in cardiovascular disease and 
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Fig. A4. Entry Clone 3 (A) and Entry Clone 4 (B) 
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Fig. A5. Entry Clone 5 (A) and Entry Clone 6 (B) 
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Fig. A6. Entry Clone 7 (A) and Entry Clone 8 (B) 
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A2: DNA Sequences of PCR primers 
 
Table A1. Primers for creating entry clones 
Primers (5’ → 3’) Length of 
amplicons 
EC1for: GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGCA 
              ATGGCTCTCAGGGTGACAG 
EC1rev: GGGGACAACTTT TGTATACAAAGTTGTGTGGGCC 
              ACCCAGGGCTC  
 
EC2for: GGGGACAACTTTGTATACAAAAGTTGTGGATCTA 
              GGCAGTGGAGAGGGCAGAG 
EC2rev: GGGGACAACTTTGTATAGAAAAGTTGGGTGGTTT 
              GGACAAACCACAACTAGAATGCAGTGTTT 
 
EC3for: GGGGACAACTTTTCTATACAAAGTTGCTTTTCGTC 
              TTCAAGAATTCGATCATATTCAATAACCC 
EC3rev: GGGGACAACTTTATTATACAAAGTTGTACTAGTG 
              AACCTCTTCGAGGGACCTAA  
 
EC4for: GGGGACAACTTTGTATAATAAAGTTGCTACATTG 
              GTCCTACTTTATCT 
EC4rev: GGGGACCACTTTGTACAAGAAAGCTGGGTACCG 









Primers (5’ → 3’) 
EC5for: GGGGACAAGTTTGTACAAAAAAGCAGGCTTAAC 
              AATGGCTCTCAGGGTGACAACAG 
EC5rev: GGGGACAACTTTTGTATACAAAGTTGTTTCCAAG 
              GGCAT GCG GCA AG 
 
EC6for: GGGGACAACTTTGTATACAAAAGTTGTGGATCTA 
              GGCAGTGGAGAGGGCAGAG 
EC6rev: GGGGACAACTTTGTATAGAAAAGTTGGGTGGTTT 
              GGACAAACCACAACTAGAATGCAGTGTTT 
 
EC7for: GGGGACAACTTTTCTATACAAAGTTGCTTTTCGTC 
              TTCAAGAATTCGATCATATTCAATAACCC 
EC7rev: GGGGACAACTTTATTATACAAAGTTGTACTAGTG 
              AACCTCTTCGAGGGACCTAA 
 
EC8for: GGGGACCACTTTGTACAAGAAAGCTGGGTACATC 
              CGCACATCCTCTTTC 
EC8rev: GGGGACAACTTTGTATAATAAAGTTGCTACAGTC 













Table A2. PCR screening primers 




































Table A3. Primers for RT-PCRs 


























Primers (5’ → 3’) 
ACTH-R_for: TCTTAAGCCTCGTGGCAGTT  
ACTH-R_rev: GCACCCTTCATGTTGGTTCT  
 
11B-EGFP transcript_for: ATGGCTCTCAGGGTGACAAC 
11B-EGFP transcript_rev: AAGTCGTGCTGCTTCATGTG 
 
AS-mCherry transcript_for: TCTCAGGGTGACAGCAGATG 




















Table A4. Primers for Real-time qRT-PCRs  

















A3: DNA sequence of 2A peptide 
2A peptide (78 bp) 
5’-AGATCTAGGC AGTGGAGAGG GCAGAGGAAG TCTGCTAACA  
TGCGGTGACG TCGAGGAGAA TCCTGGCCCA AAGGATCC-3’ 
   
 
A4: Nucleotide Sequence of Southern-blot probe  
Probe: Coding Sequence (CDS) of mCherry (720 bp) 
GATCCCGCCA CCATGGTGAG CAAGGGCGAG GAGGATAACA TGGCCATCAT 
CAAGGAGTTC ATGCGCTTCA AGGTGCACAT GGAGGGCTCC GTGAACGGCC 
ACGAGTTCGA GATCGAGGGC GAGGGCGAGG GCCGCCCCTA CGAGGGCACC 
CAGACCGCCA AGCTGAAGGT GACCAAGGGT GGCCCCCTGC CCTTCGCCTG 
GGACATCCTG TCCCCTCAGT TCATGTACGG CTCCAAGGCC TACGTGAAGC 
ACCCCGCCGA CATCCCCGAC TACTTGAAGC TGTCCTTCCC CGAGGGCTTC 
AAGTGGGAGC GCGTGATGAA CTTCGAGGAC GGCGGCGTGG TGACCGTGAC 
CCAGGACTCC TCCCTGCAGG ACGGCGAGTT CATCTACAAG GTGAAGCTGC 
GCGGCACCAA CTTCCCCTCC GACGGCCCCG TAATGCAGAA GAAGACCATG 
GGCTGGGAGG CCTCCTCCGA GCGGATGTAC CCCGAGGACG GCGCCCTGAA 
GGGCGAGATC AAGCAGAGGC TGAAGCTGAA GGACGGCGGC CACTACGACG 
CTGAGGTCAA GACCACCTAC AAGGCCAAGA AGCCCGTGCA GCTGCCCGGC 
GCCTACAACG TCAACATCAA GTTGGACATC ACCTCCCACA ACGAGGACTA 
CACCATCGTG GAACAGTACG AACGCGCCGA GGGCCGCCAC TCCACCGGCG 
GCATGGACGA GCTGTACAAGT-3’ 







Abayasekara, D.R., Vazir, H., Whitehouse, B.J., Price, G.M., Hinson, J.P., and Vinson, G.P. 
(1989). Studies on the mechanisms of ACTH-induced inhibition of aldosterone biosynthesis 
in the rat adrenal cortex. J Endocrinol 122, 625-632. 
Achermann, J.C., Meeks, J.J., and Jameson, J.L. (2001). Phenotypic spectrum of mutations 
in DAX-1 and SF-1. Mol Cell Endocrinol 185, 17-25. 
Adamson, A.D., Jackson, D., and Davis, J.R. (2011). Novel approaches to in vitro 
transgenesis. J Endocrinol 208, 193-206. 
Aguilera, G., Kiss, A., Lu, A., and Camacho, C. (1996). Regulation of adrenal 
steroidogenesis during chronic stress. Endocr Res 22, 433-443. 
Al-Dujaili, E.A. (2006). Development and validation of a simple and direct ELISA method 
for the determination of conjugated (glucuronide) and non-conjugated testosterone excretion 
in urine. Clin Chim Acta 364, 172-179. 
Al-Dujaili, E.A., Mullins, L.J., Bailey, M.A., Andrew, R., and Kenyon, C.J. (2009a). 
Physiological and pathophysiological applications of sensitive ELISA methods for urinary 
deoxycorticosterone and corticosterone in rodents. Steroids 74, 938-944. 
Al-Dujaili, E.A., Mullins, L.J., Bailey, M.A., and Kenyon, C.J. (2009b). Development of a 
highly sensitive ELISA for aldosterone in mouse urine: validation in physiological and 
pathophysiological states of aldosterone excess and depletion. Steroids 74, 456-462. 
Allen, R.G., Carey, C., Parker, J.D., Mortrud, M.T., Mellon, S.H., and Low, M.J. (1995). 
Targeted ablation of pituitary pre-proopiomelanocortin cells by herpes simplex virus-1 
thymidine kinase differentially regulates mRNAs encoding the adrenocorticotropin receptor 




Barr, M., MacKenzie, S.M., Wilkinson, D.M., Holloway, C.D., Friel, E.C., Miller, S., 
MacDonald, T., Fraser, R., Connell, J.M., and Davies, E. (2006). Functional effects of 
genetic variants in the 11beta-hydroxylase (CYP11B1) gene. Clin Endocrinol (Oxf) 65, 816-
825. 
Bassett, M.H., White, P.C., and Rainey, W.E. (2004). The regulation of aldosterone synthase 
expression. Mol Cell Endocrinol 217, 67-74. 
Begeot, M., Langlois, D., Penhoat, A., and Saez, J.M. (1988). Variations in guanine-binding 
proteins (Gs, Gi) in cultured bovine adrenal cells. Consequences on the effects of phorbol 
ester and angiotensin II on adrenocorticotropin-induced and cholera-toxin-induced cAMP 
production. Eur J Biochem 174, 317-321. 
Ben-David, S., Zuckerman-Levin, N., Epelman, M., Shen-Orr, Z., Levin, M., Sujov, P., and 
Hochberg, Z. (2007). Parturition itself is the basis for fetal adrenal involution. J Clin 
Endocrinol Metab 92, 93-97. 
Beuschlein, F., Mutch, C., Bavers, D.L., Ulrich-Lai, Y.M., Engeland, W.C., Keegan, C., and 
Hammer, G.D. (2002). Steroidogenic factor-1 is essential for compensatory adrenal growth 
following unilateral adrenalectomy. Endocrinology 143, 3122-3135. 
Bielinska, M., Kiiveri, S., Parviainen, H., Mannisto, S., Heikinheimo, M., and Wilson, D.B. 
(2006). Gonadectomy-induced adrenocortical neoplasia in the domestic ferret (Mustela 
putorius furo) and laboratory mouse. Vet Pathol 43, 97-117. 
Bielinska, M., Parviainen, H., Kiiveri, S., Heikinheimo, M., and Wilson, D.B. (2009). 
Review paper: origin and molecular pathology of adrenocortical neoplasms. Vet Pathol 46, 
194-210. 
Bitgood, M.J., and McMahon, A.P. (1995). Hedgehog and Bmp genes are coexpressed at 




Bland, M.L., Fowkes, R.C., and Ingraham, H.A. (2004). Differential requirement for 
steroidogenic factor-1 gene dosage in adrenal development versus endocrine function. Mol 
Endocrinol 18, 941-952. 
Brinster, R.L., Chen, H.Y., Trumbauer, M., Senear, A.W., Warren, R., and Palmiter, R.D. 
(1981). Somatic expression of herpes thymidine kinase in mice following injection of a 
fusion gene into eggs. Cell 27, 223-231. 
Bushman, W., Thompson, J.F., Vargas, L., and Landy, A. (1985). Control of directionality 
in lambda site specific recombination. Science 230, 906-911. 
Chalfie, M., Tu, Y., Euskirchen, G., Ward, W.W., and Prasher, D.C. (1994). Green 
fluorescent protein as a marker for gene expression. Science 263, 802-805. 
Chang S-P, Morrison HD, Nilsson F, Kenyon CJ, West JD, Morley SD. (2013). Manuscript 
submitted for publication. 
Chang, S.P., Mullins, J.J., Morley, S.D., and West, J.D. (2011). Transition from 
organogenesis to stem cell maintenance in the mouse adrenal cortex. Organogenesis 7, 267-
280. 
Ching, S., and Vilain, E. (2009). Targeted disruption of Sonic Hedgehog in the mouse 
adrenal leads to adrenocortical hypoplasia. Genesis 47, 628-637. 
Chu, Y., Ho, W.J., and Dunn, J.C. (2009). Basic fibroblast growth factor delivery enhances 
adrenal cortical cellular regeneration. Tissue Eng Part A 15, 2093-2101. 
Clyne, C.D., Zhang, Y., Slutsker, L., Mathis, J.M., White, P.C., and Rainey, W.E. (1997). 
Angiotensin II and potassium regulate human CYP11B2 transcription through common cis-
elements. Mol Endocrinol 11, 638-649. 
Copeland, N.G., Jenkins, N.A., and Court, D.L. (2001). Recombineering: a powerful new 




Coulter, C.L. (2005). Fetal adrenal development: insight gained from adrenal tumors. Trends 
Endocrinol Metab 16, 235-242. 
Crawford, P.A., Sadovsky, Y., and Milbrandt, J. (1997). Nuclear receptor steroidogenic 
factor 1 directs embryonic stem cells toward the steroidogenic lineage. Mol Cell Biol 17, 
3997-4006. 
Denner, K., Rainey, W.E., Pezzi, V., Bird, I.M., Bernhardt, R., and Mathis, J.M. (1996). 
Differential regulation of 11 beta-hydroxylase and aldosterone synthase in human 
adrenocortical H295R cells. Mol Cell Endocrinol 121, 87-91. 
Doghman, M., Cazareth, J., and Lalli, E. (2008). The T cell factor/beta-catenin antagonist 
PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. J Clin Endocrinol 
Metab 93, 3222-3225. 
Ehrhart-Bornstein, M., Hinson, J.P., Bornstein, S.R., Scherbaum, W.A., and Vinson, G.P. 
(1998). Intraadrenal interactions in the regulation of adrenocortical steroidogenesis. Endocr 
Rev 19, 101-143. 
El Wakil, A., and Lalli, E. (2011). The Wnt/beta-catenin pathway in adrenocortical 
development and cancer. Mol Cell Endocrinol 332, 32-37. 
Engeland, W.C., Gomez-Sanchez, C.E., Fitzgerald, D.A., Rogers, L.M., and Holzwarth, 
M.A. (1996). Phenotypic changes and proliferation of adrenocortical cells during adrenal 
regeneration in rats. Endocr Res 22, 395-400. 
Ennen, W.B., Levay-Young, B.K., and Engeland, W.C. (2005). Zone-specific cell 
proliferation during adrenocortical regeneration after enucleation in rats. Am J Physiol 
Endocrinol Metab 289, E883-891. 




Frigeri, C., Tsao, J., Cordova, M., and Schimmer, B.P. (2002). A polymorphic form of 
steroidogenic factor-1 is associated with adrenocorticotropin resistance in y1 mouse 
adrenocortical tumor cell mutants. Endocrinology 143, 4031-4037. 
Frohman, M.A., and Martin, G.R. (1989). Cut, paste, and save: new approaches to altering 
specific genes in mice. Cell 56, 145-147. 
Fuchs-Hammoser, R., Schweiger, M., and Oelkers, W. (1980). The effect of chronic low-
dose infusion of ACTH (1-24) on renin, renin-substrate, aldosterone and other 
corticosteroids in sodium replete and deplete man. Acta Endocrinol (Copenh) 95, 198-206. 
Gaszner, M., and Felsenfeld, G. (2006). Insulators: exploiting transcriptional and epigenetic 
mechanisms. Nat Rev Genet 7, 703-713. 
Giraldo, P., and Montoliu, L. (2001). Size matters: use of YACs, BACs and PACs in 
transgenic animals. Transgenic Res 10, 83-103. 
Go, G.W., and Mani, A. (2012). Low-density lipoprotein receptor (LDLR) family 
orchestrates cholesterol homeostasis. Yale J Biol Med 85, 19-28. 
Gondo, S., Okabe, T., Tanaka, T., Morinaga, H., Nomura, M., Takayanagi, R., Nawata, H., 
and Yanase, T. (2008). Adipose tissue-derived and bone marrow-derived mesenchymal cells 
develop into different lineage of steroidogenic cells by forced expression of steroidogenic 
factor 1. Endocrinology 149, 4717-4725. 
Goodfellow, P.N., and Camerino, G. (1999). DAX-1, an 'antitestis' gene. Cell Mol Life Sci 
55, 857-863. 
Gordon, J.W., and Ruddle, F.H. (1981). Integration and stable germ line transmission of 
genes injected into mouse pronuclei. Science 214, 1244-1246. 
Gordon, J.W., and Ruddle, F.H. (1983). Gene transfer into mouse embryos: production of 




Gorman, L.S., and Chiasera, J.M. (2013). Endocrinology review - adrenal and thyroid 
disorders. Clin Lab Sci 26, 107-111. 
Gummow, B.M., Scheys, J.O., Cancelli, V.R., and Hammer, G.D. (2006). Reciprocal 
regulation of a glucocorticoid receptor-steroidogenic factor-1 transcription complex on the 
Dax-1 promoter by glucocorticoids and adrenocorticotropic hormone in the adrenal cortex. 
Mol Endocrinol 20, 2711-2723. 
Gummow, B.M., Winnay, J.N., and Hammer, G.D. (2003). Convergence of Wnt signaling 
and steroidogenic factor-1 (SF-1) on transcription of the rat inhibin alpha gene. J Biol Chem 
278, 26572-26579. 
Haase, M., Schott, M., Bornstein, S.R., Malendowicz, L.K., Scherbaum, W.A., and 
Willenberg, H.S. (2007). CITED2 is expressed in human adrenocortical cells and regulated 
by basic fibroblast growth factor. J Endocrinol 192, 459-465. 
Haber, D.A., Buckler, A.J., Glaser, T., Call, K.M., Pelletier, J., Sohn, R.L., Douglass, E.C., 
and Housman, D.E. (1990). An internal deletion within an 11p13 zinc finger gene 
contributes to the development of Wilms' tumor. Cell 61, 1257-1269. 
Hall, J.G., Pallister, P.D., Clarren, S.K., Beckwith, J.B., Wiglesworth, F.W., Fraser, F.C., 
Cho, S., Benke, P.J., and Reed, S.D. (1980). Congenital hypothalamic hamartoblastoma, 
hypopituitarism, imperforate anus and postaxial polydactyly--a new syndrome? Part I: 
clinical, causal, and pathogenetic considerations. Am J Med Genet 7, 47-74. 
Hammer, G.D., Parker, K.L., and Schimmer, B.P. (2005). Minireview: transcriptional 
regulation of adrenocortical development. Endocrinology 146, 1018-1024. 
Hatano, O., Takayama, K., Imai, T., Waterman, M.R., Takakusu, A., Omura, T., and 
Morohashi, K. (1994). Sex-dependent expression of a transcription factor, Ad4BP, 
regulating steroidogenic P-450 genes in the gonads during prenatal and postnatal rat 




Heikkila, M., Peltoketo, H., Leppaluoto, J., Ilves, M., Vuolteenaho, O., and Vainio, S. 
(2002). Wnt-4 deficiency alters mouse adrenal cortex function, reducing aldosterone 
production. Endocrinology 143, 4358-4365. 
Hershkovitz, L., Beuschlein, F., Klammer, S., Krup, M., and Weinstein, Y. (2007). Adrenal 
20alpha-hydroxysteroid dehydrogenase in the mouse catabolizes progesterone and 11-
deoxycorticosterone and is restricted to the X-zone. Endocrinology 148, 976-988. 
Hippenmeyer, S., Youn, Y.H., Moon, H.M., Miyamichi, K., Zong, H., Wynshaw-Boris, A., 
and Luo, L. (2010). Genetic mosaic dissection of Lis1 and Ndel1 in neuronal migration. 
Neuron 68, 695-709. 
Hohenstein, P., and Hastie, N.D. (2006). The many facets of the Wilms' tumour gene, WT1. 
Hum Mol Genet 15 Spec No 2, R196-201. 
Honda, S., Morohashi, K., Nomura, M., Takeya, H., Kitajima, M., and Omura, T. (1993). 
Ad4BP regulating steroidogenic P-450 gene is a member of steroid hormone receptor 
superfamily. J Biol Chem 268, 7494-7502. 
Hooper, M., Hardy, K., Handyside, A., Hunter, S., and Monk, M. (1987). HPRT-deficient 
(Lesch-Nyhan) mouse embryos derived from germline colonization by cultured cells. Nature 
326, 292-295. 
Huang, C.C., Miyagawa, S., Matsumaru, D., Parker, K.L., and Yao, H.H. (2010). Progenitor 
cell expansion and organ size of mouse adrenal is regulated by sonic hedgehog. 
Endocrinology 151, 1119-1128. 
Ikeda, Y., Lala, D.S., Luo, X., Kim, E., Moisan, M.P., and Parker, K.L. (1993). 
Characterization of the mouse FTZ-F1 gene, which encodes a key regulator of steroid 
hydroxylase gene expression. Mol Endocrinol 7, 852-860. 
Ikeda, Y., Swain, A., Weber, T.J., Hentges, K.E., Zanaria, E., Lalli, E., Tamai, K.T., 




Dax-1 colocalize in multiple cell lineages: potential links in endocrine development. Mol 
Endocrinol 10, 1261-1272. 
Ingraham, H.A., Lala, D.S., Ikeda, Y., Luo, X., Shen, W.H., Nachtigal, M.W., Abbud, R., 
Nilson, J.H., and Parker, K.L. (1994). The nuclear receptor steroidogenic factor 1 acts at 
multiple levels of the reproductive axis. Genes Dev 8, 2302-2312. 
Irion, S., Luche, H., Gadue, P., Fehling, H.J., Kennedy, M., and Keller, G. (2007). 
Identification and targeting of the ROSA26 locus in human embryonic stem cells. Nat 
Biotechnol 25, 1477-1482. 
Ishimoto, H., and Jaffe, R.B. (2011). Development and function of the human fetal adrenal 
cortex: a key component in the feto-placental unit. Endocr Rev 32, 317-355. 
Ishimura, K., and Fujita, H. (1997). Light and electron microscopic immunohistochemistry 
of the localization of adrenal steroidogenic enzymes. Microsc Res Tech 36, 445-453. 
Ito, M., Yu, R., and Jameson, J.L. (1997). DAX-1 inhibits SF-1-mediated transactivation via 
a carboxy-terminal domain that is deleted in adrenal hypoplasia congenita. Mol Cell Biol 17, 
1476-1483. 
Jeays-Ward, K., Hoyle, C., Brennan, J., Dandonneau, M., Alldus, G., Capel, B., and Swain, 
A. (2003). Endothelial and steroidogenic cell migration are regulated by WNT4 in the 
developing mammalian gonad. Development 130, 3663-3670. 
Jimenez, P., Saner, K., Mayhew, B., and Rainey, W.E. (2003). GATA-6 is expressed in the 
human adrenal and regulates transcription of genes required for adrenal androgen 
biosynthesis. Endocrinology 144, 4285-4288. 
Johnsen, I.K., and Beuschlein, F. (2010). Role of bone morphogenetic proteins in adrenal 




Kagawa, N., and Waterman, M.R. (1991). Evidence that an adrenal-specific nuclear protein 
regulates the cAMP responsiveness of the human CYP21B (P450C21) gene. J Biol Chem 
266, 11199-11204. 
Kagawa, N., and Waterman, M.R. (1992). Purification and characterization of a 
transcription factor which appears to regulate cAMP responsiveness of the human CYP21B 
gene. J Biol Chem 267, 25213-25219. 
Kang, S., Graham, J.M., Jr., Olney, A.H., and Biesecker, L.G. (1997). GLI3 frameshift 
mutations cause autosomal dominant Pallister-Hall syndrome. Nat Genet 15, 266-268. 
Kataoka, Y., Ikehara, Y., and Hattori, T. (1996). Cell proliferation and renewal of mouse 
adrenal cortex. J Anat 188 ( Pt 2), 375-381. 
Kaufman, W.L., Kocman, I., Agrawal, V., Rahn, H.P., Besser, D., and Gossen, M. (2008). 
Homogeneity and persistence of transgene expression by omitting antibiotic selection in cell 
line isolation. Nucleic Acids Res 36, e111. 
Keegan, C.E., and Hammer, G.D. (2002). Recent insights into organogenesis of the adrenal 
cortex. Trends Endocrinol Metab 13, 200-208. 
Kempna, P., and Fluck, C.E. (2008). Adrenal gland development and defects. Best Pract Res 
Clin Endocrinol Metab 22, 77-93. 
Kim, A.C., Barlaskar, F.M., Heaton, J.H., Else, T., Kelly, V.R., Krill, K.T., Scheys, J.O., 
Simon, D.P., Trovato, A., Yang, W.H., et al. (2009). In search of adrenocortical stem and 
progenitor cells. Endocr Rev 30, 241-263. 
Kim, A.C., and Hammer, G.D. (2007). Adrenocortical cells with stem/progenitor cell 
properties: recent advances. Mol Cell Endocrinol 265-266, 10-16. 
Kim, A.C., Reuter, A.L., Zubair, M., Else, T., Serecky, K., Bingham, N.C., Lavery, G.G., 




expressing cells impairs development and maintenance of the adrenal cortex. Development 
135, 2593-2602. 
Kim, J.B., Zaehres, H., Wu, G., Gentile, L., Ko, K., Sebastiano, V., Arauzo-Bravo, M.J., 
Ruau, D., Han, D.W., Zenke, M., et al. (2008b). Pluripotent stem cells induced from adult 
neural stem cells by reprogramming with two factors. Nature 454, 646-650. 
Kim, T.E., Lee, H.S., Lee, Y.B., Hong, S.H., Lee, Y.S., Ichinose, H., Kim, S.U., and Lee, 
M.A. (2003). Sonic hedgehog and FGF8 collaborate to induce dopaminergic phenotypes in 
the Nurr1-overexpressing neural stem cell. Biochem Biophys Res Commun 305, 1040-1048. 
King, P., Paul, A., and Laufer, E. (2009). Shh signaling regulates adrenocortical 
development and identifies progenitors of steroidogenic lineages. Proc Natl Acad Sci U S A 
106, 21185-21190. 
King, P.J., Guasti, L., and Laufer, E. (2008). Hedgehog signalling in endocrine development 
and disease. J Endocrinol 198, 439-450. 
Kitagawa, M., and Era, T. (2010). Differentiation of mesodermal cells from pluripotent stem 
cells. Int J Hematol 91, 373-383. 
Klattig, J., Sierig, R., Kruspe, D., Makki, M.S., and Englert, C. (2007). WT1-mediated gene 
regulation in early urogenital ridge development. Sex Dev 1, 238-254. 
Krone, N., Riepe, F.G., Gotze, D., Korsch, E., Rister, M., Commentz, J., Partsch, C.J., 
Grotzinger, J., Peter, M., and Sippell, W.G. (2005). Congenital adrenal hyperplasia due to 
11-hydroxylase deficiency: functional characterization of two novel point mutations and a 
three-base pair deletion in the CYP11B1 gene. J Clin Endocrinol Metab 90, 3724-3730. 
Kwan, K.M. (2002). Conditional alleles in mice: practical considerations for tissue-specific 




Lala, D.S., Rice, D.A., and Parker, K.L. (1992). Steroidogenic factor I, a key regulator of 
steroidogenic enzyme expression, is the mouse homolog of fushi tarazu-factor I. Mol 
Endocrinol 6, 1249-1258. 
Lambert-Langlais, S., Val, P., Guyot, S., Ragazzon, B., Sahut-Barnola, I., De Haze, A., 
Lefrancois-Martinez, A.M., and Martinez, A. (2009). A transgenic mouse line with specific 
Cre recombinase expression in the adrenal cortex. Mol Cell Endocrinol 300, 197-204. 
Landy, A. (1989). Dynamic, structural, and regulatory aspects of lambda site-specific 
recombination. Annu Rev Biochem 58, 913-949. 
Langlois, D., Saez, J.M., and Begeot, M. (1990). Effects of angiotensin-II on inositol 
phosphate accumulation and calcium influx in bovine adrenal and Y-1 tumor adrenal cells. 
Endocr Res 16, 31-49. 
Laufer, E., Kesper, D., Vortkamp, A., and King, P. (2011). Sonic hedgehog signaling during 
adrenal development. Mol Cell Endocrinol. 
Lavoie, H.A., and King, S.R. (2009). Transcriptional regulation of steroidogenic genes: 
STARD1, CYP11A1 and HSD3B. Exp Biol Med (Maywood) 234, 880-907. 
Lee, E.C., Yu, D., Martinez de Velasco, J., Tessarollo, L., Swing, D.A., Court, D.L., Jenkins, 
N.A., and Copeland, N.G. (2001). A highly efficient Escherichia coli-based chromosome 
engineering system adapted for recombinogenic targeting and subcloning of BAC DNA. 
Genomics 73, 56-65. 
Lee, G., Makhanova, N., Caron, K., Lopez, M.L., Gomez, R.A., Smithies, O., and Kim, H.S. 
(2005). Homeostatic responses in the adrenal cortex to the absence of aldosterone in mice. 
Endocrinology 146, 2650-2656. 
Lichtenauer, U.D., Duchniewicz, M., Kolanczyk, M., Hoeflich, A., Hahner, S., Else, T., 
Bicknell, A.B., Zemojtel, T., Stallings, N.R., Schulte, D.M., et al. (2007). Pre-B-cell 
transcription factor 1 and steroidogenic factor 1 synergistically regulate adrenocortical 




Lifton, R.P., Dluhy, R.G., Powers, M., Rich, G.M., Cook, S., Ulick, S., and Lalouel, J.M. 
(1992a). A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-
remediable aldosteronism and human hypertension. Nature 355, 262-265. 
Lifton, R.P., Dluhy, R.G., Powers, M., Rich, G.M., Gutkin, M., Fallo, F., Gill, J.R., Jr., Feld, 
L., Ganguly, A., Laidlaw, J.C., et al. (1992b). Hereditary hypertension caused by chimaeric 
gene duplications and ectopic expression of aldosterone synthase. Nat Genet 2, 66-74. 
Lin, L., Gu, W.X., Ozisik, G., To, W.S., Owen, C.J., Jameson, J.L., and Achermann, J.C. 
(2006). Analysis of DAX1 (NR0B1) and steroidogenic factor-1 (NR5A1) in children and 
adults with primary adrenal failure: ten years' experience. J Clin Endocrinol Metab 91, 
3048-3054. 
Lippincott-Schwartz, J., and Patterson, G.H. (2003). Development and use of fluorescent 
protein markers in living cells. Science 300, 87-91. 
Liu, P., Jenkins, N.A., and Copeland, N.G. (2003). A highly efficient recombineering-based 
method for generating conditional knockout mutations. Genome Res 13, 476-484. 
Liu, W., Xiong, Y., and Gossen, M. (2006). Stability and homogeneity of transgene 
expression in isogenic cells. J Mol Med (Berl) 84, 57-64. 
Lois, C., Hong, E.J., Pease, S., Brown, E.J., and Baltimore, D. (2002). Germline 
transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. 
Science 295, 868-872. 
Looyenga, B.D., and Hammer, G.D. (2006). Origin and identity of adrenocortical tumors in 
inhibin knockout mice: implications for cellular plasticity in the adrenal cortex. Mol 
Endocrinol 20, 2848-2863. 
Luo, X., Ikeda, Y., and Parker, K.L. (1994). A cell-specific nuclear receptor is essential for 




Masui, S., Shimosato, D., Toyooka, Y., Yagi, R., Takahashi, K., and Niwa, H. (2005). An 
efficient system to establish multiple embryonic stem cell lines carrying an inducible 
expression unit. Nucleic Acids Res 33, e43. 
Mazilu, J.K., and McCabe, E.R. (2011a). Moving toward personalized cell-based 
interventions for adrenal cortical disorders: part 1--Adrenal development and function, and 
roles of transcription factors and signaling proteins. Mol Genet Metab 104, 72-79. 
Mazilu, J.K., and McCabe, E.R. (2011b). Moving toward personalized cell-based 
interventions for adrenal cortical disorders: part 2--Human diseases and tissue engineering. 
Mol Genet Metab 104, 80-88. 
McEwan, P.E., Lindop, G.B., and Kenyon, C.J. (1995). In vivo studies of the control of 
DNA synthesis in the rat adrenal cortex and medulla. Endocr Res 21, 91-102. 
McEwan, P.E., Lindop, G.B., and Kenyon, C.J. (1996). Control of cell proliferation in the 
rat adrenal gland in vivo by the renin-angiotensin system. Am J Physiol 271, E192-198. 
Menzies R, Dunbar DR, Mullins LJ, Mullins JJ, Bailey MA, Kenyon CJ. (2010). The effects 
of chronic ACTH treatment on adrenal cell hypertrophy, proliferation and apoptosis in mice 
[abstract]. In: Proceedings of the Physiological Society. University of Manchester (2010) 
Proc Physiol Soc 19, C144. 
Mesiano, S., Coulter, C.L., and Jaffe, R.B. (1993). Localization of cytochrome P450 
cholesterol side-chain cleavage, cytochrome P450 17 alpha-hydroxylase/17, 20-lyase, and 3 
beta-hydroxysteroid dehydrogenase isomerase steroidogenic enzymes in human and rhesus 
monkey fetal adrenal glands: reappraisal of functional zonation. J Clin Endocrinol Metab 77, 
1184-1189. 
Mesiano, S., and Jaffe, R.B. (1997). Developmental and functional biology of the primate 




Midzak, A., Rone, M., Aghazadeh, Y., Culty, M., and Papadopoulos, V. (2011). 
Mitochondrial protein import and the genesis of steroidogenic mitochondria. Mol Cell 
Endocrinol 336, 70-79. 
Mineo, C., and Shaul, P.W. (2012). Novel biological functions of high-density lipoprotein 
cholesterol. Circ Res 111, 1079-1090. 
Mitani, F., Mukai, K., Miyamoto, H., Suematsu, M., and Ishimura, Y. (1999). Development 
of functional zonation in the rat adrenal cortex. Endocrinology 140, 3342-3353. 
Mitani, F., Mukai, K., Miyamoto, H., Suematsu, M., and Ishimura, Y. (2003). The 
undifferentiated cell zone is a stem cell zone in adult rat adrenal cortex. Biochim Biophys 
Acta 1619, 317-324. 
Mitani, F., Ogishima, T., Miyamoto, H., and Ishimura, Y. (1995). Localization of P450aldo 
and P45011 beta in normal and regenerating rat adrenal cortex. Endocr Res 21, 413-423. 
Miyamoto, H., Mitani, F., Mukai, K., Suematsu, M., and Ishimura, Y. (1999). Studies on 
cytogenesis in adult rat adrenal cortex: circadian and zonal variations and their modulation 
by adrenocorticotropic hormone. J Biochem 126, 1175-1183. 
Miyamoto, H., Mitani, F., Mukai, K., Suematsu, M., and Ishimura, Y. (2000). Daily 
regeneration of rat adrenocortical cells: circadian and zonal variations in cytogenesis. 
Endocr Res 26, 899-904. 
Miyamoto, K., Yazawa, T., Mizutani, T., Imamichi, Y., Kawabe, S.Y., Kanno, M., 
Matsumura, T., Ju, Y., and Umezawa, A. (2011). Stem cell differentiation into steroidogenic 
cell lineages by NR5A family. Mol Cell Endocrinol 336, 123-126. 
Moore, C.C., Brentano, S.T., and Miller, W.L. (1990). Human P450scc gene transcription is 
induced by cyclic AMP and repressed by 12-O-tetradecanoylphorbol-13-acetate and A23187 




Morley, S.D., Viard, I., Chung, B.C., Ikeda, Y., Parker, K.L., and Mullins, J.J. (1996). 
Variegated expression of a mouse steroid 21-hydroxylase/beta- galactosidase transgene 
suggests centripetal migration of adrenocortical cells. Mol Endocrinol 10, 585-598. 
Mornet, E., Dupont, J., Vitek, A., and White, P.C. (1989). Characterization of two genes 
encoding human steroid 11 beta-hydroxylase (P-450(11) beta). J Biol Chem 264, 20961-
20967. 
Morohashi, K. (1997). The ontogenesis of the steroidogenic tissues. Genes Cells 2, 95-106. 
Morohashi, K., Honda, S., Inomata, Y., Handa, H., and Omura, T. (1992). A common trans-
acting factor, Ad4-binding protein, to the promoters of steroidogenic P-450s. J Biol Chem 
267, 17913-17919. 
Morohashi, K., Iida, H., Nomura, M., Hatano, O., Honda, S., Tsukiyama, T., Niwa, O., Hara, 
T., Takakusu, A., Shibata, Y., et al. (1994). Functional difference between Ad4BP and ELP, 
and their distributions in steroidogenic tissues. Mol Endocrinol 8, 643-653. 
Morohashi, K., and Zubair, M. (2011). The fetal and adult adrenal cortex. Mol Cell 
Endocrinol 336, 193-197. 
Muench, M.O., Ratcliffe, J.V., Nakanishi, M., Ishimoto, H., and Jaffe, R.B. (2003). Isolation 
of definitive zone and chromaffin cells based upon expression of CD56 (neural cell adhesion 
molecule) in the human fetal adrenal gland. J Clin Endocrinol Metab 88, 3921-3930. 
Mukai, K., Imai, M., Shimada, H., and Ishimura, Y. (1993). Isolation and characterization of 
rat CYP11B genes involved in late steps of mineralo- and glucocorticoid syntheses. J Biol 
Chem 268, 9130-9137. 
Mukai, K., Imai, M., Shimada, H., Okada, Y., Ogishima, T., and Ishimura, Y. (1991). 
Structural differences in 5'-flanking regions of rat cytochrome P-450aldo and P-450(11) beta 




Mullins, L.J., Peter, A., Wrobel, N., McNeilly, J.R., McNeilly, A.S., Al-Dujaili, E.A., 
Brownstein, D.G., Mullins, J.J., and Kenyon, C.J. (2009). Cyp11b1 null mouse, a model of 
congenital adrenal hyperplasia. J Biol Chem 284, 3925-3934. 
Muskhelishvili, L., Latendresse, J.R., Kodell, R.L., and Henderson, E.B. (2003). Evaluation 
of cell proliferation in rat tissues with BrdU, PCNA, Ki-67(MIB-5) immunohistochemistry 
and in situ hybridization for histone mRNA. J Histochem Cytochem 51, 1681-1688. 
Muyrers, J.P., Zhang, Y., Testa, G., and Stewart, A.F. (1999). Rapid modification of 
bacterial artificial chromosomes by ET-recombination. Nucleic Acids Res 27, 1555-1557. 
Muzumdar, M.D., Tasic, B., Miyamichi, K., Li, L., and Luo, L. (2007). A global double-
fluorescent Cre reporter mouse. Genesis 45, 593-605. 
Narayanan, K., Williamson, R., Zhang, Y., Stewart, A.F., and Ioannou, P.A. (1999). 
Efficient and precise engineering of a 200 kb beta-globin human/bacterial artificial 
chromosome in E. coli DH10B using an inducible homologous recombination system. Gene 
Ther 6, 442-447. 
Nishikawa, S., Jakt, L.M., and Era, T. (2007). Embryonic stem-cell culture as a tool for 
developmental cell biology. Nat Rev Mol Cell Biol 8, 502-507. 
Nishimoto, K., Rigsby, C.S., Wang, T., Mukai, K., Gomez-Sanchez, C.E., Rainey, W.E., 
and Seki, T. (2012). Transcriptome analysis reveals differentially expressed transcripts in rat 
adrenal zona glomerulosa and zona fasciculata. Endocrinology 153, 1755-1763. 
Nogueira, E.F., and Rainey, W.E. (2010). Regulation of aldosterone synthase by activator 
transcription factor/cAMP response element-binding protein family members. 
Endocrinology 151, 1060-1070. 
Nomura, M., Bartsch, S., Nawata, H., Omura, T., and Morohashi, K. (1995). An E box 
element is required for the expression of the ad4bp gene, a mammalian homologue of ftz-f1 




Nomura, M., Nawata, H., and Morohashi, K. (1996). Autoregulatory loop in the regulation 
of the mammalian ftz-f1 gene. J Biol Chem 271, 8243-8249. 
Nussdorfer, G.G. (1970). The fine structure of the newborn rat adrenal cortex. II. Zona 
juxtamedullaris. Z Zellforsch Mikrosk Anat 103, 398-409. 
Nussdorfer, G.G. (1986). Cytophysiology of the adrenal cortex. Int Rev Cytol 98, 1-405. 
Oertle, M., and Muller, J. (1993). Two types of cytochrome P-450(11 beta) in rat adrenals: 
separate regulation of gene expression. Mol Cell Endocrinol 91, 201-209. 
Ogishima, T., Mitani, F., and Ishimura, Y. (1989). Isolation of aldosterone synthase 
cytochrome P-450 from zona glomerulosa mitochondria of rat adrenal cortex. J Biol Chem 
264, 10935-10938. 
Paperna, T., Gershoni-Baruch, R., Badarneh, K., Kasinetz, L., and Hochberg, Z. (2005). 
Mutations in CYP11B1 and congenital adrenal hyperplasia in Moroccan Jews. J Clin 
Endocrinol Metab 90, 5463-5465. 
Pascoe, L., Curnow, K.M., Slutsker, L., Connell, J.M., Speiser, P.W., New, M.I., and White, 
P.C. (1992). Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes 
created by unequal crossovers between CYP11B1 and CYP11B2. Proc Natl Acad Sci U S A 
89, 8327-8331. 
Payne, A.H., and Hales, D.B. (2004). Overview of steroidogenic enzymes in the pathway 
from cholesterol to active steroid hormones. Endocr Rev 25, 947-970. 
Pelletier, G., Li, S., Luu-The, V., Tremblay, Y., Belanger, A., and Labrie, F. (2001). 
Immunoelectron microscopic localization of three key steroidogenic enzymes (cytochrome 
P450(scc), 3 beta-hydroxysteroid dehydrogenase and cytochrome P450(c17)) in rat adrenal 
cortex and gonads. J Endocrinol 171, 373-383. 
Peter, M., and Dubuis, J.M. (2000). Transcription factors as regulators of steroidogenic P-




Peters, J. (2012). Local renin-angiotensin systems in the adrenal gland. Peptides 34, 427-432. 
Pettitt, S.J., Liang, Q., Rairdan, X.Y., Moran, J.L., Prosser, H.M., Beier, D.R., Lloyd, K.C., 
Bradley, A., and Skarnes, W.C. (2009). Agouti C57BL/6N embryonic stem cells for mouse 
genetic resources. Nat Methods 6, 493-495. 
Phelan, J.K., and McCabe, E.R. (2001). Mutations in NR0B1 (DAX1) and NR5A1 (SF1) 
responsible for adrenal hypoplasia congenita. Hum Mutat 18, 472-487. 
Portrat, S., Mulatero, P., Curnow, K.M., Chaussain, J.L., Morel, Y., and Pascoe, L. (2001). 
Deletion hybrid genes, due to unequal crossing over between CYP11B1 (11beta-
hydroxylase) and CYP11B2(aldosterone synthase) cause steroid 11beta-hydroxylase 
deficiency and congenital adrenal hyperplasia. J Clin Endocrinol Metab 86, 3197-3201. 
Prasher, D.C., Eckenrode, V.K., Ward, W.W., Prendergast, F.G., and Cormier, M.J. (1992). 
Primary structure of the Aequorea victoria green-fluorescent protein. Gene 111, 229-233. 
Rainey, W.E., Saner, K., and Schimmer, B.P. (2004). Adrenocortical cell lines. Mol Cell 
Endocrinol 228, 23-38. 
Romero, D.G., Gomez-Sanchez, E.P., and Gomez-Sanchez, C.E. (2010). Angiotensin II-
regulated transcription regulatory genes in adrenal steroidogenesis. Physiol Genomics 42A, 
259-266. 
Romero, D.G., Rilli, S., Plonczynski, M.W., Yanes, L.L., Zhou, M.Y., Gomez-Sanchez, E.P., 
and Gomez-Sanchez, C.E. (2007). Adrenal transcription regulatory genes modulated by 
angiotensin II and their role in steroidogenesis. Physiol Genomics 30, 26-34. 
Roskelley, C., and Auersperg, N. (1993). Mixed parenchymal-stromal populations of rat 
adrenocortical cells support the proliferation and differentiation of steroidogenic cells. 
Differentiation 55, 37-45. 
Rulicke, T., and Hubscher, U. (2000). Germ line transformation of mammals by pronuclear 




Schimmer, B.P., and White, P.C. (2010). Minireview: steroidogenic factor 1: its roles in 
differentiation, development, and disease. Mol Endocrinol 24, 1322-1337. 
Schnabel, C.A., Selleri, L., and Cleary, M.L. (2003). Pbx1 is essential for adrenal 
development and urogenital differentiation. Genesis 37, 123-130. 
Schulte, D.M., Shapiro, I., Reincke, M., and Beuschlein, F. (2007). Expression and spatio-
temporal distribution of differentiation and proliferation markers during mouse adrenal 
development. Gene Expr Patterns 7, 72-81. 
Schwartzman, R.A., and Cidlowski, J.A. (1993). Apoptosis: the biochemistry and molecular 
biology of programmed cell death. Endocr Rev 14, 133-151. 
Shaner, N.C., Campbell, R.E., Steinbach, P.A., Giepmans, B.N., Palmer, A.E., and Tsien, 
R.Y. (2004). Improved monomeric red, orange and yellow fluorescent proteins derived from 
Discosoma sp. red fluorescent protein. Nat Biotechnol 22, 1567-1572. 
Shaner, N.C., Steinbach, P.A., and Tsien, R.Y. (2005). A guide to choosing fluorescent 
proteins. Nat Methods 2, 905-909. 
Shinoda, K., Lei, H., Yoshii, H., Nomura, M., Nagano, M., Shiba, H., Sasaki, H., Osawa, Y., 
Ninomiya, Y., Niwa, O., et al. (1995). Developmental defects of the ventromedial 
hypothalamic nucleus and pituitary gonadotroph in the Ftz-F1 disrupted mice. Dev Dyn 204, 
22-29. 
Shizuya, H., Birren, B., Kim, U.J., Mancino, V., Slepak, T., Tachiiri, Y., and Simon, M. 
(1992). Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in 
Escherichia coli using an F-factor-based vector. Proc Natl Acad Sci U S A 89, 8794-8797. 
Simpson, E.R., and Waterman, M.R. (1988). Regulation of the synthesis of steroidogenic 




Simpson, S.A., Tait, J.F., Wettstein, A., Neher, R., Von Euw, J., and Reichstein, T. (1953). 
[Isolation from the adrenals of a new crystalline hormone with especially high effectiveness 
on mineral metabolism]. Experientia 9, 333-335. 
Soriano, P. (1999). Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat 
Genet 21, 70-71. 
Southern, E.M. (1975). Detection of specific sequences among DNA fragments separated by 
gel electrophoresis. J Mol Biol 98, 503-517. 
Spat, A., and Hunyady, L. (2004). Control of aldosterone secretion: a model for convergence 
in cellular signaling pathways. Physiol Rev 84, 489-539. 
Speiser, P.W., and White, P.C. (2003). Congenital adrenal hyperplasia. N Engl J Med 349, 
776-788. 
Stachowiak, A., Nussdorfer, G.G., and Malendowicz, L.K. (1990). Proliferation and 
distribution of adrenocortical cells in the gland of ACTH- or dexamethasone-treated rats. 
Histol Histopathol 5, 25-29. 
Stewart PM, Krone NP. The adrenal cortex. In: Kronenberg H, Melmed S, Polonsky K, 
Larsen PR, eds. Williams Textbook of Endocrinology. 12th ed. Philadelphia, PA: Saunders 
Elsevier; 2011: chap 15. 
Szymczak, A.L., Workman, C.J., Wang, Y., Vignali, K.M., Dilioglou, S., Vanin, E.F., and 
Vignali, D.A. (2004). Correction of multi-gene deficiency in vivo using a single 'self-
cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 22, 589-594. 
Takashima, Y., Era, T., Nakao, K., Kondo, S., Kasuga, M., Smith, A.G., and Nishikawa, S. 
(2007). Neuroepithelial cells supply an initial transient wave of MSC differentiation. Cell 
129, 1377-1388. 
Takayama, K., Morohashi, K., Honda, S., Hara, N., and Omura, T. (1994). Contribution of 




CYP11A and bovine CYP11B genes through their distal promoters. J Biochem 116, 193-
203. 
Tanaka, S., and Matsuzawa, A. (1995). Comparison of adrenocortical zonation in C57BL/6J 
and DDD mice. Exp Anim 44, 285-291. 
Tanaka, S., Nishimura, M., Kitoh, J., and Matsuzawa, A. (1995). Strain difference of the 
adrenal cortex between A/J and SM/J mice, progenitors of SMXA recombinant inbred group. 
Exp Anim 44, 127-130. 
Tillmann, H.C., Schumacher, B., Yasenyev, O., Junker, M., Christ, M., Feuring, M., and 
Wehling, M. (2002). Acute effects of aldosterone on intracardiac monophasic action 
potentials. Int J Cardiol 84, 33-39; discussion 39-40. 
Trichas, G., Begbie, J., and Srinivas, S. (2008). Use of the viral 2A peptide for bicistronic 
expression in transgenic mice. BMC Biol 6, 40. 
Tronche, F., Casanova, E., Turiault, M., Sahly, I., and Kellendonk, C. (2002). When reverse 
genetics meets physiology: the use of site-specific recombinases in mice. FEBS Lett 529, 
116-121. 
Trzaska, K.A., and Rameshwar, P. (2011). Dopaminergic neuronal differentiation protocol 
for human mesenchymal stem cells. Methods Mol Biol 698, 295-303. 
Tsien, R.Y. (1998). The green fluorescent protein. Annu Rev Biochem 67, 509-544. 
Val, P., Martinez-Barbera, J.P., and Swain, A. (2007). Adrenal development is initiated by 
Cited2 and Wt1 through modulation of Sf-1 dosage. Development 134, 2349-2358. 
Val, P., and Swain, A. (2010). Gene dosage effects and transcriptional regulation of early 




Vanttinen, T., Liu, J., Kuulasmaa, T., Kivinen, P., and Voutilainen, R. (2003). Expression of 
activin/inhibin signaling components in the human adrenal gland and the effects of activins 
and inhibins on adrenocortical steroidogenesis and apoptosis. J Endocrinol 178, 479-489. 
Vinson, G.P. (2003). Adrenocortical zonation and ACTH. Microsc Res Tech 61, 227-239. 
Warzecha, J., Gottig, S., Bruning, C., Lindhorst, E., Arabmothlagh, M., and Kurth, A. 
(2006). Sonic hedgehog protein promotes proliferation and chondrogenic differentiation of 
bone marrow-derived mesenchymal stem cells in vitro. J Orthop Sci 11, 491-496. 
Waterman, M.R., and Bischof, L.J. (1996). Mechanisms of ACTH(cAMP)-dependent 
transcription of adrenal steroid hydroxylases. Endocr Res 22, 615-620. 
West, A.G., Gaszner, M., and Felsenfeld, G. (2002). Insulators: many functions, many 
mechanisms. Genes Dev 16, 271-288. 
White, P.C. (1994). Disorders of aldosterone biosynthesis and action. N Engl J Med 331, 
250-258. 
White, P.C. (2001). Congenital adrenal hyperplasias. Best Pract Res Clin Endocrinol Metab 
15, 17-41. 
White, P.C. (2003). Aldosterone: direct effects on and production by the heart. J Clin 
Endocrinol Metab 88, 2376-2383. 
Wilhelm, D., and Englert, C. (2002). The Wilms tumor suppressor WT1 regulates early 
gonad development by activation of Sf1. Genes Dev 16, 1839-1851. 
Williams, G.H. (2005). Aldosterone biosynthesis, regulation, and classical mechanism of 
action. Heart Fail Rev 10, 7-13. 
Wood, M.A., and Hammer, G.D. (2011). Adrenocortical stem and progenitor cells: unifying 




Wotus, C., Levay-Young, B.K., Rogers, L.M., Gomez-Sanchez, C.E., and Engeland, W.C. 
(1998). Development of adrenal zonation in fetal rats defined by expression of aldosterone 
synthase and 11beta-hydroxylase. Endocrinology 139, 4397-4403. 
Wyllie, A.H., Kerr, J.F., and Currie, A.R. (1973). Cell death in the normal neonatal rat 
adrenal cortex. J Pathol 111, 255-261. 
Yazawa, T., Inanoka, Y., Mizutani, T., Kuribayashi, M., Umezawa, A., and Miyamoto, K. 
(2009). Liver receptor homolog-1 regulates the transcription of steroidogenic enzymes and 
induces the differentiation of mesenchymal stem cells into steroidogenic cells. 
Endocrinology 150, 3885-3893. 
Yazawa, T., Kawabe, S., Inaoka, Y., Okada, R., Mizutani, T., Imamichi, Y., Ju, Y., 
Yamazaki, Y., Usami, Y., Kuribayashi, M., et al. (2011). Differentiation of mesenchymal 
stem cells and embryonic stem cells into steroidogenic cells using steroidogenic factor-1 and 
liver receptor homolog-1. Mol Cell Endocrinol 336, 127-132. 
Yazawa, T., Mizutani, T., Yamada, K., Kawata, H., Sekiguchi, T., Yoshino, M., Kajitani, T., 
Shou, Z., Umezawa, A., and Miyamoto, K. (2006). Differentiation of adult stem cells 
derived from bone marrow stroma into Leydig or adrenocortical cells. Endocrinology 147, 
4104-4111. 
Yu, R.N., Ito, M., and Jameson, J.L. (1998). The murine Dax-1 promoter is stimulated by 
SF-1 (steroidogenic factor-1) and inhibited by COUP-TF (chicken ovalbumin upstream 
promoter-transcription factor) via a composite nuclear receptor-regulatory element. Mol 
Endocrinol 12, 1010-1022. 
Zajicek, G., Ariel, I., and Arber, N. (1986). The streaming adrenal cortex: direct evidence of 
centripetal migration of adrenocytes by estimation of cell turnover rate. J Endocrinol 111, 
477-482. 
Zanaria, E., Muscatelli, F., Bardoni, B., Strom, T.M., Guioli, S., Guo, W., Lalli, E., Moser, 




receptor superfamily responsible for X-linked adrenal hypoplasia congenita. Nature 372, 
635-641. 
Zazopoulos, E., Lalli, E., Stocco, D.M., and Sassone-Corsi, P. (1997). DNA binding and 
transcriptional repression by DAX-1 blocks steroidogenesis. Nature 390, 311-315. 
Zong, H., Espinosa, J.S., Su, H.H., Muzumdar, M.D., and Luo, L. (2005). Mosaic analysis 
with double markers in mice. Cell 121, 479-492. 
Zubair, M., Ishihara, S., Oka, S., Okumura, K., and Morohashi, K. (2006). Two-step 
regulation of Ad4BP/SF-1 gene transcription during fetal adrenal development: initiation by 
a Hox-Pbx1-Prep1 complex and maintenance via autoregulation by Ad4BP/SF-1. Mol Cell 
Biol 26, 4111-4121. 
Zubair, M., Parker, K.L., and Morohashi, K. (2008). Developmental links between the fetal 
and adult zones of the adrenal cortex revealed by lineage tracing. Mol Cell Biol 28, 7030-
7040. 
 
 
